Neuroendocrine studies in schizophrenia - An approach to pathophysiological mechanisms by Ferrier, Ian Nicol
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
NEUROENDOCRINE STUDIES IN SCHIZOPHRENIA - 
AN APPROACH TO PATHOPHYSIOLOGICAL MECHANISMS
Submitted to the University of Glasgow for the degree of 
Doctor of Medicine
IAN NIGOL FERRIER
Clinical Research Centre, 
Harrow 1 HA1 yUJ 
January, I98S
ProQuest Number: 10647061
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uesL
ProQuest 10647061
Published by ProQuest LLO (2017). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 48106- 1346
"GLASGOW"!
UNIVERSITY
l i b r a r y
INDEX „
   Page No
List of Contents 2
List of Tables and Figures 6
Acknowledgements 9
Summary 11
•w ml   I I ifr I
Chapter 1 Schizophrenia 14
1.1 The nature of schizophrenia l4
1.1.1 Definition of the syndrome of schizophrenia l4
1.1.2 Clinical features of schizophrenia 17
1.1.5 Course of schizophrenia l8
1.1.4 Outcome 18
1.2 Aetiological theories of schizophrenia 19
1.2.1 The genetic component 19
1.2-2 Personality, environmental and family studies 20
1.2-5 Neurochemical hypothesis of schizophrenia 21
1.2.4 Disorders of the nervous system - pathological 29
and structural changes in schizophrenic brain
1.2-5 Endocrine disorders in and their relationship 55
with schizophrenia
1,5 Summary 49
Chapter 2 Neuroendocrinology 50
2.1 The hypothalarno-pityitary axis 50
2.1.1 Historical aspects 50
2-1.2 Anatomy of the hypothalamo-pituitary axis 51
2.1.5 Physiology of the hypothalamo-pituitary axis 55
2-1.4 Pharmacology of the hypothalamo-pituitary axis 69
2.2 Neuroendocrine studies of psychiatric disease 74
2.2.1 Introduction 75
2.2.2 Neuroendocrine studies in affective illness 75
2.2.5 Neuroendocrine studies in patients with anorexia 79
nervosa
2.2.4 Neuroendocrine studies on patients with organic 80
psychiatric syndromes
2.2.5 Neuroendocrine studies in patients with 8l
Parkinson's disease and other DA-related
diseases
2.2.6 Neuroendocrine studies in schizophrenia 81
2.2.7 Summary 91
Chapter 5 Materials and Methods 95
5.1 Patient selection and classification
5.1.1 Chronic schizophrenic group 95
5.1.2 Acute schizophrenia 94
5.1.5 Control subjects 9-5
5.1.4 Additional points on patient selection 96
5.2 Clinical rating techniques
5 .2.1 Mental state 99
5.2.2 Cognitive functioning 100
5.5 Sample collection, handling and storage
5.5.1 Venous sampling techniques 101
5 .5.2 Handling and storage of samples 102
5.4 Radioimmunoassay (RIA) techniques
5.4.1 Radioimmunoassay-theory 105
5.4.2 RIA - materials used 105
3.4.3 RIA - Individual assays 106
3.4.4 RIA - lodination IG9
3.4.3 RIA " Separation techniques IO9
3.4.6 RIA - Techniques of counting radioactivity 111
3.4.7 RIA - Computer analysis of raw data 111
3.4.8 RIA - Quality control 112
Basal pituitary hormone levels in acute and chronic 
schizophrenia with particular reference to 114
gonadotrophin and prolactin hormonal rhythms
1. Introduction 114
2. Subjects, materials and methods 117
3. Results 122
4. Discussion 13^
Chapter 3 Studies on the hormonal response of chronic
schizophrenic patients to synthetic hypothalamic 146
releasing hormones
1. Introduction 146
2. Materials and methods 147
3 . Results 131
4. Discussion
Chapter 6 Effect of DA blocking drugs on anterior
pituitary hormone secretion in acute and chronic 165
schizophrenia
1. Introduction I63
2. Materials and methods 169
3. Results 173
4, Discussion ' 184
194
Chapter 7 Effect of a dopamine agonist on hormonal and
clinical acute and chronic state of schizophrenics
1. Introduction 194
2. Materials and methods 199
3. Results 203
4. Discussion 214
Chapter 8 Concluding remarks: Analysis and synthesis 230
8.1 General remarks 230
8.2 Overview of results in context of psychoneuroendo- 233
crinology
8.3 Results other than neuroendocrine 244
8.4 Future work 243
Appendices 247
A. Feighner criteria for diagnosis of schizophrenia 247
B. .Present State Examination (PSE) 249
C. Krawiecka scale for rating chronic psychotic patients 231
D. Radioimmunoassay 1) lodination of proteins 233
2) Dose-response curves
3) Quality control data
E. Partial correlation co-efficients 256
Declaration of work done by author 237
References 239
List of Tables and Figures Page No
Chapter 1
Chapter 2
Chapter 3
Chapter 4
Chapter 3
Table 1 
Table 2 
Table 3
Table 1 
Table 2
Table 3 
Table 4
Figure 1 
Figure 2
Table 1 
Figure 1
Table 1
Table 2 
Table 3
Table 4
F igure 1 
Figure 2
Figure 3
Figure 'f
Figure 3
Table 1 
Table 2
Neurochemical hypotheses of 23
schizophrenia
Neuroradiological studies of 31
schizophrenic patients 
Clinical studies of hormone 48
replacement in schizophrenia
Control of anterior pituitary 58
hormone secretion
Pharmacological profiles of 70
dopamine agonists used in
neuroendocrine studies
Summary of neuroendocrine studies 76
of psychiatric patients
Summary of neuroendocrine studies 88
with dopamine agonists in
schizophrenic patients
Schematic outline of hypothalamic- 32
pituitary axis control 
Schematic diagram of gonadotrophin 36
control system in man
Details of assay protocols 107
Diagram of principles of radio- 104
immunoassay
Clinical details of patients II8
studied
Quality control data of assays 123
Basal levels of hormones in 123
groups studied
Details of serial sampling results 127
Serial Lli estimates in controls 126
Serial LII estimates in chronic 126
s c hi zophr eni c s
Serial LH estimates in acute 127
schizophrenics in remission 
Serial mean PPL levels in controls I30 
and chronic schizophrenics 
Relationship between gonado- I30
trophin estimates on two separate 
testings
Clinical characteristics of groups 149 
studied
Mean levels of basal hormones 132
in groups studied
Table j 
Table 4 
Table 5
Mean levels of incremental "132
response to LHRH/TRH
Mean GH levels before and 133
after LHRH/TEIl administration 
Comparison of basal and 133
stimulated hormone secretion 
in schizophrenics with and 
without GH increment after
lhrh/tri-i
Figure 1 Profile of LH, FSH, PRL
and TSH secretion after 
LllRH/TlHi in groups studied 
Figure 2 Relationhisp between stimulated
hormone response after LHRIi/
TRH and fluctuation of LH in 
serial samples in groups studied 
Figure 3 Correlation matrix demonstrating
relationships between basal 
and stimulated hormone secretion
133
133
137
Chapter 6 Table 1 Clinical details of groups 172
studied
Table 2 Schedule of assessments in 172
oral flupenthixol study 
Table 3 LH, FSH and PRL levels before 179
and after metoclopramide IV 
in groups studied 
Table 4 PRL, LH and FSH levels before 179
and during oral flupenthixol 
therapy in acute schizophrenics
Figure 1 Serial LH, FSH and PRL in 3 176
chronic schizophrenic patients 
while unmedicated and after 6 
months oral neuroleptic therapy 
Figure 2 Mean PRL and FSH levels before I78
and after metoclopramide IV 
in 10 chronic schizophrenics 
and 10 controls 
Figure 3 Serial LH estimates before I78
and after metoclopramide IV 
in 10 chronic schizophrenics 
and 10 controls 
Figure 4 PRL levels during oral 182
flupenthixol therapy in acute 
schizophrenics 
Figure 3 Flupenthixol levels during oral 182 
flupenthixol therapy in acute 
schizophrenics
Chapter 7 Table 1 
Table 2 
Table 3 
Table 4
Table 3
Figure 1 
Figure 2 
Figure 3 
Figure 4 
Figure 3 
Figure 6
Clinical characteristics of 
groups studied 
Hormonal changes after 
apomorphine in groups studied 
Frequency of side effects 
after apomorphine 
Clinical effects of apomorphine 
on acute and chronic schizo­
phrenics
Blink rates before and after 
apomorphine
200
203
208
211
208
200Schematic representation of 
apomorphine study
GH and PRL response to apomorphine 204 
in controls
GH and PRL response to apomorphine 204 
in schizophrenics
Scattergram of GH and PRL 203
responses in groups studied 
Clinical response to apomorphine 210 
in acute schizophrenics 
Clinical response to apomorphine 210 
in chronic schizophrenics
ACKNOWLEDGEMENTS
My thanlis are due to Dr. T.J. Crow for suggesting this 
project and for much encouragement and advice throughout. I 
am especially grateful to Dr. Eve Johnstone for her tireless 
help at many different levels and specifically for her help with 
clinical ratings. Dr. Mary Cotes provided detailed help and 
advice with RIA procedures and 1 must thank her for allowing 
so many valuable reagents to be put at my disposal.
Many colleagues have been helpful in several ways but 
1 must specifically thank Drs. D.G.C. Owens, J.F, McMillan and 
P. McKenna for clinical assistance. Practical advice and 
help has also been readily given by Drs. A.J. Cross and C.D, 
Frith, for which 1 am most grateful. 1 would also like to 
thank Mr. S. Gamble, Miss S. Copping, Ms R. Bourne and Miss C. 
Canning for their technical assistance (documented in section 
on declaration of work done by author - page 257).
I would like to thank the consultant staff of Northwick 
Park and Shenley Hospitals for permission to study their cases. 
Thanks are also due to the nursing and paramedical staffs of 
these hospitals, notably the staff of Eastlake Ward, CRG.
The generous provision of RIA reagents and methods of 
Professor S-L. Jeffcoate, Professor W-R. Butt, Drs. W. Hunter,
S. Sufi and P. Byfied is gratefully acknowledged. The assistance 
of the National Institute of Biological Standards, the US 
National Pituitary Agency and the WHO was invaluable.
1 should like to acknowledge my gratitude to the MRC and 
to the Wellcome Trust for their financial support and trust 1
1 0
Finally I should like to thank anyone I have forgotten, 
Mrs. G, Pain and Miss A. Kapoor for their typing and my father 
and my wife for their patience.
11
SUMMARY
Schizophrenia is a chronic and disabling disorder with 
marked resource implications for health care services. The 
nature of the underlying disease process(es) remains obscure.
The hypotheses that a neurochemical abnormality underlies some 
of the manifestations of schizophrenia is plausible: the most
likely candidate is an increase in dopaminergic neurotransmission. 
There are also indications of organic changes in schizophrenic 
brain which may underlie some of the features of chronic 
schizophrenia. The present series of studies investigate these 
putative pathophysiological mechanisms by examining the 
secretion of anterior pituitary hormones in unmedicated patients 
with accurately diagnosed acute and chronic schizophrenia.
The reasons for employing a neuroendocrine strategy are 
threefold. Firstly there is good evidence that hypothalamic 
neurotransmitters play a crucial role in the modulation of 
pituitary secretion: changes in these hormones may thus provide
information on central neurotransmitter function. Neuroendocrine 
changes have been found in several neuropsychiatrie diseases 
which are of potential clinical relevance. Finally there are 
several indications that a degree of hypogonadism is present 
in schizophrenic patients (pathological changes in the gonads 
reduced fertility, menstrual disorders and reductions in 
gonadotrophin secretion).
Several neuroendocrine studies are reported in this thesis. 
Firstly the basal levels of several pituitary, thyroid and 
gonadal hormones have been investigated in acute and chronic
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schizophrenics and compared with controls. The rhythms of 
gonadotrophin, prolactin and growth hormone secretion have also 
been investigated (together with examination of the reproduci­
bility of some of these measures). The hormonal response to 
synthetic hypothalamic releasing hormones has been studied in 
patients with chronic schizophrenia. In view of the interest 
in dopamine neurotransmission in schizophrenia the clinical 
and hormonal effects of dopamine antagonists and agonists in 
acute and chronic schizophrenics have been investigated. Pineal 
function in schizophrenia has also been examined and a paper 
discussing this bound into the thesis. Clinical associations 
have been examined and are emphasised throughout.
The results demonstrate selective reductions in gonadotrophin 
secretion in a subgroup of chronic schizophrenics which are 
associated with a reduction in the frequency but not amplitude 
of LH. secretory episodes. While this pattern of abnormal 
secretion appeared to be reproducible within individual patients, 
the administration of acute or chronic dopamine antagonists was 
associated with a return towards normal levels. This suggests 
that dopamine overactivity may be implicated in the genesis of 
these abnormalities and this contention is supported by the 
finding that gonadotrophin abnormalities were associated with 
low prolactin secretion. These patients exhibiting these 
abnormalities had the longest length of illness and the more 
frequent positive symptoms of schizophrenia (e.g. delusions and 
hallucinations). The growth hormone response to a dopamine 
agonist was reduced in chronic schizophrenic patients as a group
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and markedly so in a subgroup of patients, particularly those 
with negative symptoms which are characteristic of chronic 
schizophrenia and which are thought to have an organic basis.
By contrast basal levels and rhythms of putitary hormones 
were normal in acute schizophrenia. Nevertheless several 
important relationships were established in this group e.g. 
between prolactin secretion and 1) the positive symptoms of 
schizophrenia and 2) the dose and blood level of DA antagonists. 
These findings indicate that abnormalities of gonadotrophin 
secretion are unlikely to be of aetiopathological significance 
in schizophrenia but point to important relations between 
dopamine neurotransmission, clinical symptoms and anterior 
pituitary hormone secretion.
In addition, several clinical observations of the effects 
of dopamine agonists on schizophrenic patients were made 
which, although effectively negative results, have important 
theoretical implications for schizophrenia research.
The specificity, selectivity and significance of these 
results to the study of schizophrenia is extensively discussed 
in the text and possible areas of clinical relevance high­
lighted. The results strengthen the notion that there may be 
separate pathophysiological processes underlying different 
aspects of the schizophrenia syndrome and indicate that these 
hormonal changes may be useful markers of these processes. There 
are strong indications that there are abnormalities of peptide/ 
dopamine interaction in the hypothalamus in schizophrenia. Some
lines of future enquiry, based on these researches, are discussed 
which may help elucidate this complex and disabling disease.
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1. INTRODUCTION : - Schizophrenia
Schizophrenia is a common and disabling disorder of unlmown 
aetiology. It is characterised by disorders of thought, 
perception, emotion and motor behaviour. The estimated incidence 
of schizophrenia, 8 per 1,000 of the population, appears to be 
relatively constant in different countries, ethnic groups and 
social classes. Although some important advances in therapy 
have been made, schizophrenia is a disease associated with 
marked resource implications. It has been estimated that about 
1/3rd of hospital beds in the United Kingdom are occupied by 
schizophrenic patients and that in the United States about 
of the G-N.P. is spent on the care of schizophrenic patients. 
Despite considerable research the nature of the underlying 
disease process(es) remains obscure.
The studies reported here mainly concern the levels of 
pituitary and gonadal hormones in schizophrenic patients of 
differing clinical types before and after various pharmacological 
agents. The reasons for undertaking such studies are set out in 
detail below (Chapters 1.2.3 and 2.2) but to put these studies in 
context a description of the definitions, clinical course and 
outcome of schizophrenia, together with an evaluation of current 
aetiological theories, is first given.
1.1 The Nature of Schizophrenia
1.1.1 Definition of the syndrome of schizophrenia
The term schizophrenia was introduced by E. Bleuler (l902)
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to denote those disturbances of psychological function which 
Kraepelin (1919) had previously grouped together under the 
heading of dementia praecox. Kraepelin's criteria for disting­
uishing dementia praecox from other psychiatric disorders was 
firstly the absence of marked disturbance of consciousness in 
dementia praecox and secondly that the outcome of dementia praecox 
was poor. Kraepelin stated that sufferers from dementia praecox 
seldom recover completely and that progressive deterioration of 
the personality occurs. Although Kraepelin himself recognized 
that these distinctions were no more than generalizations, they 
remain a cornerstone of clinical practice to this day. While it 
is apparent that it is unsatisfactory to define a. disease by 
the exclusion of other diseases or retrospectively in terms of 
its outcome, subsequent attempts to define schizophrenia by the 
presence of features or symptoms which are characteristic of the 
disease have proved largely unsuccessful.
Bleuler (1911) formulated a series of 'primary' or 
fundamental' symptoms which he held to be characteristic of 
schizophrenia. These symptoms included a disturbance of 
associations between ideas, specific changes in affective response 
and ambivalence. However these symptoms are vague and it has 
proved difficult to devise operational definitions which can be 
applied to individual cases.
A more direct approach to the definition of schizophrenia 
was proposed by Schneider (1939) who suggested that the presence 
of certain symptoms - the so-called first-rank symptoms - defines 
an illness as schizophrenic. These symptoms include disorders
of the possession of thought, various forms of auditory hallu­
cinations and delusional perceptions. Those symptoms have been 
incorporated, with some modifications, into the standardised 
diagnostic system of the Present State Examination (PSE) (Wing 
et al, 1974). It has been demonstrated that Schneider's symptoms, 
unlike Bleuler's, can be reliably assessed by independant 
observers (Wing and Nixon, 1973) but it has also been shown that 
these symptoms can occur, albeit with low frequency, in other 
psychiatric syndromes e.g. mania and confusional states (Wing 
and Nixon, 1973)- Another problem with the phenomenological 
definition of schizophrenia incorporating Schneider's first 
ranlc symptoms is that it is not as good a predictor of poor out­
come as other diagnostic systems which apply operational 
definitions (Kendall et al, 1978).
From the point of view of biological studies into schizo­
phrenia there is no alternative to specifying the particular 
diagnostic criteria applied and also attempting to select criteria 
which are both reliable and valid (Crow et al, 1979)» Where 
possible different systems of diagnosis should be employed so 
that an attempt can be made to identify biological correlates of 
specific psychopathological features and so that comparisons can 
be made between studies.
In the present study two systems of definition of schizo­
phrenia have been used. Firstly the operational definitions of 
Feighner et al (l972) (which set out clearly defined criteria to 
be fulfilled) have been applied to the hospital casenotes. To 
further define the diagnosis the inventory of the P.S.E. (Wing
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et al, 1974) was also applied to casenotes and the full interview 
of the P.S.E. was carried out where feasible. It is important to 
recognize that these two methods will identify separate but over­
lapping groups of patients. Further comments on the reliability 
and limitations of these methods are given in the subsequent 
relevant sections,
1.1.2 Clinical features of schizophrenia
While it is clear from the above account that there are no 
specific symptoms diagnostic of schizophrenia, the main symptoms 
can be classified as disorders of thought, perception, emotion 
and motor behaviour. Disorders of thought include disorders of 
the form, the stream, the possession and the content of thought. 
Disorders of form and stream of thought are seen clinically in 
the disturbed speech and vocabulary characteristic of schizo­
phrenia known as formal thought disorder. Disorder of the 
possession and content of thought are seen clinically in the 
form of delusions. Delusions can be defined as false unshake- 
able beliefs which are out of keeping with the patient's cultural 
and educational background.
Disorders of perception in schizophrenia are seen in the 
form of hallucinations. Hallucinations are perceptions in the 
absence of external stimuli and, in schizophrenia, can be 
referable to all sensory modalities. All varieties of emotional 
disorder can occur in schizophrenia (for example anxiety and 
depression) but the abnormalities which are characteristically 
seen are flattening and incongruity of affect. Motor disorders 
are similarly varied and range from complicated stereotyped
behaviour patterns to abnormal movements of lips and. tongue.
1.1.5 Course of schizophrenia
The onset of illness is very variable ranging from an 
acute illness fully developing over a few days to a slow 
insidious progression such that the exact point of onset is 
uncertain. Hospitalisation policy is variable and is therefore 
not a good determinant of onset. The natural history of the 
disease thereafter is similarly varied. Partly this depends on 
the criteria for diagnosis used as some systems have a degree of 
chronicity as a validating criterion. While some patients with 
a first episode have no subsequent morbidity, the normal course 
of schizophrenia is for remissions and relapses usually in the 
context of a degree of progressive deterioration.
1.1.4 Outcome
Kraepelin (1919) expressed the opinion that intellectual 
functions (e.g. orientation, consciousness and memory) were 
unimpaired in schizophrenia a view which was shared by Bleuler 
(1911)- However Kraepelin did qualify his comments to describe 
'a terminal condition of dementia' in schizophrenic patients who 
exhibited 'a general decay in mental efficacy' and who become 
'impoverished in thought, monotonous in mental activity' 
(Kraepelin, 1919).
Since Kraepelin described these terminal states it has 
become recognized that a proportion of schizophrenic patients 
proceed to a state characterized by lack of productive activity, 
social withdrawal and occasionally mutism (the "defect state").
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It has become recognized that many patients with chronic schizo­
phrenia perform poorly on tests of intellectual function.
Some observations suggest that these impairments are due to 
reduced volition and that improvements are seen if the conditions 
of institutional life are made more interesting. However there 
is evidence that similar impairments are found in non-institution- 
alized chronic schizophrenics (Johnstone et al, I981). It has 
also been shown that there is a relationship between the 
characteristic symptoms of the defect state (the negative 
symptoms - flattening of affect and poverty of speech) and 
cognitive and neurological impairments of chronic schizophrenic 
patients (Owens and Johnstone, I980) which suggests an organic 
basis to the defect state. These observations have prompted a 
series of investigations into the disabilities and defects of 
these patients with chronic schizophrenia some of which will be 
reviewed below (see Section 1«3»4).
1.2 Aetiological theories of schizophrenia
1.2.1 The genetic component
There is no doubt that the incidence of schizophrenia is 
much higher among the relatives of schizophrenics than in the 
general population. The most persuasive evidence for a genetic 
determination comes from concordance studies of mono- and dy- 
zygotic twin pairs. Shields (1976) reported that the concordance 
rate of schizophrenia for mono-zygotic twins lies between 65 
and 63 percent. By contrast, the concordance rate in same-sex 
dyzygotic twins lies between 12 and l4 percent. That these
2D
rates are due to a genetic component rather than environmental 
factors is demonstrated by the fact that similar rates of concor­
dance are observed in studies of monozygotic twins reared apart. 
The genetic contribution is further supported by studies which 
demonstrate that the incidence of schizophrenia in adopted 
children resembles that of their biological parents more closely 
than that of their adoptive parents. Although the evidence for 
a genetic component is persuasive, the fact that the concordance 
in monozygotic twins is less than 100% indicates that other 
factors are also relevant. Moreover it is clear that the mode 
of inheritance within families is not readily compatible with 
any one simple theory of genetic transmission (Shields, 19?6). 
Thus schizophrenia may be analogous to other chronic diseases 
such as rheumatoid arthritis, in which there is a genetic pre­
disposition and the disease is precipitated by various environ­
mental factors.
1.2.2 Personality, environmental and family studies
The role of the personality in the causation of schizo­
phrenia has been the subject of discussion for a long time.
No clear cut predisposing personality type or environmental 
factor has been identified. Such studies are fraught with 
problems and methodological difficulties. For example the 
personality and relationship difficulties of the schizophrenic 
patient are always viewed retrospectively by investigators 
only after the diagnosis is made and the question of similar 
problems applying to the non-schizophrenic population is rarely
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tackled. It does seem that non-specific environmental changes 
('stress') may precipitate schizophrenic illness (Birley and 
Brown, 1970)- However why some individuals and not others of 
the same family develop schizophrenia in this context is not 
clear. It may be that (in many cases), early schizophrenic 
illness itself leads to environmental changes.
1.2.3 Neurochemical hypotheses of schizophrenia
As discussed above, with certain reservation regarding 
the defect state, schizophrenia can be distinguished phenomeno- 
logically from the organic states on the basis of the absence 
of marked disturbance of consciousness in schizophrenia. This 
may throw some light on pathogenesis. As Bonhoeffer (1909) 
pointed out the psychotic reactions associated with physical 
disease as varied as infection, anaemia, thyroid disturbance 
etc. cannot be distinguished clinically. A similar argueraent 
applies to chronic organic states, the dementias - illnesses 
which share with the acute organic psychoses disturbances of 
learning capacity and intellect. This suggests that in these 
organic psychoses there is a generalised disturbance in those 
cells concerned with cognitive activities and that this represents 
an insult on a significant fraction of the total cerebral mass. 
Since cognitive processes are generally unaffected schizophrenia 
must result from a cellular disturbance of a more discrete nature. 
Since the identity of the neurotransmitter is a functionally 
important feature which distinguishes systems of neurones, it 
may be the characteristic which distinguishes between cells 
affected and those not so affected.
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Any neurohumeral hypothesis of schizophrenia is greatly 
strengthened if it can be shown that drugs which are known to 
alter neurotransmitter function in the CNS in a predictable way, 
have effects on characteristic schizophrenic symptoms in a way 
which is predicted by the hypothesis. The neurochemical hypotheses 
of schizophrenia fall into three main groups a) inborn errors 
of metabolism b) production of a toxin with psychotogenic 
properties c) neurotransmitter dysfunction. Table 1.1 outlines 
the main neurotransmitter hypothesis of schizophrenia with a 
description of supporting and confounding pharmacological and 
biochemical evidence.
Proposed inborn errors of metabolism are based solely on 
observations on the body fluids or brain tissue of schizophrenics 
and do not take into account any pharmacological evidence. These 
hypotheses have either failed to be confirmed or shown to be 
artefactual-
There is little evidence to support the hypotheses of 
production of an endogenous psychotogen or neurotoxin. Initial 
claims of increases in methylated amines, which resemble some 
known hallucinogens, have not been confirmed in subsequent studies. 
In any event, it is necessary to explain how such postulated 
toxins exert their psychotogenic effects and it is likely that 
some specific neuronal system, and therefore neurotransmitter, 
would be involved.
The first neurochemical hypothesis of schizophrenia was 
advanced by Wooley and Shaw (1934). These authors proposed that 
the symptoms of schizophrenia were attributable to failure of
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TABLE 1.1
HYPOIKESIS p r o p o s e r s !DATE
PiURMACOLOGICAL ARGUMEOT 
AND EVIDENCE
POST-MORTEM BIOCHEMICAL 
EVIDENCE REFERENCES
EOR AGAINST FOR AGAINST
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Oef icienfÿ VIooley and 
Shaw ( 195-1 )
LSD p.'iycnosis
resembles schiao- "
phrer.ia.
LSD blocks
serotoain
receptors
but with some
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differences!
Tryptophan and
5-hydroxy-
tryptophan
therapeutically
ineffective
-
Serotonin turn­
over not decreased 
Serotonin receptors 
not altered
Owen et al,
I9bi
fJeiadferiaiiU-t; 
i\«yfGne 
ft -f ICI ency
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wiG<j v  r.'D
Reward processes 
r.eiiated by NA 
;;yste:r;s: Ardiedonia 
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Blockade of DBli 
by disuliiram 
does not preci­
pitate schizo­
phrenia
-
Dopamine-p- 
hydroxyluoe not 
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1 and p receptors 
unchanged
Owen et al»
1 93 1
QAi^ A , b ( V  T) uAdA inhibits 
monoamine 
i.e U'or.os. Dis- 
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m.-'noamine
u'onos con-
siTitont, wit!.
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Baclofen and 
muscimol are 
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ineffectivc
-
GABA levels and 
receptors un­
altered Owen et al,
1901
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romo circ’j!:.stances
Gonflictir;.: evi­
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effects of opiat-' 
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antagonists
-
Opiate receptors 
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Amphetamine psychosis 
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ir.inos release
dopamine
See text
Dopamine 
receptors 
increased 
(see text)
Dopamine turn­
over not 
increased 
(see text) See text
Neurochemical hypotheses of schizophrenia
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serotoninergic neurotransmission. This hypotheses was based on 
the fact that lysergic acid diethyaniine (LSD) blocked some of the 
pharmacological effects of serotonin and so the psychotogenic 
effects of LSD were attributable to central serotonin receptor 
blockade. There is however little evidence to support this 
hypothesis (see Table 1.1). The clinical features of LSD 
psychoses differ significantly from those of acute schizophrenia 
and there is no supporting evidence from PM studies ; CSF, blood 
or urine studies of schizophrenics (Table 1).
More recently the hypothesis has been advanced that a 
degeneration of central noradrenaline (NA)-containing neurones 
might account for the symptoms of the 'defect state' (Stein and 
Wise, 19?f)» This hypothesis rests upon observations on the 
behavioural effects of the neurotoxin 6-OH-dopamine, which destroys 
Na-containing neurones. There is little supporting evidence 
for this hypothesis (Table 1.1) and good evidence against it e.g.
3-raethoxy-d-hydroxy-phenylethyl0ne-glycol (MHPG) - (an indicator 
of CNS turnover of Na) is not abnormal in schizophrenia, inhibition 
of dopamine-f3-hydroxylase (DBH) (an enzyme specifically associated 
with Na neurones) does not precipitate a schizophrenia-like illness 
and D-B-H itself is not abnormal in schizophrenic brain (see Table 
1.1). Abnormalities of GABA transmission and opiate mechanisms 
have been postulated in schizophrenia. Neither of these hypotheses 
is supported by PM studies or neuropharmacological studies with 
schizophrenic patients. Details are given in Table 1,1.
The hypotheses, first put forward by Randrup and Munlcvad 
(1966), that there is dopamine (Da) overactivity in schizophrenia
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is however supported by some evidence. Firstly it is known that 
amphetamine intoxication or abuse can lead to a syndrome that is 
clinically indistinguishable from schizophrenia - a similarity 
that extends beyond florid, acute features to some similar 
affective changes (Connell, 1956). The pharmacological effects 
of amphetamine include the release of Na and DA from nerve 
terminals and blocking of re-uptake. The principal action of 
amphetamine when administered to humans appears to be release of 
d a . The schizophrenic-like psychosis of amphetamine abuse is rapidly 
and effectively reversed by DA receptor blocking drugs (neuro­
leptics) (Angrist et al, 197^) and not by a or p adrenergic 
receptor blockers. Animal v/ork, which demonstrates a characteristic 
behavioural pattern with stereotypies and reduced social inter­
actions following amphetamine administration (Ridley et al, 1979)i 
also supports the contention that the main behavioural actions 
of amphetamine are DA mediated.
The second body of evidence in support of the Da over­
activity hypothesis of schizophrenia is the therapeutic specificity 
of neuroleptics in schizophrenia. It has been shown in several 
large well designed placebo controlled studies (NIMH Study Group, 
196^) that neuroleptics have a specific action in ameliorating 
typically schizophrenic features (e.g. delusions and hallucin­
ations) and in preventing their recrudesence (Hogarty et al,
1974) - an action which is not secondary to their sedative 
properties. It has been shown that there is a strong relation­
ship between the DA-blocking potency of neuroleptics and the 
therapeutic dose - a relationship which is not found with their
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anticholinergic and u-adrenoreceptor blocking potency (Creese 
et al, 1976) - and that isomeric forms of neuroleptics with no 
DA blocking potency are not clinically effective (Johnstone et 
al, 1978).
Thus it would appear that excessive DA release can induce 
a schizophrenic-like psychoses and that DA blockade can relieve 
schizophrenic symptoms. These observations lead to the study of 
DA receptors in schizophrenic brain. It has now been shown by 
several groups of workers that there is an increase in the 
numbers of DA receptors in the striatum (putamen, caudate and 
nucleus accumbens) of post mortem schizophrenics brain (Owen et 
al, 1978; Lee et al, 1978); DA metabolism in the pre-synaptic 
neurones (as judged by the ratio of DA to homovanillic acid (HVA)) 
is however unaffected (Owen et al, 1978). The main problem with 
these studies is that many of the patients had been treated with 
neuroleptics prior to death. It has been shown in animals that 
neuroleptic medication increases the numbers of striatal DA 
receptors (Muller and Seeman, 1978). There is however evidence 
that increases in DA receptors are found in some patients drug 
free for some time prior to death (Owen et al, 198I). Moreover 
the DA receptor increase in schizophrenic brain is confined to 
one particular type of DA receptor (the DA2 receptor - according 
to the classification of Kebabian and Caine, 1979) which is not 
elevated with chronic neuroleptic therapy in animals whereas 
the DAI receptor which remains elevated for some time after 
neuroleptic withdrawal is unaltered (Cross et al, I98I).
There is thus some pharmacological evidence to support the
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DA overactivity hypothesis of schizophrenia and a possibility 
that a pathophysiological basis underlying schizophrenia has 
been identified (increased post synaptic DA receptors). However 
some major weaknesses of the DA overactivity hypothesis have been 
revealed in the search for evidence of increased DA release or 
receptor supersensitivity in untreated schizophrenic patients.
CSF studies of HVA suggest that DA turnover is not increased 
either in acute or chronic schizophrenia (Bowers et al, 1974).
It has been established that schizophrenia and Parkinson's 
disease (in which there is DA depletion) can co-exist, and that 
one disease does not substantially modify the features of the 
other, which suggests that increased DA release is not necessary 
for schizophrenic symptoms (Crow et al, 1976). There are also 
some outstanding questions regarding the pharmacological evidence, 
It is uncertain whether neuroleptics act upon the entire range 
of symptoms of the disease - it seems probable that neuroleptics 
do not influence features of the defect state (for example the 
negative symptoms (affective flattening and poverty of speech) 
(Leteniendia and. Harris, I967)) and amphetamine administration 
appears to have little effect on chronic schizophrenic patients 
(Korn et sky, 1976).
There are two additional problems for the DA overactivity 
hypothesis of schizophrenia which have direct relevance to the 
present studies. Firstly it is clear that there is considerable 
heterogenity among the schizophrenic population in terms of 
clinical response to neuroleptics, clinical outcome, CAT scan 
abnormalities (see Section 1.3.4) and DA receptor numbers in
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post mortem studies. This raises the possibility of different 
pathophysiological processes underlying schizophrenia and 
emphasizes the need for measurable biological markers of disease. 
Secondly, prolactin (PEL) secretion from the anterior pituitary 
gland is normal in schizophrenia (Meltzer et al, 1974). It is 
well established that hypothalamic DA is inhibitory to PEL 
release and that PEL levels provide a sensitive index of DA 
blockade induced by neuroleptics. If the DA hypothesis is valid 
and if DA overactivity extends to the tubero-infundibular 
neurones (TIDA neurones see Section 2.1.2) then low PEL secretion 
would be anticipated in schizophrenia (Johnstone and Perrier,
1980 for review).
Evaluation of the neurohumeral hypothesis. An attempt to 
integrate the diverse findings concerning possible neurochemical 
abnormalities in schizophrenia is bound to fail at the present 
time. Too many questions concerning, for example, the validity 
of techniques for assessing monoamine turnover or the validity, 
of otherwise, of clinical distinctions such as acute or chronic, 
paranoid or non-paranoid, schizophrenia remain. At the present 
time, the DA hypothesis has some strengths - notably its ability 
to explain the two major pharmacological facts about schizophrenia 
that symptoms are ameliorated by neuroleptic drugs and mimicked 
or exacerbated by amphetamines - but some major weaknesses.
There is an established need for an index of central events that 
could be applied to all clinical varieties of schizophrenia, 
particularly the defect state where evidence of organicity is 
accumulating (see below).
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1.2.4 Disorders of the nervous system - pathological and 
structural changes in schizophrenic hrain
Por long it has been believed by many psychiatrists that 
schizophrenia is due to a disorder of the brain, but evidence 
for this has been a long time coming. There have been several 
isolated reports of schizophrenia in association with recognized 
CNS lesions (e.g. tumours etc) in diverse brain regions. Any 
association between cerebral disease and schizophrenics raises 
three questions: 1) whether the association occurs by co­
incidence 2) whether the cerebral disease merely makes manifest 
a latent tendency to schizophrenia or 3) whether schizophrenics 
are more prone than the rest of the population to develop 
cerebral disease.
Extensive studies have revaled several associations between 
cerebral disease and schizophrenia. Davison and Bagley (I969) 
came to the conclusion that the association between schizophrenia 
and cerebral tumour and injury was significantly greater than 
chance and that the association was with lesions in the temporal 
lobe. Slater et al (19Ô2) found that the mental disturbances 
associated with epilepsy had many similarities with schizophrenia. 
Several studies have indicated that it is damage to the limbic 
structures in the temporal lobe which link temporal lobe epilepsy 
and schizophrenia (Torrey and Peterson, 1974). Birth compli­
cations and neonatal injuries which are known to damage the 
temporal lobe are found with increased normal frequency in schizo­
phrenic patients. There are several circumstantial lines of 
evidence which raise the possibility of a viral aetiology of
30
schizophrenia and some evidence of schizophrenia-like psychoses 
in patients with temporal lobe encephalitis (Torrey and Petersen, 
1974). A virus like effect of schizophrenia CSF on cell 
culture has recently been demonstrated but subsequently found 
to be present in a variety of neurological illnesses (Crow et 
all 1979)- These studies are all suggestive of a pathological 
process in the brain, perhaps in the temporal lobe, in schizo­
phrenia. However several neuropathological studies have failed 
to demonstrate evidence of a consistent pathological change in 
schizophrenic brain. Some of these earlier studies lack 
properly designed control groups. More recent studies, which 
have examined controls, have only demonstrated patchy gliosis 
and reduced cell counts in some areas in some cases (Dorn, 1976; 
Stevens, I981).
The development of radiological proceedures over the last 
twenty years has however produced a number of consistent 
observations which have renewed interest in the search for a 
neuropathological basis of schizophrenia. Following the intro- 
dunction of pneumoencephalography, there have been a number of 
reports that schizophrenics have evidence of cerebral atrophy 
and enlarged ventricles. Some of the earlier studies lacked 
proper assessments and controls, but a summary of subsequent 
studies where an attempt has been made to overcome these difficulties 
is given in Table 1.2. Table 1.2 also includes details of some 
of the many recent studies on schizophrenic patients using compu­
terised axial tomography (CAT scans).
It has become clear that schizophrenics as a group have
TABLE 1.2
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Study Date Neuroradlo logicalProcedure Patients Studied Main f ind ings
Asano 1967 Pneumo­
encephalography
53 Schizophrenics D i la t io n  of to t,  
and 3rd v e n t r ic le s  
in 70% of cases
Hoi den 
et al
1973 Echoencephaiogrom 79 Schizophrenics 
79 Controls
D i la ta t io n  o f 
3ra v e n t r ic le  
associated w ith  
treatment resistance
Johnstone 
et al
1976 CAT 17 Chronic Schizophrenics 
compared w ith  contro ls  
uiiatched age and 
preinorbld occupation)
V e n tr ic le  size 
larger in pa t ien ts  
than contro ls  
(P<D.01)
Weinberger 
et Gl
1979 CAT 65 Schizophrenics 
56 Controls 
loge matched)
D i la ta t io n  of l o t .  
v e n t r ic le s  in 50% of 
coses associated w ith  
poor treatment response
ToKohashl 
et al
1981 CAT 169 Schizophrenics D i la ta t io n  of 3rd 
ana lo t . v e n t r ic le s  
associoted w ith  
"b lunted a f fe c t " .
Examples of studies investigating ventricle size in schizophrenia. 
Dilitation seen by each of the three different neuroradiologfcal 
methods.
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enlarged ventricles, although there is an overlap with the normal 
elderly population and with other diagnostic groups. Ventricular 
dilatation has been demonstrated in some young patients soon 
after the initial diagnosis, but in general the abnormality(ies) 
are found in patients who have been ill for many years. Table
1.2 also indicates some of the clinical associations of ventricular 
dilatation that have emerged in these various studies. Overall 
there is an association between ventricular dilatation and 
intellectual impairment, poor pre-morbid adjustment, resistance 
to therapy, poor outcome and perhaps negative symptoms - 
features which correspond with the defect state. There is no 
evidence, surveying these papers together, that there is a 
relationship between ventricular dilatation and florid ('positive') 
symptoms of schizophrenia such as delusions and hallucinations.
Thus it appears there is good evidence that a subgroup of 
schizophrenic patients have structural brain disease. The size 
of this subgroup, the clinical significance of the cerebral 
changes and the fundamental cause of them however remains to be 
determined.
Table 1.2 also indicates those studies were the size of 
the 3rd ventricle has been measured. Three studies, each using 
a different technique, have demonstrated enlargement of this 
ventricle. The patients in whom this was found fall into the 
same category as those described above i.e. those with evidence 
of deterioration. The hypothalamus surrounds the third ventricle 
and is a principle endocrine and autonomic control centre. The 
possible relevance of dilatation of the 3rd ventricle in
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schizophrenia and endocrine abnormalities in schizophrenia is 
discussed below.
1.2.5 Endocrine disorders in and their relationship with 
schizophrenia
The idea that mental disorders and endocrine diseases may 
be related has its origins in antiquity. In more recent times 
Kraepelin (1919) postulated that dementia praecox was basically 
an endocrine disorder and Freud observed that disorders, which 
he was seeking to understand by psychological means, would 
eventually be treated with hormones. The reasons behind this 
hypothesis are that 1) schizophrenia is occasionally associated 
with endocrine events (e.g. puberty,^ the puerperium, menstruation 
and the menopause) and 2) schizophrenia or schizophrenic-like 
illnesses are occasionally seen in patients with established 
endocrine disease (e.g. Cushing's syndrome, hypothyroidism etc.).
A critical review of these associations however leads to a 
less positive conclusion than that of Kraepelin cited above. 
Although the onset schizophrenia is very rare prior to puberty, 
several well documented cases have been described. A few such 
cases were seen in the population from which the patients studied 
here were drawn (Owens and Johnstone, I98O). Furthermore there 
is no known relationship between the age of onset of puberty 
and the, age of onset of schizophrenia.
Schizophrenia occasionally develops in the puerperal 
period. The clinical distinction between puerperal schizophrenia 
and other psychotic illneses developing in this period is however 
often problematical. The association between the development
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of schizophrenia and the puerperium may be casual rather than 
causal in some cases and the relationship of puerperal schizophrenia 
to non-puerperal schizophrenia in terms of prognosis remains to 
be clarified.
While changes in mood associated with menstruation and the 
menopause occur in many females, reports of an increased 
incidence of schizophrenia at these times are unreliable.
Periodic psychoses associated with menstruation has been 
described (Endo et al, 1978) but an examination of the clinical 
data does not support the contention that these psychiatric 
episodes are schizophrenic. There is no direct epidemiological 
evidence to link the menopause or disorders of the menopause 
with schizophrenia.
While there is no doubt that psychological symptoms such 
as apathy, irritability and anxiety are common in established 
endocrine disease (e.g. Addison's disease, thyrotoxicosis), the 
incidence of psychotic illness is much less. The illnes;^ in 
which psychoses are most commonly seen are Cushings syndrome 
where the incidence is about 20% and hypothyroidism where the 
incidence in severe cases is about 10%. Treatment with high 
doses of steroids leads to a psychotic illness in about 5% of 
cases (Michael and Gibbons, I963). Although the symptoms of 
these psychotic episodes are occasionally typically schizophrenic 
(catatonia and first rank symptoms have been reported) more 
usually the psychoses have a strong affective and/or confusional 
component. Treatment (with adrenalectomy and thyroxine respec­
tively) is almost invariably curative.
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The observations of the clinical associations of schizo­
phrenia with steroid excess and thyroid hormone deficiency 
prompted a series of investigations into the levels of these 
hormones in schizophrenia. Reports of steroid excess or 
deficiency in schizophrenia on indirect measures were made 
originally but direct measurements of plasma corticosteroids 
revealed no consistent abnormalities (Michael and Gibbons, 1963) 
particularly in "chronic affectless schizophrenics" (Bliss et 
al, 1955). Similarly uptalee of radioiodine, protein bound 
iodine (Michael and Gibbons, I963) and thyroxine (Kline et al, 
1968) have all consistently been found to be in the normal range 
in acute and chronic schizophrenics.
Thus the investigation of the many clinical associations 
between schizophrenia and endocrine disease has failed to 
provide an adequate pathophysiological basis for schizophrenia. 
However these associations are still of great theoretical 
interest and further investigation of cases of endocrine disorder 
in which schizophrenia develops may yet throw light on the 
aetiology of schizophrenia in {general. One possibility raised 
by these clinical associations is that schizophrenia is a common 
end point of various pathological processes. This idea will be 
discussed further in chapter 8,
Another aetiological hypothesis of schizophrenia that has 
been put forward is that disorders of the hormones or the organs 
involved in reproduction may be responsible for schizophrenia. 
This hypothesis will now be examined in depth. The evidence for 
an abnormality of gonadal function is first presented followed
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by a critical analysis of this hypotheses.
1. Pathological studies
Kraepelin (1919) first postulated that dementia praecox 
(schizophrenia) realted to disease of the endocrine glands, 
especially the gonads. He suggested that toxins from the sex 
glands were the probable cause of the mental disease. This 
idea was taken up by Sir F. Rott (1919) who carried out a large 
series of post-mortems at the Maudsley Hospital on cases of 
dementia praecox. He described profound degeneration and 
fibrous change in the gonads of these patients. He found that 
the longer the illness the greater the degree of degeneration, 
although he also described profound changes in material from 
patients with acute illnesses. He was adamant that chronic 
diseases (such as tuberculosis) were not the cause of the 
findings. Rott held that these changes were a result of 
suppression of the libido in adolescence.
These observations were partially confirmed in subsequent 
studies. Lewis and Davis (1921) studied l40 cases of dementia 
praecox and 4^0 controls and concluded that gonadal atrophy was 
much more common in schizophrenia. Morse (1923) agreed with this 
conclusion but felt that the frequency of gonadal pathology had 
been overestimated. He also felt that there was no relation­
ship between the pathological findings and "psychic state". 
McCartney (1929) reported fibrosis, degeneration and sclerosis 
of the interstitial components of the tests in post-mortems from 
158 schizophrenics but reported that spermatogenis was not 
significantly altered from that found in 260 controls. McCartney
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felt that he had accrued enough evidence to state that "dementia 
praecox is primarily an endocrinopathy in which the gonads are 
consistently degenerated and hypo-functioning". McCartney found 
that toxaemias of various types, notably tuberculosis, were more 
common in the schizophrenic population but felt that this was 
not the cause of the high frequency of pathological changes in 
the testes of the schizophrenics- Pathological abnormalities 
were found by Hemphill et al (1944) in a study of testicular 
biopsies from 90 schizophrenics. In distinction to the findings 
of McCartney (1929) but not those of Mott (1919) they found 
degeneration of the semeniferons tubicles and a failure of 
spermatogenesis but no abnormalities of the interstitial compo­
nents of the testes.
The most recent pathological study of the testes in 
schizophrenia was performed by Blair et al (1952) who examined 
testicular biopsies from l4 schizophrenic patients. No consistent 
pathological abnormality was detected in any of these patients.
These authors attributed all the findings of the previous studies 
to the effect of the high frequency of diseases such as tuberculosis 
in schizophrenic subjects and to the effects of the poor diet of 
inmates of mental hospitals. As has been pointed out above 
these possibilities were considered by earlier authors and 
refuted by studying controls from the same institution as the 
schizophrenics and by looking specifically for the (then well 
recognized) changes of tuberculosis. Another problem with the 
Blair et al (1952) study (which is now considered as the 
definitive study) is that the patients had been ill for a
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relatively short time ( 3 - 7  yrs) while the previous studies had 
indicated that abnormalities were particularly found in patients 
who had been ill for many years.
Thus there does appear to be at least some evidence for 
pathological abnormalities in the gonads of schizophrenics and 
an indication that the pathophysiological basis for these 
abnormalities should be sought. These pathological studies are 
particularly relevant in view of the fact that all of them 
antedate widespread neuroleptic drug therapy for schizophrenia.
2. Studies of the fertility of schizophrenics
It is well recognized that the fertility of schizophrenics 
as a group is reduced (Stevens, I969)- Most investigators do 
not consider the possibility that this may be accounted for by 
a pathological process and search for the underlying sociological 
and psychological reasons. It is established that schizophrenics 
marry less frequently, that many schizophrenics have difficulty 
with psychosexual adaptation, that regular sexual intercouse 
with a partner of the opposite sex is often not established, 
that the rate of marriage breakdown where one or both partners 
are schizophrenics is high and that there is frequently physical 
separation due to hospital admission. In addition patients with 
schizophrenia frequently experience such problems as anxiety, 
depression, social uncertainity, withdrawal, apathy and not 
infrequently, sexual delusions which hinder the establishment of 
a normal sexlife.
Thus it is not difficult to see why investigators have 
concentrated on sociological and psychological reasons for the
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reduced fertility of schizophrenia. Nevertheless since fertility 
is also reduced when a schizophrenic patient's marriage is well 
established (Stevens, I969) it is plausible that reduced 
fertility is in part due to inadequate sperm or ova production 
in schizophrenia. Unfortunately there is no reliable evidence 
to answer this question at present (see next section).
3 Studies of sexual function and development in schizo­
phrenia
a) Males. There are considerable difficulties in 
assessing degrees of sexual dysfunction which are even more 
profound when studying schizophrenic patients. It is not known 
whether abnormalities of puberty, libido, potency or ejaculation 
occur in male schizophrenics. One study of sperm production has 
been made in schizophrenia with conflicting results (Kline et 
al, 1968) and the normality or otherwise of spermatogenesis 
from pathological studies is disputed (see above).
It appears that the development of secondary male sexual 
characteristics such as scrotal development, beard hair, voice 
change is within normal limits in schizophrenia. Part of normal 
male sexual development is the development of the male body 
habitus. This is characterised by the development of broad 
shoulders and narrow hips. An index of male physique can be 
made by measuring the biacromial and bi-iliac diameter. Using 
this index - the discriminant-androgyny score (Tanner, 1931) - 
several groups of workers have reported significantly lower, 
that is more feminine, scores in groups of patients suffering 
from schizophrenia - although the frequency of abnormality varies
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from about 73% (Bey and Goppen, 1939) to 20% (Brooksbank et al, 
1970) of the patients studied. Thus there is at least some 
evidence to suggest failure of secondary sexual development in 
schizophrenic patients.
b) Females- The general comments regarding the diffi­
culties of assessing sexual function in male schizophrenic 
patients apply equally to female schizophrenic patients. It is 
well recognized that menstrual disorders are common in schizo­
phrenic patients. The exact frequency of menstrual disorders 
in schizophrenia is unknown and the relationship of these 
disorders to schizophrenic symptoms, relapses and remissions 
and hospitalisation and to the reduced fertility of schizophrenia 
is also uncertain. In a series of studies Gimes et al (1969) 
and Ripley et al (l94l) examined cervical and vaginal smears from 
a large number of female psychiatric patients and demonstrated 
that in schizophrenia the frequency of amenorrhoea or oligo- 
menorrhoea was 73^ and that in these subjects there was a 
hypofollicular cytological picture compatible with ovarian 
dysfunction and failure of ovulation. In general, both these 
groups of workers found that the more severe the psychoses the ■ 
more marked the evidence of ovulatory failure. In some cases 
there was a reversal of the abnormal cytological pattern on 
clinical remission though the statistical basis of this obser­
vation is open to doubt. Gimes et al (I969) felt that they had 
uncovered clear evidence of "disturbed hypothalamic neural 
regulation" in schizophrenia.
However the precise significance of these findings is
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uncertain. It is anecdotally and scientifically recognized that 
menstrual irregularities are common following many situations 
(for example life events, severe stresses, neuroses and depression). 
There is convincing evidence of stress related hypothalamic 
dysfunction (Quigley et al, I980). Thus it is unclear to what 
extent evidence of menstrual disorders, ovulatory failure and possible 
hypothalamic dysfunction in schizophrenia represents a non­
specific reaction to psychic phenomena, changes in environment 
etc and to what extent they may be a pathophysiological conse­
quence of the disease process of schizophrenia.
4. Hormonal studies in schizophrenia
Over the last thirty years there has been a large increase 
in knowledge about normal endocrinological control. The 
development of radio-immunoassay (RIA) (Berson and Yallow, I967) 
in the late sixties has lead to sensitive and specific assays 
for the hormones involved in reproduction. Further technical 
developments have lead to the elucidation of the complex factors 
involved in the process of reproduction. This topic will be 
fully developed in the next chapter. In this section the argu­
ment that hormonal imbalance may be an aetiological factor in the 
development of schizophrenia is continued and an outline of the 
outstanding reproductive hormonal abnormalities in schizophrenia 
is given below.
Hoskins and Pincus (1949) investigated the secretion of 
the gonadol steroids, androgens, oestrogens and of the 17 keto- 
steroids, in the urine and blood of 29 schizophrenic men as 
part of a series of endocrine investigations in schizophrenia
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carried out at the Worcester State Mental Hospital, Massachusettes, 
USA. They found that the schizophrenic men differed from normal 
controls in three measures:- a) an elevated total oestrogen 
output, b) a lower androgen output and c) a lower androgen/ 
oestrogen ratio which tended towards female levels. They also 
reported that there was a subgroup of patients with markedly 
reduced androgen/oestrogen : these patients were said to be
much less aggressive than the remainder of the patients.
Similar findings were reported by Sands (1937% Although clinical 
information is scanty in his essentially descriptive study, 
he appeared to find reduced androsterone secretion in schizo­
phrenia and a very variable pattern of 17-oxosteroid secretion.
In 1964 Brooksbank and Pryse-Phillips reported that the mean 
excretion rate of 3 a-hydroxy-androst-l6-ene in 33 schizophrenic 
patients was markedly lower than that of healthy men and other 
psychiatric patients- However in a subsequent study Brooksbank 
et al (1970) were unable to confirm this finding although they 
did demonstrate a subgroup of the patients with extremely low 
levels of this hormone and low levels of urinary testosterone.
With the development of increasing knowledge of normal 
endocrine control attention has moved from gonadal steroid 
secretion to pituitary hormone secretion in schizophrenia. The 
first such investigation was carried out by Shader et al C1968). 
These workers measured the urinary secretion of follicle- 
stimulating hormone (FSH) by a bioassay in 10 male unmedicated 
chronic schizophrenics. There was a marked reduction in urinary 
FSH in 4 of these patients and it was found that these patients
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had been ill for longer than those with normal FSH secretion and 
that they also had a younger age of onset of schizophrenia. In 
addition FSH levels were significantly related to the mental 
state of the patients: urinary FSH was negatively associated
with increased psychopathology.
The development of EIA made the assessment of pituitary 
hormone secretion much more direct. In 1974 Dr. Brambilla and 
her collaborators reported that the secretion of FSH, lutein­
izing hormone (LH) and testosterone were reduced in a group of 
20 schizophrenic patients compared to age-matched controls. The 
patients were described as suffering from chronic hebephrenic 
schizophrenia of 'puberty onset*. The study was performed after 
neuroleptic therapy had been withdrawn. The reductions in FSH, 
LH and testosterone were marked (50%, 20% and l6% of control 
values respectively) and each hormone was significantly reduced 
at the p < 0.001 level. The hormonal pattern reported did not 
conform to any recognized endocrine disorder and suggested a 
hypothalamic-pituitary deficiency in schizophrenia.
This study was followed comprehensively by Dr. Brambilla 
in three separate but overlapping studies:
1) Brambilla et al, 1975- This investigation concerned 
the effects of neuroleptics on the reduced secretion of LH, -FSH 
and testosterone in schizophrenic patients. They reported that 
the re-introduction of neuroleptic therapy (haloperidol 6 mg/ 
day i.m.) was associated with the return of all three hormones 
to the normal range. This result is important for two reasons:- 
a) it is evidence against prior administration of neuroleptics
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as the cause of the original findings and b) it raises the 
possibility of a connection between schizophrenia, dopaminergic 
neurotransmission in hypothalamic-pituitary axis and hormonal 
abnormalities.
2) Brambilla et al (1976). In this paper it was reported 
that the FSH and LH responses to synthetic luteinizing hormone 
releasing hormone (LHRH) were enhanced compared to control values. 
This response was held to be similar to that observed by Roth
et al (1972) in children undergoing sexual maturation and to 
patients with the sexual immaturity syndrome. This pattern of 
hormonal response to LHRH in chronic schizophrenics was different 
from that found in patients with hypogonadotrophic hypogonadism 
(Roth et al, 1972) (also known as idiopathic gonadotrophin 
deficiency : IGD) and this distinction was amplified in:-
3) Brambilla et al (1977)* This paper reported the results 
of the administration of clomiphene citrate (a non-steroidal 
oestrogen analogue which blocks oestrogen and androgen-sensitive 
receptors in the hypothalamus and abolishes their inhibition of 
gonadotrophin release) to a group of chronic schizophrenic 
patients. The patients showed a normal increase of FSH level 
during clomiphene administration but with markedly blunting of the 
LH and testosterone response. This pattern of hormonal response 
to clomiphene is also different from that of IGD patients and 
resembles more closely those patients with defects in sperraato- 
genisis.
In conclusion these primary papers of Brambilla and co- 
workers indicate a) reduced reproductive hormonal secretion in
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chronic schizophrenia b) which can be reversed by neuroleptic 
drugs and c) that FSH and LH respond to dynamic tests of their 
secretion in different ways and d) that there are important 
differences between the hypogonadism of schizophrenia and that 
of IGD patients. There are two main objections to these studies :-
1) the patients studied were all of one unusual clinical type 
(chronic hebephrenic schizophrenic patients with a very early 
age of onset) and 2) the patients when studied had only recently 
(1 - 3 weeks) been withdrawn from neuroleptic drugs. These 
objections lead to a study by Johnstone et al (1977) who reported on 
LH and FSH secretion in a group of chronic schizophrenic patients 
who had never received neuroleptic drugs. This study confirmed 
the finding of low LH and FSH secretion in chronic schizophrenics 
although it was found that abnormalities were only detected in a 
proportion of the patients. Interestingly, this work confirmed 
Shader et al's (I968) observation of decreasing FSH with increas­
ing schizophrenic symptomatology and found a significant inverse 
relationship between delusions and FSH secretion.
Evaluation of studies on a hormonal aetiology of schizophrenia 
As discussed at the beginning of the previous section 
there are some clinical observations which indicate a relation­
ship between hormonal events (e.g. puberty, puerperium, menstru­
ation) and schizophrenia. It is now accepted that there is 
little evidence that abnormalities of thyroid function or 
adrenal secretion are present in schizophrenia or are in any 
way related to the schizophrenic process. There is however 
evidence that abnormalities of the hypothalamic-pituitary-gonadal
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axis are present in schizophrenia which can be summarised as 
follows:-
1) pathological abnormalities in the gonads have been 
detected by several groups of workers.
2) fertility is reduced in schizophrenia to an extent 
which probably cannot be completely accounted for by sociological 
causes.
5) there is some evidence of incomplete and inadequate 
sexual development and function in schizophrenia and
4) evidence of disordered pituitary-gonadal secretion in 
schizophrenia has been reported.
There are however two main drawbacks to the hypothesis 
that an abnormality of reproductive hormones is an aetiological 
factor in schizophrenia. Firstly schizophrenic symptoms are 
not found with any regularity in -any of the well-recognized 
conditions associated with reproductive hormone abnormalities.
It is known that schizophrenic symptoms are not increased in 
frequency in conditions such as testicular or ovarian failure, 
gonadal dysgenesis, hypopituitorism etc. Furthermore there is 
no evidence of schizophrenic features in Kalman's syndrome which 
is characterised by congenital failure of gonadotrophin secretion. 
The only dissenting voice to the above statements is that of 
McCartney (1928) who described a "typical schizophrenic affect" 
in 24 male eunchs who had been castrated on the orders of the 
Emperor of China. Since these individuals were also subjugated 
to the Imperial Court of China in the feudal times of China in 
1928 and since the actual symptoms described appear mild and
4 7
non-specific it would appear that the symptoms described could 
be accounted for by the "environmental viscissLtudes" of these 
subjects lives (Hoskins, 1943).
Thus it appears unlikely that gonadotrophin and/or gonadal 
steroid abnormalities can lead to the full range of symptoms 
seen in schizophrenia although it does remain feasible that in 
schizophrenia there is a particular pattern of abnormality 
developing at a particular time which is contributory to the 
development of schizophrenia.
The second reason why it is unlikely that reproductive 
hormones are causative, or even contributory, to the disease 
state of schizophrenia is the failure of replacement therapy 
to ameliorate schizophrenic symptomatology. There have been 
various studies of replacement therapy in schizophrenia which 
are outlined in Table 1.3. The design of these studies is 
somewhat haphazard but generally there was little evidence of a 
sustained clinical response to replacement therapy. The 
occasional dramatic response to sex hormone replacement reported 
in these studies no doubt reflects the tendency for a clinical 
response to any dramatic intervention in this condition. A 
caveat to this evidence against a hormonal aetiology of schizo­
phrenia is that it is ccnceivable that replacement therapy was 
administered unphysiologically leading to a negative therapeutic 
response. For example it is known that for LHRH to be clinically 
effective, it needs to be administered in a pulsatile fashion 
(section 2.1.3)- Continuous or high dose therapy can produce 
the opposite of the predicted effect.
TABLE 1.3
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Investigators Replacement therapy Clinical details
Rosenzwelg and 
Freeman (1942)
25 mg testosterone propionate 
and 300 units of "gonadotrophin"
20 chronic schizophrenics In double blind 
placebo study. Clinical improvement in 5 
out ot 10 patients (more psychomotor activity) 
3 patients made worse. Greater sexual 
interest in patients on active medication
Hemphill and 
Reiss (1945)
Gonadotrophin releasing hormone 
1000 U/day
22 chronic schizophrenics studied (open) 
4 Recovered 8 No change 
6 1 mproved 4 Worse
Bullmore and 
Coppen (1965)
Human chorionic gonadotrophin 
(HCG) 1500 U/day
3 adolescent schizophrenics (open) 
Clinical response not favourable
Brambilla et al 
(1974)
HOG
10,000 U/week
12 subacute schizophrenics (semi-blind) 
Apathy and affective response improved 
Synergistic with haloperidol
Summary of available studies on clinical effects reproductive hormone 
replacement in schizophrenics. There are some suggestions of a 
clinical response particularly in the symptoms of the defect state 
(see text for further comment).
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1,3 Summary
1.3 In summary the aetiology of schizophrenia remains obscure. 
There are important indications that dopamine transmission may 
be enhanced perhaps in the context of structural CNS changes and 
there is some evidence of hypogonadism. This leads to the next 
section in which the relevance of studying pituitary hormone 
secretion in psychiatric disease as a method of evaluating 
central processes (particularly neurotransmitter function) is 
evaluated.
_aHâPTER 2
Neuroendocrinology: an outline of current knowledge with special
reference to its application to psychiatric illness
Neuroendocrinology is the area of research in which close 
attention is paid to the secretion of hormones from the central 
nervoims system and their effects on the brain itself and on the 
rest of the body. There are two main areas of interest 1) The 
hypothalamo-pituitary axis and 2) The pineal gland.
Studies of pineal function in schizophrenia have been 
carried out by the author but are not further described in this 
thesis, because of constraints of space. A paper is attached 
(Ferrier et al, I9S2) which reviews this area of research and 
its implications.
2.1 The hypothalamo-pituitary axis (HPA)
2.1.1 Historical aspects
Early in the twentieth century clinicians recognised that 
disease of the hypothalamus and the pituitary were related 
following the demonstration that gonadal deficiency could be 
produced by hypothalamic lesions which spared the pituitary.
It was, however, not until the 1950s that Harris and co-workers 
(1952) in a series of elegant experiments clarified the 
relationship between the hypothalamus and the pituitary. They 
demonstrated that transection of the stalk between the hypo­
thalamus and the pituitary caused a loss of sexual function in 
rats which was restored if blood vessels regenerated in this 
area, but not if this was prevented, and that the blood flow in
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these vessels was from hypothalamus to the pituitary (Harris and 
Jacobsohn, 1952)* Subsequently Halzaszand Knigge independently 
confirmed that there is a region of the basal hypothalamus that 
contains trophic substances capable of maintaining the secretory 
function of the pituitary and the term hypophysiotrophic area 
was applied to this region. In the late sixties and early 
seventies a number of these hormones - the hypophysiotrophic 
hormones or releasing hormones - ware identified and charac­
terised principally by Schally, Guillemin and co-workers (Schally 
et al, 1973; Guillemin et al, 1971) (Table 2.1).
2.1.2 Anatomy of hypothalamo-pituitary axis
A schematic representation of the anatomy of this system 
is shown in Fig 2.1.
Hypothalamus
The hypothalamus can be divided into the medial and lateral 
portions. The medial hypothalamus contains the bulk of neuronal 
cell bodies controlling pituitary function, as well as important 
receptors of visceral function; whereas the lateral hypothalamus 
is part of a multineuronal, multisynaptic system connecting the 
limbic forebrain with the mesencephalon. The hypothalamus 
contains many nuclei which can be divided into three groups - 
periventricular, medial and lateral but whose detailed description 
is beyond the scope of this work. Based on the pituitary micro­
implantation studies it appears that the cell bodies of origin 
of the releasing hormones lie in a cresentic zone at the base of 
the 3rd ventricle and extend into the medial basal hypothalamus,
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Schematic representation of the hypothalamo-pituitary axis showing 
interplay of central, peptidergic and monoaminergic influences at 
the hypothalamic level. Putative systems of feedback control are 
also demonstrated (see text for further details)
particularly the large and important arcuate nucleus. From this 
area neurones form the tuberohypophysial tract which sweeps round 
the 3rd ventricle and enters the median eminence. This is a 
highly vascular area that makes up the contact between the end­
ings of the hypophysial-portal circulation. This area is 
characterised histologically by empydemal cells, capillary
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structures and interstitial spaces. It is known that this area 
has a poorly developed blood-brain barrier.
Monoaminergic innervation of hypophysiotrophic neurones
The biogenic amines (in particular noradrenaline (NA), 
dopamine (DA) and serotonin (5-HT)) play a crucial role in 
modulating the secretion of the anterior pituitary trophic 
hormones, although they do not act directly on the pituitary 
itself (Fuxe and Hokfelt, I969). The major pathways of hypo­
thalamic innervation are outlined in Fig 2.1. NA neurones arise 
principally in the locus coeruleus and caudal medulla and 
ascend in the medial forebrain bundle to innervate many 
structures including several separate hypothalamic nuclei and 
the median emminence. 3-HT neurones innervate the hypothalamuc 
(particularly the supracharismatic nucleus) and originate in the 
raphe nuclei of the pons and mesencephalon. It has been shown 
by lesion experiments that 3HT and NA innervation of the hypo­
thalamus is almost exclusively derived from these extrinsic 
pathways. On the other hand it would appear that the DA 
innervation of the hypothalamus is largely intrinsic. The 
neuronal cell bodies of the hypothalamic DA system - (the tubero- 
infundibular DA (TIDA) neurones) - are principally located 
in the arcuate nucleus and their processes end directly in the 
median emminence. There may be some extrinsic DA innervation 
of the hypothalamus via the incerto-hypothalamic tract 
(Bjorklund, 1975).
Connections with other CNS structures
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It is known that there are functional and anatomical 
connections between the hypothalamus and the limbic system 
(amygdala and hippocampus - via the medial forebrain bundle), 
the retina (via the direct retinocharismatic tract), the septum, 
the cortex, the midbrain, the reticular formation, the peri­
aqueductal gray substance of the midbrain and the pineal. The 
details of the anatomy of these connections are not germane to 
the current studies but there are some important functional 
aspects which will be discussed below.
Pituitary hypophysial-portal capillaries
This mesh of capillaries transports hypophysiotrophic 
hormones from the hypothalamus to the pituitary and are thus 
crucial to the control of the ilPA. CSF communication also 
exists between pituitary and hypothalamus and contributes, to 
an uncertain degree, to this control. It is believed that the 
flow of CSF is retrograde.
Pituitary
The pituitary gland is divided into three main parts ,
the anterior and the posterior pituitary and the intermediate
lobe. The main hormone secreting portion of the anterior
pituitary (adenohypophysis) is the pars distalis and this is the
primary source of the six well known pituitary hormones (see
Table 2.1). Older classifications of cell types in the ade.no-
hypophysis are now obsolete and it is known that many different
cell types co-exist in the pituitary. There are also important
receptors on the pituitary and their significance is alluded to 
below.
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2.1.3 Physiology of the hypothalamo-pituitary axis
The control of pituitary hormone secretion is complex. An 
outline of the factors which control each pituitary hormone is 
given in Table 2.1 and. is detailed for each individual hormone 
below,
1) Luteinizing hormone (Id). Secretion of LIIRH by hypothalamic 
LHRH-peptidergic neurones constitutes the final common pathway 
of control of LH secretion and LHRH is involved in the many 
aspects of LH regulation. LH levels vary markedly with the age 
and maturity of the individual for example large changes in LH 
secretion are seen at puberty, during the menstrual cycle and 
at the menopause. Feedback from gonadal steroids (Fig 2.2) is 
a very important modulator of these changes in LH secretion but 
it is also recognized that influences from higher centres play an 
important role.
Under basal conditions in both men and women, pituitary 
secretion of LH is episodic (Boyar et al, 1972). The frequency 
of these episodes of secretion of LH varies from 12 to 24 per 
day and each is followed by a gradual decline to baseline compa­
tible with the half-life of LH (Santen and Bardin, 1973). It 
would appear that these episodes of LH secretion are prompted by 
a bolus of secretion of LHRH from the hypothalamus and this is 
supported by the finding of rapidly changing LHRH levels in the 
peripheral blood synchronous with the changes in LH (Martin et al, 
1977). Pituitary responsiveness to LHRH is maintained only to 
pulsatile LHRH administration and is lost to continuous LHRH 
exposure (Jacobsen et al, 19&0). There is no diurnal rhythm of
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FIG 2.2
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Schema Lie diagram of gonadotrophin control syatoni in 
men, showing interactions of neural and hormonal feedback 
controls. Secretion of testosterone by the testis is 
stimulated by LH: maturation and growth of the tubule by 
FSH, A newly discovered peptide secretion of the testis, 
"inhibin" is believed to bo secreted by tubular epithelium 
and to exert a direct inhibitory effect on FSH secretion. 
It is not known whether inhibin affects the hypothalamus 
directly.
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level. The most important hypothalamic nuclei in maintaining 
basal and pulsatile LH secretion is the supracharismatic nucleus 
which receives inputs from many sources notably the retina and 
brain stem. There is much less certainty about the function of 
the LHRH containing neurones in the remainder of the hypothalamus 
and in extra-hypothalamic areas which have been described in 
recent immunohistochemical studies in animals and man (Barry et 
al, 1977). The main LHRH containing fibres in the CNS are in 
the septum, anterior hypothalamus, midline perventricular 
structures and in the brain stem. It has been suggested that 
these peripheral LHRH pathways may mediate some of the behavioural 
effects of LlHHi administration (such as mating behaviour) but 
this is not supported by direct evidence. Indeed the impor­
tance of afferent pathways (including monoamine containing 
neurones) entering the hypothalamus in the regulation of LH 
secretion is uncertain in humans. In the rat, lesions which 
isolate the hypothalamus disturb episodic LH secretion and the 
LH surge whereas in the rhesus monkey, both the tonic and epi­
sodic LH secretory mechanisms appear to be localized within the 
medial basal hypothalamus (Martin et al, 1977).
There is considerable evidence in experimental animals that 
the LHRH hypophysiotrophic neurones are regulated by biogenic 
amines although the precise details of this regulation are still 
unclear and a matter of controversy. A summary of the better 
recognized influences is given in Table 2.1. It has been demon­
strated by immunohistochemical co-localization studies that 
there is a close relationship between LHRH containing neurones
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TABLE 2.1
liLui-y Hypothalamic Helcaginf.^ 
Hormone Physiological Stimuli
Role of putative neurotx’ansmittero
Da Na 5HT Others
Attln Prolactin inhibitlnij 
factor, P.IF
? Prolactin releasing 
factor/?TRH
Suckling +V0
Stress +ve Sleep +ve
Pregnancyrve
P
opiates + ve 
7 ACH
;th
DOAd
Growth hormone release 
inhibiting factor 
( roraatostutin) 
growth hormone releasing 
factor
Stress +V0 
Sleep +VG
Glucosef* -ve
opiates + ve 
GAbA - ve
I Cox'ticotrophic 
releasing factor 
CCEF)
Sleep + ve 
Stress + ve 
Cortisol t- ve - ve (?) "
opiates - ve
JjUleiniuing hoi-nione 
releasing hoi'inone 
(LHRH)
? LHRH
Puberty + ve 
Tostos torone/oeB t ro- 
gen - ve
Monojiause+ ve
- ve (?) + ve(?) - vc(?) opiates -ve 
-ve ACH
Thyrotropin
releasing hormone (TRH) 
(somatostatin -ve
Cold +ve Cortisolf-ve 
+ve Stress Oestrogon+ve 
-ve
- ve oj.i ates - ve
ACll = Acetylcholine 
Du = Dopamine 
Ka = Horaclroauline 
^HT- 5 iiydroxyLryftumine
Control of anterior pituitary hormone secretion.
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and DA containing neurones in the median emminence (McNeil and 
Slalek, 1980). It would appear that DA can stimulate LHRH 
release from hypothalamic fragments in vitro. However subse­
quent studies have revealed that this is a complex phenomenon 
and that DA also plays a role in the degradation of LHRH in 
vitro (Marcanno de Cotte, 1980), The results of in vivo 
experiments of the role of DA on LH secretion yield similar 
conflicting results.
Pharmacological studies (McCann et al, 197?) demonstrated 
that DA directly injected into the ventricles causes release 
of LH. However the immunofluorescence studies of Fuxe et al 
(1969) revealed that DA levels in the hypothalamus and IH 
secretion vary inversely in such a way that these authors pro­
posed an inhibitory role for DA in IH (and by extrapolation)
LHRH secretion. The role of NA on LH secretion is probably 
facilitatory. Fuxe and co-workers (1969) noted increased turn­
over of NA at the time of ovulation and increased LH secretion. 
Blockade of NA synthesis leads to reduced LH secretion in 
response to a variety of stimuli (see Muller et al, 1977 for 
review).
A similar situation holds for the role of on LH 
secretion. Destruction of the raphe nuclei in the rat produces 
a striking reduction in pituitary LH secretion which has been 
shown to relate to changes in the hHT content of the hypothalamus 
(Wuttke et al, 1979).
The role of biogenic amines in LH secretion in man is 
uncertain. Direct experiments such as outlined above of course
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cannot be performed in man and accordingly evidence for the role 
of neurotransmitters in anterior pituitary hormone secretion 
(APHS) must rest on observations made in pharmacological studies 
which are outlined in the following section (2.1.4).
2) Follicle-stimulating hormone (FSH). There is much less 
known about the physiology of FSH secretion than that of LH
secretion. It is not even certain if there is a separate FSH
releasing factor. It is clear that under most circumstances there 
is a clear and close relationship between FSH and LH secretion 
implying a common releasing factor but there are also some 
striking discontinuities. The biochemical evidence for a 
separate releasing factor, though not extensive (Kastim et al, 
1972)1 is outside the scope of this work.
The secretion of FSH shows a similar episodic pattern of
secretion as LH although the size and frequency of epsidoes is 
much reduced and therefore more difficult to study. In gneral 
most workers find a delayed episode of FSH secretion following 
a I-iH secretory burst.
The role of biogenic amines in influencing FSH secretion 
appears to be minimal. In general, most of the effects of DA,
NA and 9^'IT neurotransmitters which have been described above for 
LH also apply to FSH but the effects are weak and often not 
statistically significant. Feedback effects from gonadal steroids 
are of much greater importance and are outlined in Table 2.1
3 ) Prolactin (PEL). It is known that many stimuli influence 
PPL secretion (Table 2.1). Although many neural stimuli can 
induce PPL release, secretion is tonically inhibited by the
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hypothalamus. Thus PRL secretion is increased by any process 
that interferes with hypothalamic-pituitary continuity. This 
means that the incubated pituitary releases large quantities 
of PEL in vitro. This has allowed considerable research into 
PEL secretion at the pituitary membrane level.
Prolactin-inhibiting factors (PIF) has been isolated 
from hypothalamic extracts and in pituitary-portal blood but 
the chemical nature of PIF is not known. DA has a direct 
inhibitory effect on PEL release in vitro, DA has been detected 
in pituitary-portal vessels (Ben-Jonathan et al, 1977) and in 
inhibitory hypothalamic fragments (in which inhibition is 
abolished by elimination of catecholamines) (McLeod et al,
1974). All these observations, combined with the presence of a 
high concentration of stereo-specific DA receptors in the 
pituitary but not in the hypothalamus (Brown et al, 1976), have 
lead to the hypothesis that DA itself is the physiological PIF, 
It has been found that hypothalamic extracts also contain a 
prolactin releasing factor (PRF) but its nature is unclear. 
Since thyrotrophin releasing hormone (TEH) releases PEI, in low 
doses and binds to lactotrophes (PRL secreting cells) it has 
been put forward as a candidate for PRF. There is evidence 
however, for discontinuity in PEL and TSH secretion in certain 
clinical situations e.g. sleep and suckling. In addition there 
is evidence that TRH can be separated from PRF enzymatically 
and chromatographically.
PEL unlike other pituitary trophic hormones lacks a 
specific target gland with which to interact in a negative
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feedback loop. Instead PRL secretion appears to be self 
regulated by a short loop mechanism. PRL administration 
dramatically increases DA turnover in the hypothalamus and this 
is evidence that this effect is mediated physiologically via 
retrograde CSF transport (Gudelsky et al, 1976),
A number of factors are known to influence PRL secretion. 
Oestrogenic hormones have a striking effect on PRL secretion 
which is thought to be a direct effect on the lactotrophe and 
not mediated by the known effect of oestrogens on DA turnover.
A variety of stresses (Table 2.1) cause significant elevation 
of plasma PRL levels (Noel et al, 1972). Most studies have 
examined the effect of physical stressors and little is known 
of the PRL response to 'psychological stress'. A teleologically 
satisfactory rationale for stress induced PRL secretion is not 
apparent. Sleep induced PRL secretion has been demonstrated 
(Sassin et al, 1972). There are episodic bursts of PEL 
secretion during sleep which are not related to specific phases 
of sleep. PRL secretion is maximal at 4 - 6 a.m. and does not 
return to baseline till about 2 hours after waking. The role 
of PIF and/or DA in these sleep associated episodes of PRL 
secretion is uncertain, particularly in man. The pathways 
involved in mediating the influences of suckling, stress and 
sleep on PEL secretion are unknown. Lesion experiments in 
animals have shown that all forms of stimuli converge in the 
hypothalamus via an anterior route since most responses can be 
blocked by lesions in the preoptic region. There is some 
evidence that the stress response is mediated via the hippocampus
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and amygdala.
Extensive evidence indicates that the monoamines, DA and 
3HT are important in the control of PEL secretion in animals 
and man (McLeod, 19?4). The evidence for the importance of 
DA is discussed above in the context that it may be the PIF 
substrate and the pharmacological evidence for the importance 
of dopaminergic drugs in humans is reviewed in the next section. 
Intraventricular administration.of 9HT stimulates PEL secretion 
in rats (McCann et al, 1977). Presumably this effect is 
mediated via some CNS mechanism since 9HT does not directly 
affect PEL secretion in vitro. The situation is however complex 
because 9NT blockers (e.g. methysergide) stimulate PEL 
secretion in rats although they block the suckling induced 
rise in PEL. NA lowers PEL only after prolonged infusion, 
blockers of NA synthesis do not have any effect on PEL levels 
and NA and precursors are ineffective on pituitary cultures 
(Muller et al, 197?). On the other hand acetylcholine (ACH) 
does affect PEL secretion in vitro. However the role of ACH 
in PRL secretion is uncertain since cholinergic agonists and 
antagonists both appear to potentiate PEL secretion (Muller et 
al, 1977 lor review).
4) Growth hormone(GH). The secretion of GH is precisely 
regulated by a complex interaction of stimulatory and inhibitory 
neural influences. This control is achieved by at least two 
hypothalamic hormones GH-releasing hormone (GEH) the structure 
of which is still unlcnown and GH-inhibiting hormone or somato­
statin (SEIF) which has been isolated and structurally identified.
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The actions of GH are numerous and include stimulation 
of growth, regulation of lipolysis and promotion of cellular 
uptake of amino acids. The pattern of GH secretion in humans 
is characterised by low (often undetectable) levels punctuated 
by pulses of GH secretion which are often of considerable 
magnitude, have a strikingly acute profile and are followed by 
a decline compatible with the Imown half-life of the hormone.
It has been suggested that these surges are the result of 
primary neural activation of GH release.
It is known that GH secretion is related to glucose, 
protein and fat metabolism although changes in these metabolic 
pathways apparently do not account for the pulses of GH 
secretion described above. Glucose metabolism is the most 
important of these influences - rapidly decreasing glucose 
levels are a powerful provocative stimulus to GH secretion whereas 
glucose excess can block a number of agents which provoke GH 
secretion.
A number of physical agents e.g. pain, trauma, pyrogens 
are known to elevate GH secretion in man. Stress effects on 
GH secretion are however very complicated and seem to vary 
depending on the type of stress (Brown et al, 1978). It is 
known that most GH secretion occurs at night. Large episodes 
of secretion occur, particularly in children and are related, 
though not directly, to slow wave sleep (Lucke and Glick, 1971).
It would appear from neuropharmacological studies that the 
regulation of sleep related GH secretion is different from that 
during the day and is dependant on 5HÏ metabolism (Brown et al,
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1978).
The neural pathways involved in the regulation of GH 
secretion have been extensively studied in experimental animals 
and much detail elucidated. How much of this information applies 
to man is uncertain and there is evidence of important species 
differences in pharmacological responses (Brown et al, 197'8),
It would appear that a ventro-medial nucleus-median emminence 
pathway is important in GH secretion but that there is also an 
inhibitory SRIF containing pathway from the anterior hypo­
thalamus (preoptic area). SRIF containing neurones have been 
found with an extensive distribution in cortex and limbic areas 
but their role in GH regulation is unknown. Simulation of a 
large number of CNS regions (e.g. ventral tegmental area, 
brain stem) have effects on GH secretion, the best recognized 
of which is the facilitatory role of the hippocampus and the 
dual role of the amygdala (Martin et al, 1977)- The physio­
logical significance of these observations is however uncertain.
Secretion of GH releasing and inhibiting hormones and 
the GH secretion induced by stimulation of extrahypothalamic 
structures is regulated by aminergic neurones acting at the 
hypothalamic level. Based on pharmacological responses it would 
appear that DA is facilitatory to GH secretion (see section 
1.4). NA is thought to be a very important regulator of GH 
secretion and the evidence for a role in man is discussed in the 
next section.
9) Thyroid stimulating hormone (TSH). The hypothalamo- 
pituitary- thyroid axis represents an ideal example of a negative
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feedback self regulatory system brought about by the interaction 
of at least three groups of hormones. Hypothalamic thyrotrophin 
releasing hormone (TEH) stimulates the release of TSH by the 
pituitary which in turn activates the thyroid to release 
thyroxine (T4) and tri-iodothyronine (T3).
TSH levels fluctuate to a small degree throughout 24 
hours “ with higher levels in the evening - the setpoint is 
principally controlled by the interplay of TRH and the level of 
T4 and T3. A number of physiological processes influence TSH 
levels though only within the limit of feedback control (Table 
2.1). Stress in general inhibits TSH but this may reflect a 
feedback from increased thyroid hormone secretion (Mason, I968). 
High levels of cortisol and GH appear to inhibit and oestrogen 
to enhance TSH secretion.
It is clear that the hypothalamus is essential for maintain­
ing basal TSH secretion. A large number of hypothalamic nuclei 
are involved in TRH secretion and thereby TSH regulation. The 
role of extrahypothalamic structures in the regulation of TSH 
secretion is much less clear. It would appear that stimulation 
of the hippocampus and amygdala respectively enhance and inhibit 
TSH secretion. TRH and TRH receptors are distributed in extra­
hypothalamic sites and while there is increasing evidence of 
the behavioural effects of extrahypothalamic TRH, its role in 
TSH regulation is unltnown (Krulich, I982).
The physiological role of monoamines in the regulation of 
TSH secretion is much less studied and understood than for 
other pituitary hormones. DA and not NA releases TRH from
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hypothalamic tissue in vitro but the suggestion of a facilitatory 
role for DA in TSH is contradicted by pharmacological studies 
in man (section 2.1.4). 9HT inhibits TSH secretion in vitro 
and the inhibitory effect of 9HT on TSH is confirmed in in vivo 
studies (Krulich, I982).
6) Adrenocorticotrophic hormone (ACTH). Neural control of 
ACTH is responsible for its characteristic secretion pattern 
which leads to corresponding changes in secretion of the gluco­
corticoids from the adrenal cortex in phase with the daily 
activity cycle and the increased output that occurs during 
emergencies. Several steroids, some with sex-hormone activity, 
are secreted by the adrenal in response to ACTH but the principal 
one is cortisol (the remainder being outside the scope of this 
work).
Studies using indwelling catheters have revealed that 
ACTH is secreted episodically for brief periods of time and that 
these are large bursts of secretion in the later stages of sleep 
(around 6 a.m., unrelated to any particular phase of sleep).
This leads to a corresponding pattern of cortisol secretion with 
low levels in the late evening and highest levels aroung 6 - 8  
a.m. The rhythm of ACTH is under neural control. Negative 
feedback from cortisol plays little role in the modulation of the 
ACTH rhythm.
The ACTH-cortisol axis is activated by a wide variety of 
stressful stimuli. An attempt to define "stress" soon leads to 
crucial and difficult questions as to the nature of homeostasis. 
As was discussed in chapter 1.2.5 and was pointed out by Mason
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(1968) psychological factors (e.g. arousal, novelty, uncertainity) 
may be the common stimulus for the adreno-cortical response, 
although there is much controversy and confusion in this area of 
research. Suppression of ACTH release can be brought about by 
the administration of exogenous steroids (e.g. dexamethasone) 
and it would appear that the neural origin of some stresses is 
powerful enough to overcome this suppression.
The regulation of ACTH secretion by the hypothalamus is 
somewhat complicated and is subserved by separate areas. On 
the basis of lesion experiments it would appear that the anterior 
part of the hypothalamus is responsible for the diurnal rhythm 
of ACTH secretion and that the stress response is mediated via 
the posterior basal hypothalamus. The final common pathway for 
ACTH secretion is corticotrophic releasing factor (CRF) secreted 
by the median emminence and whose structure is so far unidenti­
fied (summer, 1982). It is known that inputs from suprahypo- 
thalaraic structures are important in ACTH regulation. Inputs 
affecting ACTH secretion from the brain stem, limbic areas and 
septal nuclei are recognized (Weiner and Ganong, 1978). ACTH is 
found in several brain areas and the injection of some analogues 
of ACTH has behavioural effects.
The analysis of the central neurotransmitter control of 
CRF-ACTH secretion has proven to be the most difficult of all 
the anterior pituitary hormone systems. It would appear that 
there is a facilitory cholinergic input at the level of the 
final CRF-containing neurone (Muller et al, 1978). The issue of 
the role of catecholamines in the control of ACTH remains
69
unresolved - particularly in man (see section 2.1.4): conflicting
evidence points to an inhibitory, an excitatory or no role for 
each neurotransmitter. It is virtually certain that DA plays 
no role in ACTH regulation. The most commonly held view is 
that 5tFf is facilitatory to most physiological ACTH secretory 
episodes (Checkley, 1980) and there is an inhibitory noradrenergic 
control of stress related ACTH secretion mediated by p adreno- 
receptors and opposed by a adrenoreceptors (Nalcai et al, 1973)«
2.1.4 Pharmacology of the hypothalamic-pituitary axis
An outline of the main changes in pituitary hormone 
secretion following the administration of neuropharmacological 
agents in man is given in Table 2.2. Important observations 
germane to this study are outlined below. It is important to 
recognize that despite considerable knowledge of the neuro­
transmitter modulation of H-P secretion and of the pharmacology 
of drugs the site of action of a drug in an individual hormone 
response is by no means certain,
a) Dopamine (DA)
1) DA agonists. There are several drugs in this category 
and their principal modes of action are outlined in Table 2.2. 
Apomorphine (APO) is a direct agonist on DA receptors although 
there is considerable evidence (see chapter 7«l) that at low 
doses it preferentially stimulates pre-synaptic DA receptors 
("autoreceptors") leading to an effective reduction in DA neuro­
transmission. Whether this phenomenon is involved in the 
pituitary hormone response to APO is not clear: most evidence
indicates a uniform dose-hormone response curve (Cleghorn et al, 1982)
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TABLE 2.2
ACTIONS OF DOPAMINE AGONISTS USED IN ENDOCRINOLOGICAL RESEARCH
DRUG
1) Apomorphine Potent DA receptor agonists, 
effective on DA sensitive adenylate 
cyclase system, ? selectively 
labels presynaptic DA receptors, 
decreases in DA turnover, ? 
increases 5NT turnover.
2) Ergot derivatives
a) bromocriptine
b) lisuride
c) lergotrile
3) L-DOPA
High affinity for DA receptor 
sites, no stimulation of DA-sensitive 
adenylate cyclase system in vitro, 
reduce DA turnover« Probable 
effect on 5DT receptors but ? 
effect on D^T turnover.
Increases synthesis of DA and NE 
and 5HT.
4) Amphetamines Indirect presynaptic agent - 
releases biogenic amines - NE and 
DA and blocks re-uptake - increase 
in turnover of DA, NE and ? 5HT.
Pharmacological profile of dopamine agonists used in neuroendocrine 
studies of psychiatric patients
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APO administration provokes GH secretion and suppresses PRL 
secretion (Lai et al, 1973; Ettigi et al, 1973). Baseline 
effects are important in this response: PRL suppression is
marked when PRL levels are high and reduced when PRL levels are 
low (Langer et al, 1979); GH response to APO is reduced in 
cases with high basal GH levels (Cleghorn et al, 1902). Since 
there is discontinuity between the emetic effects of APO 
(caused by stimulation of DA receptors in the medulla) and its 
hormonal response and since APO administration has no effect on 
ACTH secretion, it is generally held that the hormonal effects 
are pharmacologically specific rather than stress related. GH 
and PRL responses to APO are blocked stereospecifically by DA 
receptor blockers (Lai et al, 1977)- APO appears to have no 
consistent effects on LH, FSH, TSH or ACTH secretion.
The ergot derivatives (bromocriptine, lisuride and 
lergotrile) have a slightly different pharmacological profile 
but somewhat similar endocrine effects as APO. These drugs are 
more specific agonists at DA2 receptor (Table 2.2) and this is 
the predominant type of DA receptor on the pituitary surface 
(see chapter 1 section 2.3 for outline of this classification) 
which argues in favour of a direct pituitary site of action for 
these drugs. However the evidence for this is not complete 
and indeed there is evidence in favour of a hypothalamic site 
of action for these drugs and for APO (Brown et al, 19^2).
There is a dispute, which may be a theoretically important one, 
regarding the effect of bromocriptine and DA infusions on LH 
secretion (Johnstone and Ferrier, I980).
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L-DOPA is a drug with weak and partial actions as a DA 
agonist. The effect of L-DOPA on PRL secretion is small and 
inconsistent (Lai et al, 1973) and the GH response is blocked 
by 3HT antagonists which make it a poor drug to use in testing 
DA receptor function. A similar argument applies to amphetamine - 
weak and inconsistent effects on PRL secretion are noted (Wells 
et al, 1978) and the GH response appears to be largely mediated 
via noradrenergic synapses (Checkley, 1980).
2) DA antagonists. The hormonal responses to this group 
of drugs has been intensively investigated both as part of 
basic science research and also because of their importance in 
psychiatric treatment and the need to monitor their administration. 
Administration of DA antagonists leads to a large and rapid 
secretion of PRL both in vitro (McLeod et al, 197^) and in vivo.
It is generally held that this response is due to blockade of 
pituitary DA receptors and resultant loss of inhibitory DA tone. 
There is a close linear relationship between the DA blocking 
potency of neuroleptics in vitro and their PRL elevating proper­
ties (McLeod et al, 1973)- It has been shown that the adminis­
tration of neuroleptics leads to reproducible and dose-dependant 
elevation of PRL secretion in the individual subject (Langer et 
al, 1979) but that there is a large inter-individual variation.
A ceiling of PRL secretion occurs after repeated or large doses 
of neuroleptics (Gruen et al, 1978). The question of tolerance 
to neuroleptics will be discussed in the subsequent relevant 
sections.
There is much conflicting data on the effect of DA
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antagonists on growth hormone secretion. The basis of these 
differences appears firstly to be a significant species differ­
ence between primate and sub-primate (Weiner and Ganong, 1978) 
and secondly the varying a receptor blocking activity of 
different neuroleptics. It would appear that neuroleptics can 
reduce the GH response to many physiological stimuli but that 
they have no effect on basal GH secretion (Checkley, 198O for 
review).
In general most studies (Beumont et al, 1974&',Cotes et al, 
1978) have shown no effect of neuroleptics on LH secretion 
directly although a reduction in LH is believed by some authors 
to follow from neuroleptic-induced chronic hyperprolactinaernia 
(Glass et al, 197$). There are some instances of neuroleptics 
increasing LH where it was previously low. This phenomenon 
will be discussed more fully subsequently.
There is no conclusive evidence for an effect of neuro­
leptic medication on ACTH secretion in man. Recently small but 
clear-cut elevations in TSH secretion have been observed follow­
ing the acute administration of the dopamine antagonist meto- 
clopramide (MCP) (Healy and Burger, 1977)»
b) Noradrenaline (NA)
1) Agonists. It appears that drugs of this type e.g. 
clonidine stimulate the release of GH but have little effect on 
PRL secretion- Amphetamine has been used extensively in research 
into psychiatric disorders- It would appear to act through 
a-adrenergic receptors to elevate GH and ACTH although clonidine 
which is a more specific a-adrenergic agonist does not elevate
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AGTH secretion (Checkley, I980 for review).
2) Antagonists. a) P receptor blockers have been used 
to treat schizophrenic patients. They appear to potentiate the 
GH and AGTH response to most physiological stimuli but to have 
no endocrinological effects alone (Checkely, I980).
b) a blockers, a blockade inhibits the GH and AGTH 
response to a wide variety of stimuli but has little effect on 
PEL or LH secretion in man.
c) Acetylcholine (AGH). It has been suggested that anti­
cholinergic medication causes elevation of PEL levels (de Eivera 
et al, 1976). This claim is important in research into the 
hormonal response of schizophrenic patients to neuroleptic drugs 
as drugs with this pharmacological property are frequently 
prescribed for schizophrenic patients as an adjunct to neuro­
leptic therapy. However the evidence is not strong and the 
results of basic research on this point are conflicting (see 
chapter 6).
d) Opiates. There is currently controversy regarding the 
effect of opiate agonists and antagonists on GH and PEL secretion 
in man which is probably due to pharmcodynamic reasons. For
the'purposes of these studies it is only important to note that 
there is increasingly good evidence that opiate agonist decrease 
and opiate antagonists increase (Moult et al 1 I981) LH levels 
and LH pulsatility and this may be particularly relevant where 
LH levels are low (Quigley et al, 'I98O).
2.2 Neuroendocrine studies of psychiatric illness
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2.2.1 INTRODUCTION
This is a rapidly advancing field of study. These studies 
have two basic aims:- l) the discovery of a hormonal marker 
for disease that will be useful as an index for diagnosis, 
treatment and prognosis and 2) the elucidation of an hormonal 
abnormality will aid understanding of any underlying neuro- 
transmitter abnormality and hence aetiology. To use the 
American argot of the day - these studies are using pituitary 
hormones as a "window on the brain". How well the physiology 
and pharmacology of anterior pituitary hormone secretion stands 
up to this sort of analysis is outlined above and discussed in 
the appropriate sections.
The studies reported in subsequent chapters (4, 6, ?)
concern patients with a diagnosis of schizophrenia. An outline 
of neuroendocrine studies in other psychiatric conditions is 
first given. The diagnostic specificty of the hormone abnor­
malities reported is a major concern of this work and future 
studies. An outline of the more established hormonal abnormal­
ities in various psychiatric disorders is given in Table 2.3.
2.2.2 Neuroendocrine studies in affective illness
a) Depression
This group of illnesses have been studied extensively from 
a neuroendocrine angle. The basic abnormalities detected are:-
1) Hypersecretion of cortisol. Extensive work has been done 
on this phenomenon which was first recognized in the late 
sixties. It has been observed that many depressed patients have 
elevated cortisol levels with a loss of the normal diurnal rhythm 
(Carroll et al, 1980). In addition the high levels of cortisol
TABLE 2.3
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CONDITION
Dopamine Agonists
Dromocryptine (D romo), 
L-DOPA (L-D) 
APOMORPHINE (APO)
g NoradrenGrp;ic Agonists
GLONiDINE AHPllE'rAJ-lIIŒS
Normal (see text) PRL A GH t 
? LH ACTH — ►
GH Î PRL — » 
ACTH— * LH— >
GHt PRL? 
ACTH I LH — b
Schizophrenia
? enhanced GH f and 
reduced PRL ^  to APO 
in some acute patients 
blunted GH ^  and PRL ^ 
to APO in many chronic 
pat icnts
-
Normal GH responses
Huntington's Chorea
enhanced GH t to BROMO 
but reduced PRL^ -
--
Pai'kinron'G dioOanu Reduced GH to BROMO 
Normal/
Reduced GH to L-D
-
--
Acromegaly GH ^ PRLj - -
Affective lilnesn
Normal PRL4 
Normal GH | Î Reduced GH in 
depression Reduced cortiuol ' 
in depression 
Reduced GH ^ 
in depression ,
Summary of neuroendocrine studies in neuropsychiatry with particular 
reference to studies with provocative agents.
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in many cases fail to suppress normally, on the administration 
of exogenous steroids e.g. dexarnethasone. The dexamethasone 
suppression test (DST) has now been carried out on many hundreds 
of patients and is held by some workers to be highly selective 
for a group of patients with endogenous depression. It is 
also claimed that the DST is unaffected by phenomena such as 
anxiety and agitation or drug therapy and that it is able to 
predict treatment response and relapse (Carroll et al, I98O 
for review). Claims of selectivity and specificity however are 
somewhat weakened by the finding of abnormal DST results in 
patients with anorexia nervosa (Cerner et al, 1981). Another 
problem is that basal ACTH secretion does not appear to be 
abnormal in depression.
2) Blunted TSH response to TRH. It is now well established 
that a proportion of depressed subjects have a markedly blunted 
TSH response to TRH administration in the presence of normal T3 
and T4 and no clinical evidence of thyroid disease (Asnis et al, 
1981). The incidence of this abnormality is about ,53% of well 
diagnosed depressed patients. There is much argument about 
whether this is a trait or state dependant phenomenon. There is 
general agreement that the blunted TSH response does not exhibit 
a clear relationship to abnormalities of the DST.
3 ) Aberrant hormonal secretion to LHRH and TRH, It has been 
reported that in a group of depressed patients there was evidence 
of disturbed pituitary secretion in response to synthetic 
releasing hormones. Not only is the TSH response to TRH blunted 
in a number of cases (see above) but a number of unusual responses
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e.g. LH and GH responses to TRH and PRL and GH response to LHRH 
have been reported (Brambilla et al, 1978; Maeda et al, 1975)* 
These authors proposed a functional disconnection between the 
hypothalamus and the pituitary in depression.
4) Diminished pituitary secretion in response to insulin hypo- 
glycaemia. A number of authors have demonstrated reduced GH 
and ACTH responses to insulin hypoglycaemia in depression 
(Gheckley, 1980). Since there is a close concordance between 
the presence and severity of this abnormality and abnormalities 
of the DST, it is thought that these blunted hormonal responses 
are non-specific and that raised cortisol prevents an adequately 
provocative hypoglycaemia.
5) Reduced hormonal response to a-adrenergic agonists. There 
is some good evidence for a reduced GH response to clonidine
in depressed pabients which reverts to normal after amelioration 
of clinical state with electro-convulsive therapy (ECT). A 
similar blunting of the GH and ACTH response to amphetamine 
administration has been reported (Checkley et al, 1979). 
Amphetamine is thought to act mainly as an a-adrenergic agonist 
(see section 2.1.4).
6) Abnormal gonadotrophin secretion. There have been isolated 
and poorly substantiated claims of reduced LH and FSH secretion 
in depression (Brambilla et al, 1979).
One study on 3 post-menopausal depressed patients found 
a reduction in LH pulsatility (Altman et al, 1979) but the 
number of subjects studied precluded adequate statistical
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evaluation of this phenomenon.
Summary of neuroendocrine studies in depression
As can be seen from the foregoing account several abnor­
malities of pituitary hormone secretion have been noted in 
depression. The outstanding problems are to what extent these 
abnormalities are specific for the diagnosis of depression and 
to what extent secondary factors (e.g. weight loss) may account 
for them. The pathophysiological basis of these abnormalities 
is still obscure: most evidence points to a hypothalamic
abnormality and the possibility of an adrenergic and/or cholin­
ergic deficit. Some of these issues will be addressed in 
subsequent sections.
b ) Mania
Neuroendocrine studies on patients suffering from mania 
or hypomania are few although there are more studies available 
on patients with bipolar affective illness. These studies 
have recently been comprehensively reviewed by Whalley (1982). 
Cortisol, PRL and TSH secretion are poor discriminators between 
different types of affective illness. It does however appear 
that the GH response to DA agonists or a agonists is different 
between depressed patients and those patients with mania or a 
history of it. These responses are blunted in depressed patients 
but frequently enhanced in the latter group of patients. The 
pathophysiological significance of this finding remains to be 
determined.
2.2.3 Neuroendocrine studies in patients with anorexia nervosa (AN)
Amenorrhoea in female A.N. patients is invariable and 
there are clear indications of hormonal perturbation in these 
patients. LH and FSH secretion is low and loss of pulsatility 
of LH secretion has been demonstrated. Urine and serum levels 
of oestrogens are also markedly reduced (Marshall et al, 1979).
The endocrinological picture is frequently compared with pre­
pubertal girls and the endocrinological pattern goes through 
the stages of puberty on clinical imporvement and weight gain.
It is now more or less accepted that these hormonal 
abnormalities are mediated at the hypothalamic and not the 
pituitary level. The LH response to a bolus or continued 
infusion of LHRH is frequently blunted. However if IHfflH is 
administered in frequent low doses, responsivity to LHRH and 
the normal episodic release pattern is soon restored (Valk et 
al, I98O; Jacobsen et al, I98O). The endocrinological status 
of those few male patients with A.N. has not, unfortunately, 
been studied.
These patients frequently have other hormonal abnormalities 
e.g. borderline Tk levels with reduced T3 levels and elevated 
GH levels. These abnormalities are closely related to weight 
loss and revert to normal on weight gain. Abnormalities of the 
DST in A.N. were alluded to in section 2.2.2. Hypersecretion 
of cortisol has also been demonstrated in A.N. and in normal 
subjects on a fast (Doerr et al, I981).
2.2.4 Neuroendocrine studies on patients with organic psychiatric 
syndromes
Neuroendocrine studies on patients with organic mental
disorders (e.g. dementia, confusional syndromes) are few. The 
best conducted and controlled study demonstrated normal LH, FSH 
and PRL secretion rhythms in patients with senile dementia of 
the Alzheimer type (Touitou et al, I981).
2*2.9 Neuroendocrine studies in patients with Parkinson's 
disease and other DA-related diseases 
Several groups of workers have shown that the GH response 
to DA agonists is either reduced (Parkes et al, 19?6) or 
reversed (Hyppa, 1978) in patients with Parkinson's disease.
The pathophysiological basis of this disease is degeneration of 
DA containing neurones. The typical pathological changes of the 
disease are found in the hypothalamus and reductions in hypo­
thalamic DA content have been demonstrated (see references 
above) in Parkinson's disease brains. The GH response to DA 
agonists is most probably mediated at the hypothalamic level and 
so the abnormal responses discussed above are representative of 
the underlying pathophysiology of the disease.
The satuation is less clear-cut with Huntington's chorea - 
a disease in which cell bodies of the striatum degenerate lead­
ing to perturbation of GABA/DA interplay- In this disorder 
enhanced GH responses to DA agonists are predicted. There is 
one such report in the literature (Caranceni et al, 1977) but 
there are several conflicting and negative studies.
2.2.6 Neuroendocrine studies in schizophrenia
A summary of tne available neuroendocrine studies in schizo­
phrenia is given below, taking each hormone in turn, Some of
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this information has been discussed in chapter 1 from the 
aetiological point of view. These two different approaches are 
discussed in chapter 1.2.9 and again in chapter 8.
a) Prolactin (PPL). In view of the inhibitory influence 
of the tubero-infundibular DA (TIDA) system on PRL secretion, 
the DA overactivity hypotheses of schizophrenia predicts that 
PRL secretion will be low in patients untreated with neuroleptic 
drugs. Several groups of workers have investigated this question 
and there is general agreement that basal PRL levels are normal 
both in acute (Meltzer et al, 1974; Pandey et al, 1977) and 
chronic schizophrenia (Brambilla et al, 1976; Johnstone et al, 
1977)' This result can be interpreted in several ways,for 
example :-
1) The DA hypotheses of schizophrenia has no validity
2) DA overactivity does not extend or apply to the TIDA neurones
3) Feedback effects restore PRL levels to normal. These 
possibilities, together with supporting and confounding 
evidence, are discussed in the appropriate sections.
Other aspects of PRL secretion in schizophrenia have also 
been extensively studied. The most important of these is the 
PRL response to neuroleptic drug administration. It has been 
shown that there is no difference in the timing or the magnitude 
of the PRL response to acute neuroleptic administration between 
schizophrenics and controls (Gruen et al, 1978). Langer et al
(1979) have reported that if DA is infused IV following the 
acute administration of neuroleptics to elevate PRL to approxi­
mately half maximal, the PRL suppression observed is greater in
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schizophrenics than in controls. These authors suggested this 
is evidence of supersensitive DA receptors on schizophrenic 
pituitary glands. However it is obvious that there are consider­
able interpretative difficulties associated with this experiment 
which, in any event, requires replication.
The effects of chronic therapeutic neuroleptic adminis­
tration on PRL secretion have been studied by several groups of 
reserachers in the hope that PRL secretion would prove to be a 
useful index or marker of central DA blockade. It has been 
found that in general there is a relationship between the dose 
of neuroleptic administered and associated increments of PRL 
secretion (Rao et al, I980). However there are several 
important points to be noted regarding this relationship.:- 
1) The PRL response to neuroleptics varies markedly between 
male and female controls and between male and female schizo­
phrenics (Cotes et al, 1978) so that it is important to examine 
these groups separately. 2) A ceiling effect develops such 
that subsequent administration of neuroleptics will not further 
elevate PRL secretion (Gruen et al, I978). j) There is a 
remarkable inter-individual variation in the PRL response to 
neuroleptics (Langer et al, 1977)- 4) The chronicity of this
relationship is uncertain as there is considerable debate as to 
whether or not tolerance to the PRL elevating effects of neuro­
leptics occurs. Meltzer et al (1976) reported that tolerance 
did not occur, but this study was over a relatively short time 
scale. Several studies have shown that over a prolonged period 
of neuroleptic administration (> 5 years) PRL levels return
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towards the normal range particularly in elderly men (de Rivera 
et al, 1976; Huws and Groom, 1977).
There is also uncertainity about the relationship between 
neuroleptic administration, PRL secretion and clinical efficacy 
and side effects. With two possible exceptions all drugs which 
are known to be effective neuroleptics cause elevation of 
prolactin secretion. Clozapine elevates PRL to only a slight 
extent and is held to have anti-psychotic properties. Simi­
larly the {3 blocker, propranolol, appears to be effective in 
high dosage in the treatment of schizophrenia but has little 
or no effects on PRL secretion (Johnstone and Perrier, 198O 
for review). Indeed while there is an overall statistical 
relationship between the acute PRL elevating potency of neuro­
leptics and their clinical efficacy (Langer, 1977) and some 
clinical demonstrations of a positive relationship between the 
antipsychotic effect of neuroleptics and the associated 
elevation of PRL secretion (Meltzer et al, 1976; Langer et al, 
1977), it is clear that this relationship is not a strong one 
and does not necessarily apply to individual cases (e.g. a good 
clinical response to neuroleptics may be observed associated 
with a low increment in PRL secretion and vice versa).
Other clinical relationships between PRL secretion and 
neuroleptic administration that have been demonstrated are;-
1) a more marked elevation following neuroleptics of PRL in 
cases of tardive dyskinesia (Glazer et al, I981) Z) a more 
rapid rate of fall of PRL on neuroleptic discontinuation in 
those cases with extrapyramidal side effects (Brown et al, 1979)
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and 3) higher PRL levels in those patients with extrapyramidal 
side effects of neuroleptics (Kolakowska et al, 1975). All 
these studies require confirmation. Aspects of the above 
relationships are investigated in the present study.
Another dynamic test of PRL secretion that has been 
studied in schizophrenic patients is the PRL response to TEH.
This was examined by Prange et al (1979) who found a normal 
response. This study will be discussed in critical detail in 
the subsequent relevant section.
Despite the normality of PRL levels in schizophrenia, 
mentioned at the beginning of this section, and this finding's 
seeming lack of support for the DA hypothesis of schizophrenia, 
investigators have continued to examine PRL secretion in schizo­
phrenia looking for a clinical correlate of PRL secretion. One 
such finding was reported by Johnstone et al (1977) who clinically 
rated 16 neuroleptic unmedicated patients and measured PRL on 
two well-separated occasions and found a significant relation­
ship between increasing positive (delusions and hallucinations) 
symptoms and decreasing PRL secretion- This finding emphasizes 
the importance of looking at the dynamic aspects of pituitary 
secretion. A similar finding has recently been reported by 
Kleinman et al (1982) who found a negative relationship between 
positive symptoms and PRL secretion only in those patients with 
normal ventricular size on CAT scan- This relationship was 
studied in some detail in Ihe present studies.
b) LH and FSH secretion. As was discussed in section
1.2.5 (in the context of aetiological hypotheses) three separate
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groups of works have noted reduced LH and FSH secretion in 
unmedicated male chronic schizophrenics (Shader et al, I968; 
Brambilla et al, 1976; Johnstone et al, 1977). Further evidence 
that a degree of hypogonadism is manifest in a subgroup of 
schizophrenic patients was also outlined in the proceeding 
chapter.
The significance of these findings is not clear at the 
present time. Summarising the work of all three studies it is 
apparent that low LH and FSH are found only in a subgroup of 
patients and there is a degree of overlap with the normal 
range. It is clear that any defect of LH and FSH regulation in 
schizophrenia is only one of degree (the FSH and LH levels 
are not as low as those patients with absence of LHRH secretion 
(idiopathic gonadotrophin deficiency : IGD patients)). There is 
however evidence that reduced LH and FSH secretion may have some 
relationship to clinical state - both Shader et al (1968) and 
Johnstone et al (1977) found that those patients with the more 
disturbed psychopathology had the lowest FSH levels and Brambilla 
et al (1975) found that the therapeutic administration of 
haloperidol was associated with a return of LH and FSH to the 
normal range.
Single sample studies are an unreliable method of investi­
gating hormonal secretion as the levels of most hormones, 
including LH and FSH, fluctuate widely (as was outlined in 
section 2.1.6) and steps were taken in the present study to 
overcome this problem.
c) GH and PRL response to dopamine agonists in schizophrenia.
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It is accepted that basal PEL secretion is normal in schizophrenia 
(see section 2.3*7 )) and there appears to be a similar
acceptance that basal GH secretion is normal in schizophrenia 
(Cleghorn et al, I982). The discovery that DA agonists adminis­
tration produce reproducible and large changes in PPL and GH 
secretion (see chapter 2.1.4 for details) has provoked a number 
of research groups to investigate these hormonal responses in 
schizophrenic patients looking for evidence of a change in 
dopamine receptor sensitivity. As discussed in chapter 2.1.4 
the most direct DA agonist and drug with the purest neurochemical 
and hormonal profile is apomorphine (APO). Studies with schizo­
phrenic pabients have also been performed with less direct DA 
agonists e.g. amphetamine and L-DOPA. The results of these 
studies are outlined in Table 2.4 and a synthesis of the studies 
with APO given below.
There have been 3 such studies involving a total of $4 
patients of various clinical types with differing dose regimens. 
Generally speaking most groups of workers find that the GH 
response to APO is blunted in patients with "chronic schizophrenia" 
although there are many such patients with results in the normal 
range. The relationship between the clinical states of these 
patients (in terms of such phenomena as negative or positive 
symptoms and cognitive impairment) and the GH response has not 
been comprehensively studied. Similarly there is controversy 
as to whether DA receptor subsensitivity in chronic schizophrenics 
relates to either previous neuroleptic drug therapy or to 
subsequent neuroleptic drug response-
TABLE 2.4
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Invest iga to rs Patients Studied Drug!Dose Response Comment
Longer 21 Normals Amphetamine Normal GH response Blunted GH response
et al (1976) 8 Schizophrenics sulphate In depressed
17 Depress Ives O.img/kg patien ts
E t t ig I 17 Chronic schizophrenics APO Blunted GH response B lunting re la ted
et c l (1976) 21 Controls 0.75ing sc. Normal PkL response to drug therapy
Pandey 9 Acute schizophrenics APO GH response elevated NO re la t io n  to
e t al (1977) 15 Chronic schizophrenics 0.75i)ig sc, in acutes and drug therapy
8 Controls Dlunted in chronics
Rotrosen 10 Controls APO Blunted PRL and GH important baseline
et al (1976) 17 Schizophrenics O.Siiig sc, response to APO e ffe c ts
L-DOPA
500 mg po.
Tnnriilnga 10 Controls APO Blunted GH but NO re la t io n  to
et al (1977) 10 schizophrenics 0 , 75mg normal PRL response drug therapy or
l- dopa to APO ana L-dOPA side e f fe c ts
500mg po.
Rotrosen 21 Controls APO Normal mean GH and Blmoddl GH response
et al (1979) 2b Schizophrenics 0,5iiig sc. PRL responses
Summary of neuroendocrine studies with dopamine agonists in schizophrenic 
patients-
B9
GH studies after APO in patients with schizophrenia of 
more recent onset or accompanied by acute symptoms have given 
potentially interesting results. It is now accepted that while 
acute schizophrenics as a group have normal GH responses to 
APO, they also (as a group) exhibit markedly more variable GH 
responses than the normal population (some patients exhibit 
grossly elevated GH levels after APO whilst others have little 
or no response). The clinical correlates of this divergence 
are unknown at present - at one time it was claimed that this 
response was a predictor of neuroleptic drug response (Pandey 
et al, 1977) but this has subsequently been retracted (Rotrosen 
et al, 1979). Recently Cleghorn et al (1982) have reported, 
in a small number of patients, that the GH response increases 
markedly in those patients who are in the process of relapsing. 
This raises the possibility that the GH response to APO is a 
state, as opposed to trait, marker of the schizophrenic process.
All studies of this type share the problem that the 
patients studied must be drug free: several of the above studies
were performed after neuroleptics had been discontinued - some­
times for as short a period as 7 days. Animal studies have 
shown that neuroleptic withdrawal increases DA receptor 
sensitivity in striatal areas (Burt et al, 1977). The only 
comparable study on pituitary DA receptors indicated a reduced 
DA receptor sensitivity in vitro after drug withdrawl (Friend et 
al, 1977). However from the functional point of view there is 
evidence for increased DA receptor sensitivity after neuroleptic 
therapy in animals in that the PRL suppression after APO was
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exaggerated (Lai et al, 1977)• The PRL response to APO in 
schizophrenic patients appears to be comparable with that found 
in the normal population. However there are technical and 
practical difficulties in employing the PRL response to APO 
as a measure of DA receptor sensitivity. These are fully 
developed by Rotrosen et al (1979) and Johnstone and Perrier
(1980) and include:- 1) the narrow range between normal PRL 
levels and the lower limit of detection of the assay system
2) the floor effect beyond which even massive doses of the drug 
do not further suppress PRL secretion 3) the response does 
not exhibit adequate dose-response properties 4) the nausea 
and ernesis that APO may produce is "stressful" which may produce 
endocrine effects.
Attempts to circumvent these theoretical and practical 
problems have been made in the present study (chapter 7)-
d) Studies on adrenal and thyroid function in schizophrenia 
As was outlined in chapter 1 (section 2.3) intensive investi­
gation of adrenal and thyroid function in schizophrenia was 
undertaken during the 1930s and 1940s (the era before neuroleptic 
drug treatment) and no convincing abnormality was identified 
(Kline et al, I968). In more recent times several groups of 
workers have found normal levels of cortisol secretion in schizo­
phrenia associated with a normal diurnal rhythm. Similarly 
normal T3 and T4 (Prange et al, 1979) and TSH levels (Johnstone 
et al, 1977) have been reported in schizophrenia. The TSH 
response to TRH appears to be normal in schizophrenia in dis­
tinction to depressive illness (Asnis et al, I981).
91
2.2-7 Summary
Several pituitary hormone abnormalities have been detected 
in various psychiatric diagnostic categories. The most 
studied disease is depression where hypersecretion of cortisol, 
blunted TSH response to TRH and reduced GH response to a agonists 
have been demonstrated with varying rates of frequency. There 
is evidence that the DST test is a useful clinical marker 
although this rests heavily on the work of one group (Carroll 
and collaborators. An Arbor, USA). Whether these findings are 
epiphenomena or related directly to the pathophysiology of the 
disease remains to be clarified. There are striking abnorma­
lities of pituitary hormones in anorexia nervosa which appear 
to relate directly to weight loss. Dementia does not appear 
to be specifically associated with any neuroendocrine abnormality, 
Abnormalities of neuroendocrine function have been noted in 
Parkinson's disease and Huntington's chorea but the extent they 
reflect the known changes in neurotransmitter functions in 
these diseases is disputed.
As regards schizophrenia, there is evidence for selective 
reductions in gonadotrophin secretion with some evidence that 
these impairments relate to clinical state. While it is 
probable that these changes ai’e not causative (see chapter 
1.2,5) their relationship to the underlying pathophysiological 
process of the disease remains to be clarified. PRL secretion 
appears normal in schizophrenia but there appear to be so tne 
relationships between clinical state and neuroleptic drug 
administration wliich could prove fruitful areas of research.
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The GH response to DA agonists appears abnormal in several 
different ways in patients with schizophrenia and the relation­
ship of this response to drug therapy and clinical state require 
further evaluation. These questions have been the focus of the 
present research which will now be described in detail.
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CHAPTER 3
3. MATERIALS AND METHODS
3.1 Patient selection and classification
The studies reported here are principally on three groups 
of subjects:- a) chronic schizophrenic patients b) acute 
schizophrenic patients and c) controls- The exact details of 
the groups studied will be made clear in the description of 
individual studies (chapter 4 - ?) but an outline of the methods 
of patient selection are given below. Patients who do not fall 
into the above three categories (for example the few patients 
with affective illness and the small group of acute schizophrenics 
in remission) are described in detail in the appropriate sections.
3-1.1 Chronic schizophrenic group
This group were all long-stay patients of a neighbouring 
large mental hospital (Shenley Hospital, Herts). With the co­
operation of the local consultants a survey of the population 
(hospitalised for more than a year) of this hospital was carried 
out (which has been reported in detail elsewhere (Owens and 
Johnstone, I980)). A diagnosis of schizophrenia was made in 
those patients who conformed to the criteria of Feighner et al
(1972). These criteria are fully described in Appendix (A). 
Operational criteria are applied to the casenotes (and so refer 
to symptoms at any point in the patient's history and not to the 
current clinical state). The diagnosis requires the presence 
of clearcut, unequivocal delusions and hallucinations in the 
presence of clear consciousness and in the absence of several 
other features for example alcoholism. In addition, to satisfy
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these criteria, there must have been no return to the pre-morbid 
level of functioning six months after admission. These criteria 
therefore, to a certain extent, select out a group of patients 
with an unfavourable clinical response to hospitalisation and 
therapy. In any event this was ensured by the criteria of one 
year's continuous hospitalisation adopted by the survey. In 
practice all of the patients had been hospitalised continuously 
for a considerable number of years at the time of the present 
studies despite intensive attempts at rehabilitation and discharge. 
It is important to note therefore that the patients reported on 
here are at the poor end of the prognostic spectrum. The mental 
states of these patients at the time of study was rated separately 
(see section 3 -2) and varied considerably.
In addition the patients were classified according to the 
Catego system of classification (Wing et al, 1974). The features 
of the illness at its worst were recorded by the application to 
the casenotes of the syndrome check list of the Present State 
Examination. A basic description of this techniques and an 
outline of the types of diagnostic groups that are thereby 
identified is given in Appendix (B). Items were recorded only 
where there was a clear description of the patients' mental state 
e.g. statements that the patient was hallucinated or incoherent 
alone did not qualify for a positive recording. Further details 
regarding the selection of this group of patients (e.g. ages, 
physical health and drug status) are described in section 3-1-4.
3-1-2 Acute schizophrenia
This group of patients were all inpatients in the research
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ward of the Division of Psychiatry, Clinical Research Centre.
A clinical diagnosis, on the basis of the presence of delusions 
and hallucinations, in clear consciousness and not based on 
affect, was first made. Only pationLs who had developed new 
symptoms during the past month were included. A full interview 
of the Present State Examination was carried out (Wing et al, 
1974) which involves rating 90 symptoms and 50 signs. These 
interviews were carried out by research psychiatrists specifi­
cally trained and experienced in the use of this technique. Only 
patients in whom at least one feature of nuclear schizophrenia 
(essentially the presence of a Schneiderian first rank symptom) 
was unequivocally present were included. Some of these patients 
were first-episode cases; others had had one or more relapses - 
details are outlined in individual studies.
Üüy a few patients deemed suitable for study on the above 
criteria proved unbeatable because of their clinical condition. 
Problems included refusal to participate, excessive suspicious­
ness, hostility and physical aggressiveness.
5.1.5 Control subjects 
A total of 68 controls were studied- They were selected 
on the basis principally of age-sex matching with the various 
schizophrenic groups. Groups selected for a particular study 
are described in the individual studios. An outline of the 
basis of selection is given below. Controls were of various 
types as follows
1) Young control group - I6 healthy male laboratory or 
hospital staff.
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2) Elderly control group was made up of four subgroups
(a mixture of patients from these subgroups made up a control
group for a particular study).
a) 15 healthy normal controls consisting of hospital staff and 
volunteers.
b) 8 patients attending medical clinics at Northwick Park 
Hospital with non-endocrine, non-raetabolic disease e.g. 
ischaemic heart disease, peptic ulceration, bronchitis.
These were included because it is considered unwise bo 
selecb control groups on the basis of health as this can 
induce bias.
c) 10 patients attending the psychiatric clinic with a diagnosis 
of mild reacbive depression, anxiety or personality disorder. 
Psychotic illness was excluded by clinical examination, 
prolonged outpatient observation and application of the 
Feighner criteria to casenotes. These patients to some 
extent provide a control group for the non-specific effects 
of psychiatric disease.
d) l6 patients who were inpatients in Northwick Park Hospital 
admitted for minor elective orbhopaedic surgery (e.g.
removal of pins, ganglion, contractures).
e) 5 long stay patienbs of Shenley Ilospibal with a diagnosis of 
affective illness by the St. Louis criteria (Feighner et al,
1972) but whose mood was normal at the time of study.
5-1-4 Additional points on patient selection
(1) Sex/ Age
With the exception of a few patients, described in chapter
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6, all the patients studied were male. This was to avoid the 
complications of the variable effects of the menstrual cycle on 
pituitary hormone secretion and the additional difficulties of 
the effects of either amenorrhoea or the menopause on hormonal 
levels. There is good evidence that post-menopausal females 
respond to provocative hormonal tests in a qualitatively different 
way from menstruating females. Patients between the ages of 16 
and 69 were considered for selection.
(2) Consent
All the patients and controls studied gave consent for 
the procedures undertaken. In the case of all of the controls 
and the majority of the schizophrenics this consent was informed 
i«e. the subjects were aware of the issues involved, their 
right to refuse and the fact that the procedures were not part 
of routine investigation or treatment. A few of the schizo­
phrenics were unable to grasp this proposition but co-operated 
willingly - in these cases consent was obtained from the nearest 
relative. In a very few cases the full experimental protocol 
could not be completed due to non-compliance. These patients 
are alluded to in chapter 6.
(5) Physical health
A clinical history was taken from all patients and controls 
and a basic physical examination performed. All patients with 
major endocrine, metabolic or neurological disease were excluded. 
Schizophrenics with a history of epilepsy or leucotomy were 
excluded. A number of the chronic schizophrenic patients had 
evidence of some non-psychiatric disease e.g. peptic ulceration,
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osteoarthritis, mild hypertension, vascular disease. It was 
therefore felt that matched controls must not be selected on the 
basis of perfect physical health.
(4) Drug and alcohol intake
All of the chronic schizophrenic patients were unmedicated 
with neuroleptic drugs at the time of study. Some of the acute 
patients (chapter 6) had been medicated with a variety of drugs 
prior to admission but the majority (and all those subjects 
studied in chapters 4,5 end 7 had not received neuroleptic drugs 
(as defined below).
In the case of the chronic schizophrenics the minimum 
accepted time since neuroleptic drug administration was one year 
and this was assessed by careful scrutiny of the medical and 
nursing notes. Several of the patients had never been exposed 
to neuroleptic drug at any time. This was accounted for by 
the presence in Shenley of a group of patients who had been 
admitted before the widespread use of neuroleptic therapy and 
who had subsequently been managed on a ward which employed 
psychotherapy and a token economy. Most of the patients had had 
brief or minimal exposure to neuroleptic medication usually many 
years in the past which had been discontinued due to either 
failure of therapeutic effect, side effects or non-cooperation.
A smaller group of patients had been prescribed large doses of 
neuroleptics for many years which had been discontinued - also 
for the reasons given above.
In the case of acute schizophrenics the minimum drug free 
period for study was one month in the case of oral therapy and
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six months in the case of depot neuroleptics. This was assessed 
by a combination of the accounts of the patient, their relatives 
and their general practioners. The unit in which these studies 
were performed has frequently intimated to the surrounding 
health care services an interest in schizophrenia and our 
willingness to see any suspected patients at very short notice. 
This service has undoubtedly ensured that a lot of patients have 
remained unmedicated who would normally have been placed on 
neuroleptics while awaiting outpatient appointments etc.
The ingestion of several other groups of drugs e.g. anti­
depressants, anticonvulsants, lithium was also proscribed and 
no patients or controls had ingested these drugs within a month 
of testing. Benzodiazepine therapy and hypnotics were permitted 
but not within 12 hours of testing. All cases suspected of 
excess alcohol consumption or addiction were excluded,
A few of the schizophrenic subjects had been treated with 
a course of EOT and 2 had received modified insulin coma.
3*2 Clinical rating techniques
3.2.1 Mental State
This was assessed in terms of the standardised psychiatric 
assessment scale for rating psychotic patients devised by 
Krawiecka et al (1977). With this instrument the 8 variables - 
depression, anxiety, flattening and incongruity of affect, 
psychomotor retardation, hallucinations, delusions, incoherence 
of thought and poverty of speech/muteness - are assessed on a 
0 - 4  point scale. In this study, flattening of affect and
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incongruity of affect were rated separately to yield a total of 
9 variables. Krawiecka et al provide a schedule describing how 
to elicit and how to rate these symptoms and some examples are 
given in Appendix C.
These ratings were carried out by two research psychiatrists 
experienced in the use of this schedule. In most cases these 
interviews were performed on the basis of a normal psychiatric 
interview. In the case of the apomorphine study (chapter 7) an 
interview constructed around the Krawiecka interview was video­
taped and the recording subsequently rated by two psychiatrists 
independently.
Delusions, hallucinations, incongruity of affect and 
incoherence of speech were taken together as 'positive symptoms' 
and flattening of affect and poverty of speech as 'negative 
symptoms' as described in Wing et al ('197^ )* The maximum 
possible score on positive symptoms was 15 and for negative 
symptoms 8. The maximum score for positive symptoms is 15 because 
if a maximum score of 4 is rated for incoherence then only a 
maximum of 5 for delusions can be scored. This is because 
excessive incoherence precludes a full assessment of psychotic 
features such as delusions which require clear description. The 
non-specific features of retardation, depression and anxiety 
were recorded. No subject exhibited depression to a morbid degree, 
3*2.2 Cognitive functioning
This was assessed in terms of the Withers and Hinton (19?1) 
series of tests of the sensorium. Previous experience with this 
type of population showed this test to be satisfactory in that
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most patients are able to attempt it and achieve some score.
No testing of control populations was undertaken for the 
present study but several control groups have previously been 
studied by the investigators who performed the ratings for the 
present study (Johnstone et al, 19?8). Control groups matched 
for age and educational background with chronic schizophrenic 
patients and a group of physically disabled subjects have been 
studied and the mean score for these groups (± SD) is 80 ± 20.
A few more specific measurements were made (e.g. blink 
rates) which will be described in the appropriate sections.
3*3 Sample collection, handling and storage
3 .3.1 Venous sampling techniques
Venepuncture was performed in the standard way from ante- 
cubital veins.
Serial venous samples were obtained by the following method: 
a 21 gauge butterfly needle attached by a short length (18 cm) 
of plastic tubing to a rubber sampling bung was inserted and 
taped into a forearm vein below the cubital fossa. Samples 
(approx. 5 ml) were withdrawn by syringe and needle from the 
rubber bung and the cannula flushed by the injection of 1 ml 
dilute heparinised saline solution (2 ml 1000 units preservative- 
free heparin/ml with 10 ml saline). Prior to venous sampling 
2ml was first withdrawn and discraded to minimise saline dilution 
and heparin contamination of the sample. These butterfly cannula 
were very successful both in terms of not restricting patients' 
movement and activity and in terms of remaining patent for 
venous sampling. In general it was noted that the vein became
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somewhat tender about 2 hours after insertion but this did not 
prove a major restriction. The actual insertion of the cannula 
was marginally more painful than direct venupuncture and usually 
a period of 15 - 30 min was left prior to taking the first test 
sample.
5 .5.2 Handling and storage of samples
Blood was immediately transferred to a plastic container 
and placed in a 4 fridge. After 24 hours the samples were 
centrifuged at 5 % 103 rpm for 15 min in a bench centrifuge.
Serum was pipetted off and dispensed into .5 - 1.0 ml aliquots in 
plastic containers. These were then transferred immediately to 
a liquid nitrogen store (-170 °C) where they were stored until 
assay. When samples were assayed they were allowed to thaw 
slowly. After assay the samples were snap frozen by plunging 
them into liquid nitrogen. Subsequently the samples were stored 
at -40 °C. Since several aliquots had been made at the time of 
the original preparation of sera and the number of assays performed 
relatively limited the number of times that each sample was 
thawed and frozen was never more than two.
5.4 Radioimmunoassay (RIA) techniques 
Nine different hormones were measured in sera from schizo­
phrenics and controls. LH, FSH, GH, PRL, TSH and testosterone 
were measured in the CRG, by previously published methods (see 
Table 5*l)i by the author. T3 and T4 were measured by standard 
RIA techniques by Miss S. Copping in the Division of Endocrinology 
Research, CRG. Oestradiol was measured at the WHO Collaborating
I U J
Centre for the measurement of reproductive hormones, Chelsea Hospital 
for Women, London, 8W3 by Dr. I. Rincon-Rodriguez.
An outline of the reagents and methods of each of these 
assays is given in Table 3-1 and a brief description of theory 
and practice is given below. The iodinated tracer for assay of 
the LH, FSH, PRL and GH was prepared by the author and methods for 
purification and evaluation of this material developed. These 
procedures are outlined below and amplified in Appendix D.
Finally descriptions of the methods of separation of bound and 
free label, containing radioactivity and quality control procedures 
are discussed.
3 .4.1 Radioimmunoassay - theory
The basic theory of RIA is depicted in Fig 3.I. The basis 
of the assay procedure is the competition for binding between 
specific antibody and isotopically labelled antigen (Ag) and 
unlabelled Ag. In the presence of large amounts of unlabelled 
('cold') Ag in a sample, the amount of labelled antigen bound to 
antibody is reduced by displacement. A suitable method for 
separating bound and free Ag must be devised. Standard displace­
ment curves are derived using known concentrations of the Ag (in 
this case a hormone) and the amount of displacement produced by 
an unlcnown concentration can then be measured and its equivalence 
in hormonal units determined.
A number of aspects of assays must be considered. The con­
centration of labelled antigen and antibody are carefully adjusted 
to give optimum binding within the range of expected hormone 
levels. To increase sensitivity of the assay a pre-incubation of
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Diagram oi' principles of radioimmunoassay. Upper 
part shows addition of Ag* to antibody (Ab) and 
precipitation of the labelled hormone with donkey 
anti-rabbit serum (DAKS). In lower part, addition 
of unknown sample results in competition with Ag* 
for AB, The reduction in Ag* bound to AB result;; 
in fewer counts in tlie precipitate.
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sample/standard and antiserum prior to addition of labelled antigen 
was carried out. If a sample proves to be above the level of 
the sensitivity of the assay then it must be diluted with buffer 
or other solutions till its level is within the range of the 
assay. Before this can be performed with confidence the 
parallelism of the assay needs to be checked; that is that the 
assay system reacts to naturally occurring hormone diluted 
serially in the same way as the standard hormone. The parallelism 
of all assays used in the present studies has been fully checked 
and is satisfactory (Cotes et al, unpublished). Details are 
also available in the original methodological descriptions cited 
in Table 7.1.
The antibodies used in a RIA immunoassay must be specific 
and the labelled Ag virtually pure. Cross-reactivities with a 
variety of possible interfering substances for each of these 
assays have been checked and were invariably less than 1%. It 
must be emphasized that RIA measures immunological and not 
biological activity. A detailed description of the precise 
structure of the hormones studied here and the extent to which 
the antibodies used react with either a pro-hormone or subunits 
of the hormone is beyond the scope of this work.
7.^.2 RIA - materials used
a) Buffers were made up as indicated in Table 7«1 using 
the purest reagents available (Analar), pH and conductivity of 
buffers were checked on each occasion on a Philips Digital pH 
me bar and a Radiometer (CDC 104) respectively.
b) Assays were performed in 2 ml Sardstedt polypropylene
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tubes which were vortexed mixed after each addition of reagent.
c) Samples were pipetted into tubes using a "Compupette" 
(General Diagnostics, N.J., USA). This machine allows for the 
dispensation of 10 - 2000 \il of fluid. It is highly reliable 
(the variation was frequently checked and found to be of the 
order of ± 1^) but was less accurate (± 7%).
d) Standards were stored in freeze-dried preparations 
and a range for assay was made up by serial dilutions on each 
occasion of assay.
e) Antisera and iodinated antigen were also stored at 
-40 °C prior to use.
f) Methods were otherwise as described in original papers, 
and the following sections (7,4,7,6,7) and appendices.
7.4.3 RIA - individual assays
All samples and standards were assayed in duplicate.
1) LH. The LH assay was carried out according to the 
protocol in Table 7*1 by the method described in Cotes et al 
(1976). Results are expressed in U/L according to 1st Inter­
national Reference Preparation (IRP) of human LH for immunoassay 
(MRC 68/40), The mean range of sensitivity of the assay (see 
section 7*6.6 for this definition) was 2.0 - 50 U/L. An example 
of a typical LH standard curve isctisciaeBed in Appendix D.
2) FSH. This was carried out according to the protocol 
in Table 7*1 and the method of Cotes et al (1978). Results a m  
expressed in U/L in terms of the IRP of human FSH and LH for 
bioassay (MRC 69/104). The sensitivity of the assay was O.5 - 
50 U/L.
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3) GH. This was measured in outline as described above. 
Results are expressed in niU/L in terms of the 2nd UK Working 
Standard and the test range of the assay 0.6 - 12 mU/L.
4) PRL was measured according to the protocol set out in 
Table 7.1. This method is as set out in Cotes et al, 19?8 
except that the peptide for iodination was modified from the 
Vl/Speptide to the purer HPRL (Lowry). The standard for PRL was 
the International Reference Preparation of Human Prolactin for 
Immunoassay (73/504) and the sensitivity of this assay lay 
between 50 - 800 lU/L.
5) TSH was measured by RIA according to the method of 
Byfield et al (1979). The standard was the WHO 1st International 
Reference of Human TSH for Immunoassay (MRC 68/38) and the 
sensitivity of this assay was 2.0 - 25 mU/L,
6) T4 and T3. Thyroxine and tri-iodothyronine were 
measured by a semi-automated radioimmunoassay in routine use at 
Northwick Park Hospital. The interassay co-efficients were 
respectively and 5/* The normal adult ranges for the T4 
assay is 60 - 150 nmol/l and 1.2 - 2.8 nmol/l for the T3 assay.
7) Testosterone. Samples for testosterone assay were 
first extracted in pure ethyl alcohol which was evaporated with 
liquid nitrogen. The method is described in the WHO Collabor­
ating Centre Manual (I98I). Standard was supplied as 10 ng/ml 
testosterone and diluted serially. Separation was carried out 
by the addition of ice cold charcoal-dextran (see below)-
8) Oestradiol. Samples were extracted as documented above 
for testosterone. The method is described in the WHO Colloborating
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Centre Manual (I98I). The method used was a modification of the 
method of Emment et al (1972) so that ^H-oestradiol was replaced 
by T25i_oestradiol.
3 .4.4 RIA - Iodination of peptides
The following antigens were labelled with l"123 by the 
author:- FSH, LH, GH and PRL. The antigen used for each is 
delineated in Table 3*1* A chloramine-T method was used in the 
case of FSH, LH and GH: PRL was iodinated by the lactoperoxidase 
method. The methods used are fully described in Hunter (1982) 
but an outline is given in Appendix D where some specific 
examples are also shown.
3 .4.3 RIA - Separation techniques
An adequate method of separating bound from free labelled 
antigen is essential in any RIA system. The methods employed 
in the assays of the present studies are outlined in Table 3*'l*
As can be seen these were broadly of two types: a) addition of 
a second antibody directed to antibody or b) the addition of 
charcoal.
The second antibody employed in the current study was 
donkey anti-rabbit sterum (DARS) raised against rabbit IgG (the 
antibodies used in the RIA system were raised in rabbits). Thus 
antibody would be precipitated and where this was linked to 
labelled antigen counts would be measurable. To add stability 
to precipitates a small amount of normal rabbit serum (MRS) was 
added. The concentrations of DARS and MRS were carefully adjusted 
to obtain maximum precipiiation of antibody with maximum stability 
of the precipitate and with good safety margins. It was
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demonstrated that the optimal concentrations were 4 |il DARS/tube 
and 0.23 pi NRS/tube and these concentrations were used through­
out. It was shown that separation could be satisfactorily be 
performed 8 hours after the addition of DARS but in practice 
separation was performed after overnight incubation with DARS/
MRS (approx. 16 hours). At this point 1 ml of buffer with a trace 
of detergent (Triton 100 - final concentration .2%) was added - 
the so called "wash". This additional volume ensured that when 
the supernatant was discarded it was relatively dilute and so 
if traces of fluid could not be displaced then their contribution 
in terms of radioactivity would be minimal. The addition of 
detergent also reduced the surface tension of the supernatant 
to minimise retention when inverted- The samples were then 
centrifuged at 2.3 x 10 rpm in a refrigerated centrifuge for 43 - 
60 minutes. The tubes were then rapidly inverted over a pronged 
rack so that the supernatant was discarded. The tubes were then 
left to drain for 15 min prior to counting.
Charcoal
Merit A Charcoal (Sigma) was dissolved in phosphate buffer 
with an equal weight of dextran ?0. The separation is performed 
at 4 °C. 1 ml of dextran coated charcoal (maintained in sus­
pension by a magnetic stirrer) was added quickly to all tubes.
The contents were mixed on a rota mixer, allowed to stand for 
13 min and centrifuged (4 °C, 2000 g, 13 min). The dextran coated 
charcoal adhers to the bottom of the tube and the supernatant 
containing the bound fraction was decanted into vials containing 
10 ml of counting fluids
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3.4.6 RIA - Techniques of counting radioactivity
After the supernatants were decanted, the précipitants were 
allowed to dry and the activity of 1/23 counted on a NEI6OO 
scintillation counter (Nuclear Enterprises, Reading, UK) with an 
efficiency of approx. 60/ in batches of I6 samples. Counts were 
continued long enough for trace (no unlabelled antigen) binding 
tubes to reach approximately 10,000 counts (usually 200 - 3OO 
seconds). Standards and samples were counted for the same 
length of time immediately consecutively. Background counts were 
repeatedly checked and for the range of counting times cited 
above were below 200 counts. No background subtraction was made. 
A paper tape was made which could be read directly into a computer 
file.
The scintillation fluid used for the testosterone assay 
consisted of 2 volumes toluene, 1 volume of Triton X~100 and 4 g 
PRO per litre of mixture. Before counting samples were allowed 
to equilibrate for at least an hour. Samples were counted on a 
Wallach counter (LKB, Sweden).
3 .4.7 RIA - Computer analysis of raw data
Potency estimates were derived from observations of radio­
activity counts bound, using a computer program written by Dr,
R. Wootton based on Healy's (1972) 4-parameter log-dose logit- 
response standard curve. An example of the type of curve 
generated is discussed ii Appendix D. Samples with binding greater 
than 83/ and less than 13/ trace binding (no unlabelled antigen) 
were deemed outside the range of sensitivity of the assay (see 
Appendix D for further details).
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This computer program has been checked against various 
other methods of calculating estimates at the National Institute 
of Biological Standard and Control. The program rejected poor 
duplicates depending on the magnitude of their discrepancy and 
their position on the dose-response curve.
3.4.8 RIA - Quality control
It is increasingly being recognized that it is very 
important to set up a system of quality control for RIA whereby 
the accuracy and the variability of assays can be checked.
These two measures can vary independently i.e. an accurate assay 
may give very variable results from assay to assay: alternatively
a reliable assay may produce very "tight" data but generate data 
nowhere near the 'true' result. For each of the assays performed 
here at the CRC (assays 1 - 7 )  section 4.3) the following 
protocol for establishing inter and intra assay variation was 
performed.
Samples were obtained which contained high (near the upper 
limit of assay detection), medium and low (near the lower limit 
of detection) concentrations of the hormone under test. These 
samples were obtained from a variety of sources (e.g. high FSH 
and LH samples were obtained from post menopausal females, high 
TSH samples from patients with hypothyroidism, high GH sample 
from a control subject taking 'Bovril', high PRL sample from a 
patient on neuroleptics etc.). Various sera were then mixed to 
reach approximate concentrations. These samples were then 
aliquoted, so that an aliquot could be measured in every assay.
The inter assay variation was then calculated by finding the mean
1 1 3
and SD of these estimates and dividing the SD by the mean (co­
efficient of variation = SD/mean X 100/). Assays were only 
accepted when the estimates for each of the high, medium and low 
quality controls (QC's) fell within the mean ± the co-efficient 
of variation. If assays were within this range then values 
estimated were accepted and no correction factors were applied. 
Intra-assay variation was checked by repeated random estimations 
of a sample (whose level was close to the expected levels of the 
normal population) within one assay. Details of the QC's used 
for each assay and the calculated inter and intra assay variations 
over all the assays performed are given in Appendix D. In 
practice, a series of assays were undertaken for one particular 
study and the assay variations for the series are given in the 
methods section of each separate study.
To minimise the effects of inter assay variation, each assay 
contained all the samples from one patient on one particular 
test protocol and each assay contained samples from patients and 
controls.
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CHAPTER 4
Basal pituitary hormone levels in acute and. chronic schizophrenia, 
with particular reference to gonadotrophin and prolactin hormonal 
rhythms
INTRODUCTION
As discussed in chapter 2 there is increasing interest in 
the study of pituitary hormone secretion in psychiatric illness. 
This is largely based on the hope that thereby diagnostic 
markers may be developed and an understanding of the aetiopatho- 
logical basis made. This section reports on hormonal estimates 
from acute and chronic schizophrenics, diagnosed according to 
strict criteria. Particular reference is paid to hormonal 
rhythms since dynamic aspects of hormonal secretion have important 
underlying control mechanisms and single estimates of hormones 
are methodologically problematical.
As discussed in chapter 1 (section 2.3) and chapter 2 
(section 2.6) 3 groups of workers have demonstrated low gonado­
trophin secretion in patients with chronic schizophrenia, although 
the frequency of these abnormalities varied from 30/ of cases 
(Shader et al, 1968; Johnstone et al, 1977) to 100/ (Brambilla 
et al, 1973)" Gonadotrophin secretion in acute schizophrenic 
patients has scarcely been studied. It has become recognized 
that the secretion of LH is episodic. There are bursts of LH 
secretion occurring at irregular intervals throughout the 24- 
hours (Boyar et al, 1972). There are 12 - 20 of these episodes 
per day (defined as an increment greater than 30/ of the proceed­
ing level) (Santen and Bardin, 1973). FSH exhibits a similar
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though less marked pattern. In this study LH and FSH were 
measured serially in patients with chronic schizophrenia in order 
to a) examine the incidence of gonadotrophin secretion abnorma­
lities in a population of chronic schizophrenics b) determine 
whether the normal episodic secretory pattern of gonadotrophin 
secretion is disturbed in schizophrenia and the degree of 
reliability of various measures of this and c) assess the 
relationship between gonadotrophin secretion and various clinical 
characteristics of the patients studied.
In addition, the following hormones - PRL, GH, 13i T4, TSH, 
testosterone and oestradiol were measured in schizophrenic 
patients and the reasons for the inclusion of each of these 
hormones are set out below.
PRL and GH secretion are of considerable theoretical 
importance in neuroendocrine studies of schizophrenic patients, 
since DA is important in the regulation of both these hormones. 
Several studies reviewed in chapter 2 (section 2.6) have 
indicated that the basal levels of these hormones are normal in 
both acute and chronic schizophrenia. However these hormones 
have characteristic neural-regulated rhythms of secretion 
(detailed in chapter 2 (section 1.3)) and these rhythms have not 
been studied in schizophrenic patients.
Several studies have indicated that thyroid function (e.g. 
Kline et al, 1968) (including TSH secretion (Johnstone et al, 
1977)) is normal in schizophrenia. The present study provided 
an opportunity to replicate and extend such work. Abnormalities 
of thyroid function can alter hormonal responsivity to various
1 1 6
agents (e.g. drugs and hypothalamic releasing factors) and so 
thyroid function estimations are important prior to embarking on 
studies which employ such provocative agents (chapter 3, 6 and 7)*
Testosterone was measured in schizophrenic patients in an 
attempt to resolve some outstanding problems raised by previously 
published studies. These are:- 1) Brambilla et al (1973) 
reported a large reduction in serum testosterone in all of the 
chronic schizophrenic patients they studied. This has not 
subsequently been replicated. Moreover urinary testosterone has 
been found to be reduced only by a small amount and only in a 
sub-group of chronic schizophrenics (Brooksbank et al, 1970)
2) Beumont et al (l974y^reported that serum tesbosterone levels 
rose (into the normal range) in chronic schizophrenics after 
neuroleptic therapy was withdrawn. These studies indicate that 
the large reductions found in testosterone by Brambilla et al
(1973) may have been due to the short time following neuroleptic 
withdrawl prior to study.
This study was also used as an opportunity to measure serum 
oestradiol levels in schizophrenic patients. This measure is 
of particular interest because levels of oestrogens have been 
shown to influence both LH secretory rhythms (Santen and Bardin,
1973) and PRL secretion (Martin et al, 1977) both of which were 
assessed in the present study. In addition there are strands 
of evidence from older studies that urinary secretion of 
oestrogens is increased in schizophrenic subjects (Hoskins and 
Pincus, 1949; Sands, 1937) which have not been replicated using 
more modern methodology.
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SUBJECTS, MATERIALS AND METHODS 
Subjects
Five groups of subjects were studied as outlined below. 
Clinical characteristics are given in Table 4.1.
1) Chronic schizophrenic group (CS)
Twenty long term inpatients were selected from a large 
sample of schizophrenic patients who conformed to criteria of 
Feighner et al (1972) (see chapter and Appendix A). The
large sample from which the group studied here was drawn have 
been documented in detail elsewhere (Owens and Johnstone, I980). 
Some results from that survey were presented in chapter 1. The 
20 patients studied here were selected on the basis that they
1) were male
2) were aged less than 70 yrs
3) had been off neuroleptic medication for at least a year prior
to the study (see chapter 2 for further details of the
analysis of drug history and Table 4.1 for specific details 
for this group ) and
4) were agreeable to inclusion (see chapter 2 for further details)
These patients exhibited normally developed secondary 
sexual characteristics. Because of the nature of their mental 
state and life in a large psychiatric hospital it was impossible 
to assess libido or estimate the frequency or type of sexual 
experience. Physical examination did not reveal any significant 
medical abnormality other than arthritis (probably osteoarthritis) 
and mild hypertension (1 case each). As can be seen from Table
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4.1, the weight of this group was less than their age-matched 
control group (2 below) but this difference is not significant.
On a subsequent occasion some 3 - 9 months later eleven 
of these patients were retested in a similar fashion to that 
described below. The clinical state and drug free status of 
these patients w^ as identical on the second occasion of testing.
2) Controls (CONT)
Seventeen subjects were studied as controls (Table 4.1).
This group was comprised of several subgroups as follows
a) 3 normal healthy volunteers
b) 3 were long stay patients of the same hospital as the CS 
patients (group 1, above) with a diagnosis of manic depressive 
psychoses on the Feighner criteria (see Appendix A). At the 
time of the study none of these patients showed evidence of 
affective disturbance.
c) 5 men attending outpatients with a diagnosis of mild reactive 
depression (Using the criteria of Feighner et al (1972) 
these patients fell into the cateogy of "unspecified psychi­
atric disorder - category 1" and all were symptom free at 
the time of study).
d) 6 were patients recently admitted to an orthopaedic ward 
for elective surgery for non-metabolic disease (osteo­
arthritis (2), ganglion (l), Dupytren's contracture (2), 
removal of pin (l)).
None of the above subjects were taking psychoactive medication 
at the time of study. Other drugs ingested by this group are 
documented in Table 4.1. There was no evidence that any subject
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in this (or indeed in any) group abused alcohol or drugs.
3) Remission from acute schizophrenia
Three patients who had previously been admitted with acute 
nuclear schizophrenia (NS 4- on Catego program of the PSE - see 
chapter 2) were studied. These patients had been admitted, vith 
their first episode of schizophrenia 19 - 3^ months previously. 
Mental state was normal (see below) at the time of study. All 
were gainfully employed. They had discontinued neuroleptic 
medication of their own accord 6 - 9  months prior to this study 
(2 have subsequently relapsed).
In addition single venous samples were taken from*.-
4) Acute schizophrenia
30 male patients recently admitted with acute schizophrenia 
(see section 1.2 , chapter 3 for the definition of this classifi­
cation) were studied. These patients were also the subjects of 
the studies described in chapters 6 and ?. All patients were 
drug-free at the time of study (see section 1.4, chapter 3 
for definition of drug-free for this group). Further clinical 
details are furnished in Table 4.1.
3) Reference Populations
Single venous samples were obtained from two groups of 
volunteer subjects selected to age match groups (1) and groups
(3) / (4) respectively (Table 4.1). These were respectively
a) 30 men - 13 normal healthy normal volunteers and 13 attending 
outpatients with non-endocrine disease (e.g. peptic ulceration, 
chronic bronchitis, minor orthopaedic problems) and b) 11 normal 
male healthy medical and paramedical hospital staff.
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Methods
Venous sampling
All subjects from groups 1, 2 and 3 were studied under 
similar circumstances» After an overnight fast a butterfly 
cannula was inserted at 8.00 a.m. and kept open with dilute 
heparanised saline which was discarded prior to sampling (further 
details are given in chapter 3*3-3)• Blood samples were taken 
at 15 - 20 minute intervals for 2.3 - 4 hours. Sampling periods 
were comparable in both groups (see table 4.1 for details). At 
0900 hours a light breakfast was given.
Single samples were obtained by venupuncture from subjects 
in groups 4 and 5- Samples from acute schizophrenics (group 4) 
and their age-matched control group (3i b ) were taken fasting 
at 0830 hrs. Samples from group 3a) (older reference group) 
were taken between 0930 and IO3O hrs as they were control samples 
for the mean levels of the CS group (I).
Sera was prepared as outlined in chapter 3-3-3.
Radio-immunoassay
The following hormones were estimated in samples from these 
groups LH, FSH, PRL, GH, TSH, T3 , T4, testosterone and oestradiol„ 
A full description of the methodology of each of these assays 
was given in Chapter 3 (section 4.3). For estimates of each 
substance, all the samples from each patient were estimated in a 
single assay. All assays contained samples from patients and 
controls in a balanced design. Theoretical aspects of quality 
control protocols were discussed in Chapter 3 (section 4.8). 
Specific details of the number of assays performed and the intra
1 2 2
and inter-assay variation for a range of quality controls is given 
in Table 4.2.
Serial estimations of LH, FSH, PRL and GH were made for 
groups 1, 2 and 3 whereas T3, Ta, TSH, testosterone and oestradiol 
were measured in single samples only in all of the groups- In 
the case of LH and FSH, a mean value has been calculated for the 
series of estimates and the co-efficient of variation (CV/) was 
computed by dividing the standard deviation (SD) by the mean (CV/ = 
SD/mean X 100/).
Mental State Mental state of the schizophrenic patients was 
assessed on a 0 - 4 scale according to the method of Krawiecka 
et al (1977) which is described in detail in chapter 3 (section 
2.1)0 Cognitive function was assessed in the CS group by the 
Withers and Hinton (1972) test of the sensorium (see chapter 3-2.2) 
Statistics In relating clinical data to hormonal estimates in 
serum a non-parametric analysis (Spearman's rank correlation test) 
was performed. Comparisons between groups were made using the 
Student's t-test (two tailed) unless otherwise stated. An 
examination of LH and FSH data revealed a skewed distribution.
Plots of LH and FSH indicated that the transformation X z: 
was adequate to make the data normally distributed. Comparisons 
between groups in terms of LH and FSH were analysed by one way 
analysis of co-variance. Parametric correlations were performed 
on untransformed data.
Results
Levels of hormones estimated in all of the groups are set
1 2 3
TABLE 4.2
Hormone No. of Assays
Qua i i t y  Control Data
Intrassay
v a r ia t io nQCi QCg QC3 QCij
LH
iU/1 15
Mean
SO
CV%
50.3
7.6
15.1
11.4
0.5
4.6
10.7
1.2
10.9
6.8
1.0
14.6
5%
FSH
U/1 8
Mean
SD
CV%
5.7
0.6
10.5 I i
2.2
0.1
6.8
- 5%
GH
iiiiU/I 12
Mean
SD
CV%
10.1 
0.9 
8.9 ë 0.212.5
0.8
3%
PRL
miU/1 12
Mean
SD
CV%
41
11.6
411
48
11.7
167
13
7.6
- 4%
TSH
niu/1 5
Mean
SDcv%
2.0
0.2
10.0
20.4
2.2
10.8 - -
6%
Testosterone 
n mol/1 4
Mean
SD
Cv%
21.9
3.6
16.8
44.6
4.9
11,0
- 10%
Quality control data for assays reported in chapter 4. Intrassay 
variation is small for each of the assays. Co-efficiencts 
of variation are of the order of 10/ in the middle of the 
assay range but somewhat larger towards the limit of assay 
sensitivity (see chapter 3 (4.8) and appendix D for further 
details)
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out in Table 4.^. Values for LH, FSH, PRL and GH are the means 
of mean values for groups 1, 2 and 3 but are from single samples 
for the remaining hormones and for all estimates from groups 4 
and 3*
a) Comparison of results between CS group (1) and their age- 
matched control group (groups 2 and 3&)
There was no difference between the CS group and each of 
the control groups or both combined in thyroid function (TSH,
T3i T4), gonadal steroids (testosterone and oestradiol) or PRL 
and GH secretion. Ill and FSH secretion were significantly 
reduced in the CS group compared to either control group and 
both groups combined (see Table 4.3 for significance levels).
An effect of age on LH and FSH secretion was noted in both 
groups (see below) and therefore a one way analysis of co-variance 
was carried out allowing for this effeck. Using this analysis 
LH and FSH were significantly reduced below the control group 
(F(1,62) = 4.371 P < 0.05 : F(lj62) - 11.23, P < 0.001 respec­
tively) .
b) Comparison of results between acute schizophrenics in 
remission (group 3), acute schizophrenics (group 4) and age- 
matched control group (group 3b)
As can be seen from Table 4.3 there were no differences in 
LH, FSH, GH, PRL or oestradiol secretion between these groups.
c) Results of serial sampling (Figs 4.1, 4.2, 4.3)
1) LH and FSH. The co-efficient of variation (CV%) from 
all estimates of LH and FSH was calculated as described above for 
each subject for whom serial samples were obtained; the mean
TABIxE 4.3
1 2 5
TSHinu/1 Oestradiol  p mol/1Testosterone n mol/1PRLmiU/lFSHU/1Group n mol/1 n mol/ImU/1lu/1
1. Chronic schizophrenics 27.4
±2.7
150 71,1
±0.3 ±0.3 ±0.5 ±3.0±16 +5.9
155 25.12. Controls 70.3
±0.1 ±7.0±2.4
3. Remission from acute 169
±26schizophren io ±0.3 ±0.3
2254. Acute schizophrenics 52.1
±23±0,2 ±7.3
(10)
a) Older 
group 159 76.79.8
+0.2±1.3 ±0.1
(13)
±1.7
(13)5. Reference 
Populations
b) Younger 
group 234 60.1
±0.5 ±0.3
(10)
±9.5±0.5 ±23
(10)
Basal levels of hormones in 5 groups studied (see text for details). * p < 0.05 
*+ p < 0.01 compared with chronic schizophrenics. No other significant 
differences. Number studied in parentheses.
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Serial LH levels in 3 acute schizophrenics in remission. 
All exhibit evidence of episodic secretion.
TABLE 4.4
LH(IU/L FSH U/L
Nur.ibor df
p iLienta with 
«viuonce ol’ a
Mean number of 
positive Lll
Mean SD cv% Mean SD cv% Ui increment .^ j'eater than 
■5(^ 0 of baficlpi^
increments per 
hour of sampling
I) CS n-20 Mean
SD
6.2
2,7
0.9
1.0
14.8 
11.1
2.7
0.3
0.4
0.3
14.2
5.0
7 (35%) 0.12
Mean 
2) CONT nH7
SD
9.1"
4 .5
1.7**
1.1
18.6*
6.6
7.7**
13.0
0.9*
0.3
12.8
7.4
12(71%) 0.39***
3) AS n»3
Mean
SD
5.5
0.9
1.0
0.3
18.0
5.3
1.7
0.6
- - 3(100%) 0,56***
LH, FSH and the co-efficient of variation for serial estimates 
of LH and FSH (CV%) in groups studied (means ± SEM) : percentage 
of patients with and frequency of positive LH increments.
* p < 0.3 ** p < 0.01 p < 0.001.
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values for each group, together with the mean serum level for the 
group, are shown in Table 4.4. Previous workers (Boyar et al, 
1972; Santen and Bardin, 1973) have defined an LH secretory 
episode as a positive increment of '^QP/o above the previous level. 
The number of subjects in each group whose serial sample estimates 
gave evidence of this phenomonen is shown in Table 4.4. The mean 
number of such episodes per hour for each group is also shown in 
Table 4.4
The mean level of LH and FSH is lower in the schizophrenic 
group than in the COM’ group. The coefficient of variation is 
lower in the CS group compared with the C O M  group for LH (p < 
0.03, standard Student’s t-test) but not for FSH.
There was a cluster of CS patients (n ~ 10) in whom the 
coeficient of variation for LH is less than 10^ (twice the within- 
assay coefficient of variation), whereas none of the controls 
exhibited such low levels of fluctuation in serial LH estimates 
(Figs 4.1? 4.2).
According to the criteria set out above for defining an LH 
secretory episode, 12 of the 17 controls (71%), but only 7 out of 
the 20 chronic schizophrenics (33%), exhibited evidence of 
episodic LH secretion. All of the young schizophrenic patients 
had evidence of episodic LH secretion (see fig 4.3). An episode 
of LH secretion tended to be followed by the characteristic 
decrement in the LH level to baseline.
As shown in Table 4.4, the frequency of LH episodes per 
hour is much less in the OS group (0.12 episodes per hour or 1 
episode every 8.3 hours) than in the C O M  group (0.39 episodes
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per hour or 1 episode every 2.6 hours) and this difference was 
statistically significant at the p < 0.005 level. The mean 
frequency of LH secretory episodes in the AS group (0.57 episodes 
per hour or 1 episode every 1.8 hours) was significantly (p < 
0 .005) greater than in the CS group, but not so when compared 
with the mean frequency in the CONT group (p > O.5). There was 
no difference in the amplitude of LH pulses between the groups.
FSH levels also fluctuated in an episodic pattern but 
much less markedly in all groups, so that no significant differ­
ences between groups were observed. In general, FSH secretory 
episodes followed those of LH.
2) GH. As can be seen from Table 4-. 5 there was no 
difference in mean GH levels between the groups tested with serial 
venous sampling. There was also no difference in the pattern of 
GH secretion over the time of sampling. A substantial proportion 
of patients from the CS group (75%) and from the CONT group
(71%) exhibited no change in GH secretion during the time of 
sampling greater than the intra assay variation (5%)« An 
episode of GH secretion was seen in 4 CS patients and 5 of the 
CONT group (in 1 subject from each there was a peak increment 
> 5 mlU/l). No relationship between these spontaneous increments 
in GH secretion and gonadotrophin secretion or any other parameter 
was demonstrated.
3) PRL. There was a comparable decrement in PRL secretion 
during the test period (approx. 8 - 11 a.m.) in each of the 
groups studied (Fig 4.4). There was no statistical difference
in PRL level between the groups at any time point. As discussed
Fig. 4.A
250
200
z5 150
Û-:
Q_
100
50
Mean s i  SEM 1 3 0
20 Chron ic  Schizophrenics. 
17 Controls o <3,
0800 0900 1000
Clock Time (hrs).
1100
Mean serial PRL levels between 0800 and 1100 hrs in 20 
chronic schizophrenics and 1? controls. No significant 
differences between groups.
Fig. 4.13
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Relationship between mean Ml, FSH, standard deviation (SD) 
and co-efficient of variation (CV%) of serial LH estimates 
on two separate occasions in 11 unmedicated chronic schizo­
phrenics.
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above a group of CS patients (n = 10) exhibited very little 
change in LH secretion over the 3 hours of testing ( LHGV% of 
10% or less*mean 7.3%)* It was found that the mean 8 a.m. PRL 
level in these patients (137 1 l4 (SLM mlU/l) was significantly 
lower (p < 0.01) than those in 10 CS patients whose LHCV%. was 
greater than 10% (mean 24%) (mean 8 a.m. PRL level of this group 
was 281 ± 39 (SEM) mIU/1).
d) Results of retesting
Eleven patients were retested in a similar way on a subse­
quent occasion as documented in the methods. The relationship 
between the mean initial and retest levels of both LH and FSH 
and the degree of fluctuation of serial LH estimates (measured 
by calculating the SD and the CV of all estimates)on the two 
occasions is shown in Fig 4.3» It can be seen that both the 
levels of LH and FSH and the degree of pulsatility of LH show 
close intra-individual reproducibility.
3 patients of the original group of 20 CS patients were 
subsequently started on neuroleptic therapy. These patients were 
also retested and the results will be described in chapter 6.
e) Correlation between measured variables
1) Hormonal variables. There was a highly significant 
relationship between LH and FSH in samples from the total group 
studied (r - O.67, n - 111, p < O.OOI). This relationship was 
evident in samples from all patient groups. Regression analysis 
revealed that there was no difference in the slope of this 
relationship between schizophrenic patients and control subjects.
A positive relationship was established between LH and
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testosterone (r = 0.44, n = 50, p < 0.05) in samples from control 
subjects (CONT group (n = 1?) and part of the reference population 
(5a, n - 15) but not in samples from any other group.
There was a highly significant relationship between LH CV% 
and 8 a.m. PRL levels in samples from the CS group (r = 0.62, 
n = 20, p < 0 .01). This relationship also held, though less 
strikingly, with mean PRL levels (r = 0.55, u = 20, p < 0.05).
In other words those patients with little evidence of LH 
pulsability (low LH CV%) also exhibited lower early morning PRL 
levels. This relationship was not demonstrated in the CONT 
group (group 2). No relationship was established between mean 
LH and FSH levels and 8 a.m. or mean PRL levels in any of the 
groups studied. A significant inverse relationship between the 
oestradiol and PRL levels of the same samples was noted in those 
patients in whom oestradiol measurements were obtained (r =
-O.29, n - 70, p < 0.05). This relationship may come about 
because of the opposite effects of age on these two parameters 
(see below).
2) Relationship between clinical variables and hormonal 
data
a) All subjects. Age: There was a significant positive
relationship between age and LH and FSH levels in the total
population studied (LH: r - 0.25, n = 111, p < 0.01; FSH: r =
0,25, n = 111, p < 0.05). This relationship was also seen in 
the control group as a whole (groups 2 and 5, n = 58 ; LH: r =
.32; FSH: r = -26, p < O.O5) but not in the total schizophrenic
group (groups 1, 3 and 4, n - 53; LH: r = .09; FSH: r = .I8 ,
1 3 3
p > O.l) (although a positive trend for increasing gonadotrophin 
levels with increasing age was noted in the older schizophrenic 
group). No significant effects of age on LH CV% or on the other 
hormones were noted. Trends (significant at the p < 0.1 level) 
were noted for oestradiol to increase with age (r = .29, n = 70) 
and for PRL to decrease with age (r - -.21, n - ?0). These age 
effects appear (by calculation of partial co-efficients-see Appendix: E) to 
account for the inverse relationship between PRL and oestradiol 
mentioned above.
Weight: There was no correlation between the weight of
the patients and any of the hormonal variables measured and 
specifically no weight effect on gonadotrophin secretion or LH 
pulsatility was shown.
b) Schizophrenic patients. Correlations were examined between 
clinical variables recorded on the schizophrenic subjecs and 
measured hormonal data, the more important of which are given 
below. There are limitations to the relevance of these corre­
lations since a) a large number were examined and therefore a 
small number may be significant by chance and b) complex inter­
actions may occur between parametric and non-parametric data (for 
example age and symptomatology) which require more complex 
statistical evaluation.
1) Length of illness. There was a negative relationship between 
the degree of LH fluctuation (LH CV%) and length of illness of 
the CS patients (r =: -0.46, n - 20, p < 0.05).
2) Age at first hospitalization. This varied between l6 and 40 
years of age in the schizophrenic group under study. There
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was a positive relationship between age at first hospitalization 
and FSH (r - 0.4-9, n - 53, P O.Ol).
3) Effect of drugs. There was no difference in any of the 
hormonal variables between the patients who had never received 
drugs and those who had received minimal or substantial doses 
in the past.
4) Relationship to mental state. There was a significant, 
inverse relationship between FSH, but not LH, secretion and 
positive symptoms in the CS group (r = -0.47, n = 20, p <
0.05 Spearman's ranli correlation). No such relationship was 
noted in the acute schizophrenic group. There was a non­
significant trend for decreasing PRL secretion with increasing 
positive symptoms scores in the acute schizophrenic patients 
(r - -0.33, n - yO, P 0.1), but no such trend was seen in 
the CS patients. There was no significant relationships 
established between hormonal measures and negative symptom 
scores, cognitive function scores or Catego classification 
(see Appendix B) in either group studied.
DISCUSSION
In summary, these results confirm that a number of patients 
with chronic schizophrenia have low LH and FSH levels compared 
with an aged matched population. This is associated with a 
reduction in the frequency, but not amplitude, of LH secretory 
episodes. Basal levels of PRL, GH, T3, T4, TSH, testosterone and 
oestradiol were not different between these groups. By contrast, 
no abnormalities of gonadotrophin or other hormonal secretion
I J  Ü
were noted in patients with, acute schizophrenia and 3 such patients 
gave evidence of normal rhythm of LH. secretion some time after 
their acute episode. Some evidence was found to suggest that the 
abnormal rhythm of gonadotrophin secretion in chronic schizophrenia 
was associated with low early morning PRL levels and increasing 
length and severity of illness.
Abnormalities of gonadotrophin secretion cannot be regarded 
as specific for the diagnosis of schizophrenia. Definite abnor­
malities of LH and FSH secretion were found only in 30% of the 
chronic schizophrenics studied and 23% of the patients had both 
a typical schizophrenic illness and a perfectly normal hormonal 
profile. Abnormalities of gonadotrophin secretion have been 
detected in several psychiatric syndromes notably depression 
(Brambilla et al, 1978), anorexia nervosa (Beumont et al, 197^,b) 
and neurotic states (Lachelin and Yen, 1978).
The non-specific effects of psychiatric illness which might 
account for the finding of reduced gonadotrophin secretion in 
schizophrenia therefore need to be considered first. These 
include the effects of stress, the effects of prolonged hospital­
isation ("institutionalisation”), weight loss and previous drug 
therapy. The role of these various possibilities will now be 
discussed in turn.
The patients and controls (some of whom suffered from 
neurotic illness) were subjected to the same technical procedures 
of cannulation and repeated sampling. The chronic schizophrenics 
did not appear "stressed" during the procedure. This however is 
weak evidence against the notion that stress may be the cause of
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the present findings since it has been demonstrated that chronic 
schizophrenics as a group have evidence of over-arousal on skin 
galvanic responses while appearing emotionally flat (Deal^in et 
al, 1979)* However effects of "stress" on gonadotrophin secretion 
have not been reported in man though Rose et al (19Ô9) reported 
reduced testosterone secretion in army personnel under stressful 
circumstances.
The effects of long term care are a perennial problem in 
research into chronic schizophrenia because of the difficulties 
in the selection of appropriate control group. It is noteworthy 
however that, in the present study, no abnormalities of gonado­
trophin secretion were detected in 3 manic-depressive patients 
hospitalised in the same environment as the CS patients for 
comparable periods. There is evidence from animal studies that 
environmental factors can affect gonadotrophin secretion (e.g. 
Tach^ et al, 1978) but no comparable evidence is yet available 
in man. (See chapter 8, for further discussion).
Neuroleptics have been implicated in causing gonadotrophin 
and/or gonadal dysfunction either directly (Shader and Di Mascio, 
1970) or via hyperprolactinaemia (Glass et al, 1973). The 
evidence for an effect of neuroleptics on MI and FSH is open to 
debate (Johnstone and Ferrier, I98O) - particularly in the case 
of chronic neuroleptic therapy (Beumont et al, 1974a), where it 
has been shown that prolactin levels tend to return to the normal 
range (De Rivera et al, 1976; Huws and Groom, 1977)* In the 
present study no difference in LH, LH episodic release, FSH or 
testosterone was noted between patients who had never received
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neuroleptics and those who had received substantial amounts in 
the past.
Weight loss has been implicated in some of the neuroendocrine 
abnormalities detected in anorexia nervosa and in depression (see 
chapter 2.2.7). However in the present study no relationship 
between body weight and the hormonal abnormalities of chronic ■ 
schizophrenia was established and abnormalities were found in 
patients whose weight was in the normallange.
It is also unlikely that other psychotropic medication 
(e.g. antidepressants, anxiolytics) could cause the present 
findings. Firstly concurrent medication with these drugs was 
specifically excluded (see chapter 3). Secondly the effects of 
these drugs on gonadotrophin secretion are weak and variable 
(Johnstone and Ferrier, 1980 for review). Finally several of 
the control group (6 subjects) had also been treated with psycho­
tropic medication in the past. Further discussion on the non­
specific effects of psychiatric illness on pituitary hormone 
secretion together with selection of appropriate controls is 
given in chapter 8.
Before going on to discuss possible causes of gonadotrophin 
reduction in chronic schizophrenia more specifically related to 
disease processes, the time scale of the development of these 
abnormalities will first be discussed. Because no abnormalities 
of gonadotrophin secretion are seen in patients either with 
acute schizophrenia or in remission from it and because it appears 
that increasing length of illness seems to be associated with 
reduced LH pulsatility, it is tempting to speculate that these
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abnormalities relate to the development of impairments of chronic 
schizophrenia and perhaps therefore have an organic basis (see 
chapter 1, section 2.4 for summary of the evidence for an organic 
basis underlying chronic schizophrenia). However there was no 
relationship between gonadotrophin secretion and accepted measures 
of impairment in the chronic schizophrenics (e.g. cognitive 
function tests, negative symptom score). Indeed a negative 
correlation between FSH secretion and positive symptoms was 
established in the chronic schizophrenic group (confirming the 
similar observations of Shader et al, 1968 and Johnstone et al,
1977).
It appears that the age of onset of schizophrenia has an 
effect on FSH levels estimated many years later: that is, the 
earlier the age of onset, the lower the estimated FSH. The 
relationship between the age of onset of schizophrenia, age at 
puberty and subsequent gonadotrophin secretion is clearly an 
important area for investigation, though such studies are proble­
matical since the onset of illness is often hard to define and 
hospitalization policy is variable. The effect of age of onset 
on FSH may account for the high frequency of gonadotrophin 
abnormalities in Brambilla's study, as most patients in that study 
had an onset of schizophrenia in the early and raid teens (Brambilla 
et al, 1975)* These findings are also of particular interest in 
relation to some neurochemical studies (Spokes et al, I98O) 
which suggest a particular pattern of biochemical changes in the 
brains of early onset schizophrenics.
It is also noteworthy that the association of increasing
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age with increasing gonadotrophin secretion found in the total 
normal control group studied here and reported in other studies 
(Wide et al, 1973; Baker et al, 1976), was not found across 
the schizophrenic group as a whole. However a non-significant 
trend for increasing gonadotrophin levels with increasing age 
was seen in the CS group of patients and therefore the effect 
was talcen into account in analysis of gonadotrophin secretion 
differences. The lack of an age effect across the total schizo­
phrenic group suggests some change in testosterone/gonadotrophin 
feedback in schizophrenia as is further discussed below.
Thus no clear answer to the question of the natural history 
of these abnormalities can be given at present and the relation­
ship of them to the natural history of schizophrenia is similarly 
uncertain. Further, larger studies will have to be performed 
to answer these questions. These matters are further discussed 
in chapter 8.
It appears, from the evidence of this study, that the 
site of reduced gonadotrophin secretion in chronic schizophrenia 
lies at the hypothalamic level. This is because there is good 
evidence that pulsatile IH secretion (reduced in these patients) 
is prompted by the pulsatile secretion of LHRH from the hypo­
thalamus (Belchetz et al, 1978).
Several factors control the release of IHRH from the 
hypothalamus. Among the most prominent of these is feedback from 
gonadal steroids. However neither oestradiol (which in excess 
is known to reduce episodic LH secretion (Santen, 1973) nor 
testosterone was abnormal in the chronic schizophrenic group nor
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was either statistically related to flattening of the LH secretory 
profile. An abnormality of the testosterone/LH feedback relation­
ship in schizophrenia has been postulated by Beumont et al (1974). 
In this regard it is noteworthy that there was a significant 
positive relationship between testosterone and LH in controls, 
but not in the schizophrenics and that an age effect on gonado­
trophin secretion (seen in controls and thought to be due to 
the effects of decreasing testosterone feedback with increasing 
age) did not occur in the total schizophrenic group. The nature 
of the disturbance in testosterone/gonadotrophin feedback in 
schizophrenia is not clear but may repay further study.
Animal studies have indicated that several neurotransmitters 
have effects on pulsatile secretion of LH (Gallo, I98O), but 
much less evidence is available in man. There is some evidence 
that opiate agonists reduce (Grossman et al, I981) and opiate 
antagonists increase (Moult et al, I98I) the frequency of LH 
secretory episodes. Noradrenergic, serotonergic and dopaminergic 
drugs have little effect on LH secretion in man (Johnstone and 
Ferrier, 1980). However, recent evidence indicates that dopamine 
(DA) infusions produce lower LH levels and a reduction in the 
number of episodes of LH secretion (Le Blanc et al, 1976;
Kaptein et al, I98O; Huseman et al, 198O), a similar pattern to 
that seen with dopamine agonists in experimental animals (Gallo, 
1980). Thus it is conceivable that the low flat LH secretion 
pattern of some chronic schizophrenics may reflect overactivity 
of DA neurotransmission in the hypothalamus or a change in DA 
receptors in the pituitary. However, if this were the case.
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alterations of PEL secretion would be expected. However there 
was a marked relationship between PEL levels and the LH CV% in 
the CS patients (such that patients with low PEL also exhibited 
low LH CV%): both these phenomena might be caused by excess 
release of DA from the hypothalamus.
Another possible cause of the impairment of gonadotrophin 
secretion in the chronic schizophrenics relates to ventricular 
enlargement, which is known to be present in quite a large 
number of chronic schizophrenic patients and to extend to tirethird 
ventricle (see chapter 1, Table 1.2 for review). It is conceiv­
able that hypothalamic damage could result from this enlargement 
leading to a disruption of releasing factor secretion. However 
the hormonal deficit found was selective for the gonadotrophins 
and did not extend to other pituitary hormones e.g. TSH, GH.
Abnormalities of gonadotrophin secretion in chronic 
schizophrenia have now been reported by several groups of workers. 
The evidence points to an abnormality in the hypothalamus, 
either in the LHRH neuronal pathway or some closely related 
pathway. This ties up with the clinical evidence of hypogonadism 
in subgroups of chronic schizophrenics cited in chapter 1 (section 
2.3). The pathophysiological significance of these findings 
will be discussed further in the final chapter (8) where the 
results from all the studies undertaken will be synthesised.
PRL levels were not statistically significantly reduced 
in the chronic schizophrenic patients studied here which confirms 
previous observations (Brambilla et al, 1976; Johnstone et al, 
1977). In the present study it was also found that the rhythm
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of PRL secretion in the early morning was not different from 
that of controls. It should be noted however that the present 
study was not principally designed to examine the diurnal 
rhythm of PRL. To do this comprehensively would require venous 
sampling while the subject was asleep and recording the exact 
time of wakening. Times of waking and of getting up were not 
controlled in the present study. With these reservations in 
mind, it does appear that PRL is elevated in the early morning 
and falls to baseline to the same extent in schizophrenics as 
controls.
It is however interesting that those patients with the 
lower early morning PRL levels were also those patients who 
exhibited little evidence of LH episodic secretion (LH CV% of 
10% or less - see results). Since this latter phenoraon is 
pathological, this close relationship implies that PRL secretion 
is also pathologically low in the early morning in these patients 
(and indeed compared to the controls and remainder of the CS 
group PRL levels were significantly reduced in these patients).
High levels of early morning PRL levels are thought by some 
workers (on somewhat limited evidence) to represent a reduction 
in hypothalamic dopaminergic tone. If this is so, then the low 
early morning PRL levels seen in some of the chronic schizophrenic 
patients may represent an overactivity of hypothalamic DA. As 
was discussed above, there is theoretical evidence to suggest 
that the excessive DA release or effect could be responsible 
for the flattening of the LH profile. Other factors may be 
responsible, but the closeness of the relationship between LH GV%
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and 8 a.m. PRL, and the reduction of both these values, in some 
chronic schizophrenics considered along with the putative role 
of excess DA in both processes may indicate that the DA over­
activity hypothesis of schizophrenia has been confirmed in living 
patients. However the outstanding problem is that these abnor­
malities are detected only in a subgroup of patients. Theoretical 
implications of this are further discussed in chapter 8.
The presence of the trend for lower levels of PRL with 
increasing age (which has been found by some but not all previous 
workers) is important since it accounts for bhe observation that 
PRL levels are lower in chronic schizophrenic patients compared 
to acute schizophrenics. This difference was also found in a 
smaller sample of patients reported in chapter 7 where this 
observation was of theoretical importance.
No abnormality of basal or episodic GH secretion was 
detected in the schizophrenic patients. This is in agreement 
with previously published studies (Cleghorn et al, I982).
Although there is some evidence for dopaminergic influences on 
GH secretion in man there are significant differences in the 
pharmacology of GH responses compared to the pharmacology of 
LH and PRL responses (see chapter 2 section 1.3 and chapter 7)*
No abnormalities of thyroid function were detected in the 
schizophrenic subjects in the present study which confirms 
previously published studies (Kline et al, I968; Frange et al, 
1979). As was discussed in chapter 1 (section 2.5) abnormalities 
of thyroid function and schizophreniform illnesses are occasion­
ally related but there seems to be no association between 'typical'
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schizophrenia and disturbances of thyroid function.
No abnormalities of hormonal secretion were noted in 
patients with acute schizophrenia or in acute schizophrenic 
patients in remission. This is further support for the contention 
outlined in chapter 1 (section 2.5) that hormonal dysfunction 
is not an aetiological factor in schizophrenia. FSH was noted 
to be lower in acute schizophrenics and patients in remission 
compared with aged-matched controls, but this difference was 
not significant. The reduction was greatest in those patients 
with an earlier age of onset. These observations require 
replication and extension before their significance can be 
judged.
There was a trend for PRL levels to be inversely related 
to the positive symptom scores of the acute schizophrenic 
patients. A similar, but significant, relationship has been 
noted in a group of chronic schizophrenic patients (Johnstone 
et al, 1977) and in a group of schizophrenic patients without 
evidence of ventricular enlargement (Kleinman et al, I982).
This relationship is of great theoretical interest to research 
workers in biological psychiatry since dopaminergic influences 
are known to be important in PRL control and are thought to be 
involved in the genesis of positive symptoms (Grow, I980).
In summary abnormalities of gonadotrophin secretion have 
been detected in chronic but not acute schizophrenic patients. 
These abnormlaities do not appear to be caused by the non­
specific sequelae of psychiatric illness such as weight loss, 
"stress" or "institutionalization". There are several lines of
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evidence which implicate overactivity of hypothalamic DA as 
the cause of these disturbances. Further investigation of these 
abnormalities are described in Chapters 5 and 6.
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CHAPTER 5
Studies on the hormonal response of chronic schizophrenic patients 
to synthetic hypothalamic releasing hormones
INTRODUCTION
This chapter reports on the pituitary hormonal response to 
synthetic releasing hormones and refers only to patients with 
chronic schizophrenia. The main purpose of these studies is 
to examine whether the abnormalities of gonadotrophin secretion 
reported here (chapter 4) and elsewhere (Brambilla et al, 1975; 
Johnstone et al, 1977) have their basis at the pituitary or 
at the supra-pituitary level.
Brambilla et al (1976) reported reduced FSH and LH in 
chronic schizophrenia and as part of their investigation of 
this phenomenon administered LHRH to the patients under study.
They reported enhanced LH and FSH responses to LHRH - both in 
terms of the magnitude and the duration of the response. The 
patients studied were somewhat unrepresentative of the chronic 
schizophrenic population in that they all had hebephrenic 
schizophrenia of very early age of onset (13 - I7 yrs, Brambilla - 
personal communication). All had recently been withdrawn from 
neuroleptics. In view of these reservations it was felt that 
it was necessary to repeat this study in a group of patients more 
representative of the total chronic schizophrenic population and 
who had been drug free for much longer periods of time.
The PRL and TSH response to TRH have also been investigated 
in patients with chronic schizophrenia- There is controversy 
concerning the magnitude of the PRL response to TRH in schizophrenia
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Brambilla et al ('1978) finding an enhanced and Frange et al 
(1979) a normal response. Normal TSH response to TRH has been 
reported in schizophrenia (Prange et al, 1979) in distinction to 
patients with affective illness (Asnis et al, I98I).
Abnormal growth hormone secretion following LHRH and TRH 
administration has been reported in depression (Maeda et al, 1975)1 
anorexia nervosa (Maeda et al, 1976) and in a variety of other 
conditions, e.g. renal and hepatic failure. A similar abnormal 
response has been noted in adolescent schizophrenic boys (Gil-Ad 
et al, I9S1) but not in a group of adult schizophrenics (Prange 
et al, 1977)* The hormonal responses to synthetic releasing 
hormones have been investigated in a group of long stay male 
schizophrenics all of whom had been unmedicated with neuroleptic 
drugs for at least a year. Neuroleptic drugs have been shown to 
alter the PRL response to TRH (Lankford et al, I98I). A full 
assessment of hormonal status, including serial measurements of 
LH and FSH, was made to allow comparisons with other groups 
e.g. men with hypogonadotrophic hypogonadism. The TSH and PRL 
responses to TRH have been shown to be related to basal steroid 
levels (Spitz et al, 1979) and these relationships were investi­
gated in the schizophrenic patients.
MATERIALS AND METHODS 
Patients studied:
a) Chronic schizophrenic group, 18 of the 20 patients 
studied in group 1 of the previous chapter were included in this 
part of the study and were administered LHRH and TRH after the
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3 hour period of serial sampling. 2 patients were omitted due 
to external factors unrelated to clinical state. These patients 
were therefore selected on the criteria set out in that study 
namely a) they conformed to the criteria of Feighner et al 
(1972) for the diagnosis of schizophrenia b) they had not 
received neuroleptic medication for at least a year prior to 
study (see Table 5*1 for details) and c) they were agreeable to 
beirg studied. Clinical data is similar but not identical with 
that from the group 1 (chapter 4) and is shown in Table 5-1-
b) Control subjects. 9 of the 17 men in the control 
group of study 1 were administered LilRli and TRH at the end of 
the period of serial sampling. They comprised - 3 normal 
volunteers, 5 patients attending outpatients with a diagnosis 
of neurosis or reactive depression (all fell into the category 
of "undiagnosed psychiatric illness" on the Feighner criteria 
and were symptom free and off medication when studied) and 1 
long stay patient of the same hospital as the schizophrenic 
patients with a diagnosis of manic depressive psychosis (but 
whose mood was normal and who was off medication at the time of 
study). The reasons for studying these particular 9 patients 
out of the group of I7 were random and fortuitous. Further 
clinical details are given in Table 3.1-
Methods
After an overnight fast a butterfly cannula was inserted 
in a forearm vein at approx. 8 a.m. and kept open with dilute 
heparinised saline which was discarded prior to sampling. Samples
TABLE 5.1
U 9
Group n Weight (kcj) cl) Age (yrs) b) Age at onset 
of illness 
(yrs)
Length of 
illness 
a - b
Medication
Chronic
S.cfiizophrenia
18 66. 0 ±  15.3 57.8 ± 7 .8  
(39 - 68)
25.4 ±  4.8 
(18 - 39)
32.0 ±  8.2 Off neuroleptics for 
1-12 years (mean 4.5 
yrs)
1 on ibuprofen 
1 on Diuretics
1 Controls 9 75. 6 i  8.1 57.2 t  9.3 
( 40- 69)
1 on Phenobarbitone 
50 mg tid 
Off antidepressant 
and/or anxiolytic 
medication for 
V 1 2 - 5yrs
Clinical characteristics of groups sLudied.
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were taken at 15 - 20 minute intervals until 11 a.m. (a light 
breakfast was given at 9 a.m.). At 11 a.m. (± 15 min) anintra- 
venous bolus of 100 |ig LHEH (Ayerst) and 200 p.g TEH (Roche) 
was administered over ^0 seconds and samples taken at +20, +40, 
+60 and +90 minutes. Side effects were infrequently reported by 
both groups and included minimal drowsiness and weakness and a 
desire to micturate. Samples were stored at 4 for 24 hours 
prior to the separation of sera which was snap frozen over 
liquid nitrogen and stored at -40 until assay.
Hormone assays
LH, FSH, PEL, GH and TSH were measured by the methods 
outlined in chapter 5 and in the same series of assays as the 
studies reported in the proceeding chapter (the same quality 
control data therefore apply). Testosterone and oestradiol were 
estimated in the 9 a.m. sample by methods outlined in chapter 5*
Statistics
Serial estimates of LH were made as described above and 
a meaii standard deviation and co-efficient of variation of LH 
(LHCV^) were computed as outlined in chapter 4. The area under 
the response curve for each hormone after LHEH/TEH was computed 
by subtracting the baseline level (mean of previous 3 readings) 
from each subsequent level, linear extrapolation and resolution 
into triangles and rectangles.
Log transformation of the data was carried out when this 
was required to render the distribution normal. Student's t-test 
was carried on this data. Correlations were performed by the 
method of least squares and were performed on untransformed data.
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RESULTS
A. Baseline values. Table 5-2 presents the mean level 
of each hormone estimated for the two groups studied. Results 
for LH, FSH, PRL and GH are means of serial samples prior to the 
administration of LHRH and TRH in the schizophrenic and control 
groups but are in single samples for the remaining hormones.
LH and FSH were significantly reduced in the schizophrenic 
group (p < 0.05 and p < 0.01 respectively) with respect to 
controls but no other differences were noted. Thyroid function 
(T3 , T4, TSH) was normal in all subjects.
B. Go-efficient of variation for LH (LHCV%). LHCV^ 
was computed as outlined above. The mean levels for the two 
groups is shown in Table 5*2. There was a significant difference 
(p < 0.05) between the two groups (i.e. the samples from controls 
showed greater fluctuation of LH than those from the schizophrenic 
patients).
C. Response to TRH/LHRH.
1) LH, FSH, TSH, PRL. These results are presented in Fig 5-4 
which depicts the pituitary responses in the two groups according 
to time and in tabulated form in Table 5-3-
It can be seen that the FSH response to LHRH is reduced in 
the schizophrenic group both in terms of the area under the 
curve (p < 0 .01) and in terms of maximal increment (p < 0,03).
The PRL response to TRLI is similarly blunted (p < 0.03 and p < 
0.05 respectively). The LH response to LtlEH and the TSH response 
to TRH were non-significantly reduced in the schizophrenic group.
TABIuE 3.2
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Group n GH FSH LH PRL T3 Î4 TSH Testosterone LHCV
niU/l U/l I l l / I miU/t nmol/i n mol/l mU/l n mol/l j i  mol/l %
Chronic 18 1.5 2.8 6.1 154.4 2.1 78.6 3.5 25.6 72.6 12.1
Schizophrenia ±0.4 10.4 10.7 ±20.4 ± 0 . 1 13.0 10.5 ± 2 . 2 I f ) .  1 ±2.8
Controls 9 1.1 6 .9 '' 8.7* 174.2 2.9 2&5 66.6 19.7*
10.2 ±1.5 ± 1 . 1 ±36.3 10.3 ±2.9 ±10.7 ±2.5
Mean levels of hormones in 18 chronic schizophrenics and 9 controls in period 
prior to LHRH/TEH administration. * p < 0.03, ** p < 0.01 compared to 
chronic schizophrenics.
TABLE 3.3
HORMONE LH FSH PRL rsH
Baseline
lU/l
PeakLi
ilJ/i
Area
lU/l.
min
Baseline
U/l
PeakA
U/l
Area
L)/l.
min
Baseline 
m i U/l
PeakA
m it l / l
Area 
mi U/l. 
min
Baseline
mU/i
PeakA
mU/l
Area
mU/l.
min
Chronic  
Schizophrenia  
n * 18
6.3
10.8
2 A 
±3.0
1503.2
±212.1
2.7
10.3
4.2
iO. 7
256.1 
145.0
159.8  
±20.1
546.4
±55.6
30374
±3510
3 .5
.10.5
9 .5
12.2
537.5
±128.4
Controls  
n “ 9
8.6
t i . O
Z3.5
14,2
1605.2
±295.1
L O
±1.4
6.8
i l . l
434 1 
183.1
190.1
138.4
806.4  
162,9
42990
13375
2 .9
1Û.3
15.8
±3.0
857.4
±136.9
"—- -- ---- -- - --- —----- -^-- .
Basal, peak increment (A) and area under response curve of LH, FSH,
PRL and TSH following LHRH/TRH administration in 18 chronic schizophrenics 
and 9 controls. * p < 0.03, p < 0.01, *** p < 0.001 compared to 
chronic schizophrenics (basal level are mean of 3 levels prior to LHRH/ 
TRH),
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2) GH. GH results are shown in Tables 5*^ and 5*5* It was 
noted that there was a GH increment following LHRH/TRH adminis­
tration in 9 out of the 18 schizophrenic patients, but none of 
the control subjects. Comparison was made by calculating the 
percentage change from baseline (mean of three levels prior to 
LHRH/TRH administration) of each subsequent GH estimation in each 
subject. 9 of the schizophrenics had percentage increments that 
were greater than the control mean plus 2 SD of the mean (95% 
confidence limit). The timing of this increment was variable.
In 5 of the patients it was evident at either +20 or +40 minutes 
post LHRH/TRH or both. In the remainder it was noted at either 
+60 or +90 minutes. Due to this variability of response, no 
significant difference in GH level between schizophrenics and 
control were found at any time point during the test procedure.
No evidence of spontaneous fluctuation of GH prior to 
LHRH/TRH administration was noted in either group and no subjects 
had high baseline GH levels.
4 of the schizophrenic patients had a very marked increment 
of GH secretion (> 300%) of baseline. It was found that these 
patients had significant reductions in the size of the LH response 
to LHRH (p < 0.0'i) and PRL response to TRH (p < 0.01 ) compared 
with the remainder of the schizophrenic subjects who exhibited no 
or slight rise in GH secretion following LHRH/TRH administration 
(Table 3»5)- The size of the FSH increment following LHRH, and 
the basal LH, FSH, PRL and LHCV% levels, were also reduced, but 
not significantly in GH responders. There was no significant 
relationship between change in GH secretion and LH, FSH or PRL
TABLE 3.4
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Group
rime after LHRH/TRH administration (mins)
0 20 40 60 90
Chronic 
Schizophrenia 
n = 18
GH mU/i 1.5
±0.4
2.5
±0.8
2.1
±0.7
1.5
±0.4
1.7
±0.4
GH as Percentage 
of time 0
100 174
±48.5
170
±48.7
119
±27.1
145 
±36.0
Controls
GH mU/i 1.1
±0.2
1.0
iO.2
1.0
m i
1.0
±0.2
1,0
±0.1
n = 9 GH as percentage 
of time 0
100 97
±3.6
99
±7.9
95
±4.1
95
±5.0
GH in mU/L and as percentage of time 0 in 18 chronic schizophrenics 
and 9 controls at various intervals after LHRH/TRH administration.
TABLE 5.5
Group FSH
U/l
FSH
Response 
Area U/l. 
min
LH
lU/l
LHCV
%
LH
Response 
Area lU/i. 
min
PRL
miU/l
PRL
Response 
Area miU/l, 
min
Schizophrenic patients 2.5 174 4.8 10.6 831*' 168 16269"
(n “4) with large increment 
in GH (>300% baseline) 
after LHRH/TRH adminis­
tration
io.4 ±57 ±0.7 ±4.6 ±132 ±37 ±3505
Schizophrenic patients 2.9 280 6.5 17.2 1695 217 34392
without large movement 
In GH secretion (n“14)
±0.4 ±57 ± 0.8 ±3.2 ±254 ±28 ±3933
Comparison of basal and stimulated gonadotrophin and PRL secretion 
between chronic schizophrenics with and without a large increment in 
GH secretion post LHRH/TRH. ** p < 0.01.
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secretion following LHRH/TRH administration across the whole group 
of schizophrenics.
D. Correlation between hormonal variables. Significant 
correlations are set out in Table 5*6 in the form of a corre­
lation matrix.
Basal LH, FSH: There was a significant relationship
between basal LH and basal FSH and between each of these hormones 
and the area of LH response and the FSH response to LHRH.
Basal PRL: There was a highly significant relationship
between basal PRL and the area of the PRL response curve after 
TRH.
Testosterone/Oestradiol: Neither testosterone nor
oestradiol related to any other hormonal variable or response 
but there was a significant positive relationship between them.
Co-efficient of variation for LH (LHCV%): There was a
highly significant relationship between the degree of fluctuation 
of LH estimates prior to releasing hormone administration and 
the size of the area under the LH, FSH and PRL response curve 
(Fig 5»2)» As can be seen from fig 5.2 these relationships 
between LHCV% and size of the LH and FSH area under the curve 
held for both schizophrenic and control subjects (LH: r - 0.82, 
n = 18 chronic schizophrenics, p < 0 .001: r = 0.72, n = 9 controls, 
p < 0.05; FSH: r = 0.84, n = 18, p < 0.001: r = O.9I, n = 9, 
p < 0.001). However the relationship between IlICV/ and PRL 
response area was non-significant in the case of the control 
subjects (r - 0.46, n = 9 1 p 2 O.I) whereas it was highly so in 
the case of the schizophrenic patients (r - 0.64, n - I8 , p < 0 .01)
FIG 5-3
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n = 27
Correlation matrix demonstrating relationships between 
basal and stimulated hormone levels before and after 
LliRH/TRH administration in total group studied,
(n = 27). Area (A) refers to area under response curve.
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It was also noted that there was a significant relationship 
between LHCV% and basal LH, FSH but not PEL levels i.e. patients 
with reduced basal gonadotrophin levels also tended to have 
reduced spontaneous LH fluctuation.
In addition there was a highly significant relationship 
between the LH, FSH and PEL responses i.e. the higher the response 
in one hormonal variable the higher the other hormonal responses. 
There was no statistical relationship between any of the hormonal 
measurements and patient age or weight (note - the ranges of 
age and weight of the groups studied were rather narrow).
Patients only: There was no relationship between any of
the hormonal variables past LHRl/lRHand cLnical characteristics 
of the patients such as length of illness, age at onset of 
illness and positive and negative symptoms (ratings made as 
described in chapter 3)-
DISCUSSION
The results of this study indicate that in chronic 
schizophrenia,in addition to reductions in LH and FSH secretion 
and reduced spontaneous fluctuations of LH, the hormonal response 
to synthetic releasing factors was disturbed with a reduced FSH 
response to LHRH, a reduced PEL response to TRH and GH increments 
after LHRH/TRH in a number of patients. These changes were 
highly inter-related: patients who had one abnormality were likely 
to have the others.
There was considerable variability in hormonal results in 
both groups. Abnormalities were observed only in a subgroup of
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the schizophrenics (approx. 50%) and 25% of the schizophrenic 
patients were in the normal range on every variable measured.
The cause of this hetereogenity is not clear at present. Mis­
diagnosis appears unlikely as all the patients studied appeared 
to have had classical schizophrenic illnesses. A similar 
situation is encountered in studies on patients with affective 
illness (see chapter 2.2.2). The problems of interpretation 
raised by this heterogenity of hormonal response are further 
discussed in chapter 8 .
It should be emphasized that these findings refer only to 
a group of patients hospitalised for many years. The effects of 
long terra care and non-specific effects of psychiatric illness 
are a perennial problem in research into chronic schizophrenia 
because of the difficulties of selecting an appropriate control 
group. Theoretical spects of this problem and practical attempts 
carried out to circumvent these problems are more fully discussed 
in the concluding chapter (8)-
Spontaneous episodic secretion of LH and to a lesser extent 
FSH is a well recognized phenomenon. Serial venous sampling 
techniques have revealed that there are 1 2 - 2 0  bursts of LH 
secretion per day in men (Santen and Bardin, 1975)* There is 
good evidence that this pattern of gonadotrophin secretion from 
the pituitary is regulated by pulsatile secretion of LHRH from 
the hypothalamic median eminence (Belchetz et al, 1978). Serial 
LH estimates revealed that the frequency of spontaneous episodes 
of LH secretion was reduced in the schizophrenic group as a whole 
and was almost completely absent in a subgroup of patients.
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There was a significant relationship between IjHCV% (a measure 
of the degree of fluctuation of serial LH estimates) and the size 
of the FSH and LH response to synthetic releasing hormones in 
the total group studied and both groups separately. A similar 
relationship between LHGV% and the size of the PRL response in 
the total group and the schizophrenic group and a similar tendency 
in the controls was also demonstrated. This indicates that 
those patients with reduced stimulated hormone responses were 
also those who exhibited little spontaneous fluctuations of LH. 
Since this latter phenomenon is most likely to be secondary to 
reduced spontaneous secretion of LHRH from the hypothalamus, 
these close relationships may indicate that the reduced hormonal 
response to synthetic releasing hormones in schizophrenia may 
have their basis in reduced spontaneous endogenous releasing 
hormone secretion. However, while this is a conceivable patho­
physiological explanation for the reduced FSH response to LHRH, 
it does not explain why the LH response was not significantly 
reduced from control levels, nor does it explain the reduced PRL 
response to LHRH/TRH administration.
Reduced spontaneous secretion of hypothalamic LHRH is 
though to be the underlying pathophysiological process in hypo- 
gonadotrophic hypogonadism (Spitz et al, 1979)- It would be of 
considerable interest to investigate whether the repeated 
administration of exogenous LHRH to schizophrenic patients restores 
normal FSH responsiveness to LiffiH as has been shown to be the 
case in hypogonadotrophic hypogonadism (Jacobsen et al, I980) 
and anorexia nervosa(Marshall and Reich, 1979)-
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There are however, several important distinctions between 
the hormonal results of the schizophrenic patients and patients 
with hypogonadotrophic hypogonadism (also called isolated gonado­
trophin deficiency or IGD), IGD patients also have a reduced 
PRL response to TRH, but this has been shown to be a consequence 
of the altered steroid milieu found in these patients (reduced 
oestradiol and testosterone levels) as treatment of these patients 
with hCG or testosterone restores PRL responsiveness to TRH to 
normal (Spitz et al, 1979)- By contrast testosterone and 
oestradiol were not abnormal in the schizophrenic patients and 
blunted PRL responses were found to relate to the reduced spon­
taneous fluctuation of LH and not to testosterone or oestradiol 
levels. Similarly IGD patients exhibit a markedly reduced LH 
but normal or exaggerated FSH response to LHRH (Roth et al,
1972) whereas the schizophrenic patients have a normal LH but 
reduced FSH response.
The endogenous release of hypothalamic releasing factors 
is under complex control and pituitary responsiv®fieæ to these 
agents is a complex and incompletely understood phenomenon. 
Monoamine neurones innervate the hypothalamus and are known to 
be related to hypophysiotropic neurones, anatomically and 
functionally (see chapter 2). Some of the changes noted here 
could conceivably be related to an excess release of DA from the 
hypothalamus e.g. DA infusion has been reported to lower LH 
levels and reduce the frequency of LH secretory episodes (Huseman 
et al, 1980) and DA infusions are known to reduce the PRL response 
to TRH (Besses et al, 1979)- Brambilla et al (1979) reported a
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return of LH and FSH levels to the normal range in schizophrenic 
patients after the administration of DA blocking therapy. In 
support of the notion that overactivity of DA could be respon­
sible for reduced LH secretion in some circumstances it has 
recently been observed that acute DA blockade with metaclopramide 
restores LH secretion to a more normal pattern in female 
patients with hypothalamic amenorrhoea (Quigley et al, 'I980).
However there are several lines of argument against the 
hypotheses that overactivity of DA could be responsible for the 
present findings. For example, the normality of basal PRL 
levels is strong evidence against this hypothesis. Furthermore 
DA infusions are known to reduce the TSH response to TRH (Besses 
et al, 1979)1 but this response was normal in this study.
The pathophysiological significance of abnormal GH hormone 
secretion following administration of LHRH and TRH in a variety 
of apparently disparate syndromes is uncertain. Animal evidence 
indicates that this response occurs when there is "hypothalamic- 
pituitary disconnection " (Muller et al, 1979)-
In this regard, it is noteworthy that those schizophrenic 
patients with marked GH secretion after LHRH/TRH administration 
also exhibited markedly reduced LH and PRL responses (Table 9-9)• 
In other words these patients had the most evidence of hypothalamo- 
pituitary derangement,
Gil-Ad et al (198I) described marked GH elevations in a 
group of adolescent schizophrenic boys (mean age 19 y 8 months) 
and found that neuroleptic drugs reversed the GH response to 
LHRH but not to TRH. Since Prange et al (1979) did not find GH
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secretion after TRH in their group of adult schizophrenic patients 
this raises the possibility that the early age of onset of Gil- 
Ad' s patients is the critical factor. However there was no 
difference in the present study between the age of onset of 
schizophrenia of those patients who exhibited abnormal GH 
increments and those who did not. The determination of the age 
of onset of schizophrenia is, however, often a difficult clinical 
problem especially in groups of patients where the duration of 
illness is long.
GAT scan evidence of ventricular dilatation has been 
found in cases of chronic schizophrenia (see Table 1.2). There 
is evidence from echo-encephalographic, pneumoencephalographic 
and CAT scan studies that dilatation of the ^rd ventricle may 
occur in chronic schizophrenia (see Table 1.3i chapter 1). It 
is conceivable that damage to the hypothalamus could result 
from this enlargement leading to derangement of releasing factor 
secretion. However if hypothalamic damage was the cause of the 
results reported here then disruption of all aspects of pituitary 
secretion (e.g. basal TSH and PRL secretion) would be expected 
but does not occur.
The results reported here differ from those reported by 
Brambilla et al (19?6) (who found exaggerated LH and FSH responses 
to LHRH) and to those of Prange et al (1979) (who found a normal 
PRL response to TRH in schizophrenia). Possible reasons for the 
discrepancies are that both the above studies were performed on 
patients recently withdrawn from drugs (in distinction to the 
minimum of a year and mean of 4.9 yrs (Table 9*1) off medication
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in the present study) and the different dose regimens of releasing 
factors employed. For example the dose of TRH employed here 
was 200 |ig which is below that required to produce a maximal TSH 
response (400 ng) and below used by Prange et al (1979).
LHRH and TRH were administered concominantly in the present 
study (as is the practise in conventional endocrine diagnostic 
studies). However in research studies in which abnormal responses 
to releasing hormones are seen (e.g. in depression (Brambilla et 
al, 1978)) it is preferable to administer LHRH and TRH 
separately and studies with schizophrenic patients need to be 
repeated in this way.
In summary, the administration of LHRH and TRH to chronic 
schizophrenics revealed some abnormalities of hormonal response 
which have similarities with, but some important differences 
from, other clinical and diagnostic groups. The pattern of the 
abnormalities noted and their clear relationship to abnormalities 
of pulsatile LH secretion indicates that the level of disruption 
is above the pituitary level and most probably resides in the 
hypothalamus. This study indicates ways in which the neurohumeral 
disturbance of these particular patients could be further investi­
gated and perhaps elucidated.
I B S
CHAPTER 6
Effect of DA blocking drugs on anterior pituitary hormone secretion 
in acute and chronic schizophrenia
INTRODUCTION
Neuroleptic drugs are effective in relieving schizophrenic 
symptoms. This has been shown to be specifically related to the 
DA blocking properties of these drugs and to be unrelated to 
their other pharmacological effects e.g. their anticholinergic 
or sedative poperties (see chapter 1.2.3 for references). There 
has been much recent interest in the study of anterior pituitary 
hormone secretion (APHS) in response to neuroleptic drugs in 
schizophrenia for the following reasons: 1) a change in hormone
secretion may act as an index or marker of drug level and/or 
therepeutic efficacy and 2) to investigate whether abnormalities 
of APHS in schizophrenia are DA-related.
PRL secretion has been extensively studied in schizophrenia 
because of the importance of the TIDA neurones in inhibiting 
PRL secretion (Meites et al, 1972). It is generally accepted 
that PRL secretion is normal in acute (Meltzer et al, 197^;
Ettigi et al, 1976) and chronic (Brambilla et al, 1976; Johnstone 
et al, 1977) schizophrenia and there is evidence that the PRL 
response to acute neuroleptic administration in patients with 
schizophrenia is similar to that found in controls (Gruen et al, 
1978). Whether the PRL response to chronic neuroleptic therapy 
and whether tolerance to PRL raising effect of neuroleptics varies 
between schizophrenics and controls has not been tested.
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Several research groups have investigated the clinical 
correlates of the PRL response to neuroleptics. Rao et al 
(1980) found significant relationships between the dose of 
neuroleptic prescribed, plasma level of neuroleptic and PRL 
level in a series of female chronic schizophrenics on stable 
doses of haloperidol. However in two series of schizophrenic 
patients treated on an acute basis with chlorpromazine (Kolakowska 
et al, 1979; Kolakowska et al, 1979) a significant relationship 
between plasma neuroleptic level and PRL was found, but relation­
ships with dosage were not established. In these latter studies 
the numbers were relatively small and the dosage of chlorpromazine 
was determined by clinical judgement.
A positive relationship between the antipsychotic effects 
and PRL elevating effects of neuroleptics has been established 
(Meltzer and Fang, 1976; Langer et al, 1977; Cotes et al, 1978). 
However this association is not strong: some patients show a 
good response with little change in PRL secretion and vice versa. 
Moreover because there is a ceiling effect, this relationship 
may not be apparent at all doses (GrUen et al, 1978).
The relationship between PRL levels and extrapyramidal 
side effects of neuroleptics has been less widely studied. Rao 
et al (1980) did not find the two significantly related. Wiles 
et al (1976) found a non-significant tendency for extrapyramidal 
side effects to be associated with higher PRL levels and a 
similar tendency significant in some but not all comparisons 
was found in the study of Kolakowska et al (1979)- It has been 
shown that PRL rises (Glazer et al, 198I) and falls (Brown et
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al, 1979) to a greater extent and more rapidly in those patients 
with neuroleptic induced neurological side effects. The problems 
of studying this type of relationship is that the patient 
populations tend to be heterogenous and include patients of 
variable age, sex and past neuroleptic experience and it may 
be that these factors have tended to obscure or create relation­
ships between extrapyramidal effects and PEL which might not 
otherwise be found.
Another problem in correlating PEL secretion, neuroleptic 
blood levels and clinical effects is the differential effects 
on these variables of other drugs prescribed during the treatment 
of acute schizophrenia. For example some (Rivera CalimRn et 
al, 1976) but not all (Simpson et al, I98O) studies have found 
that anticholinergic medication (prescribed in treatment of or 
prophylaxis against the neurological side effects of neuroleptics) 
reduce plasma neuroleptic levels. Lai et al (1979) found that 
anticholinergic medication enhanced the PRL elevation induced 
by acute neuroleptics. However de Rivera et al (1976) found 
that anticholinergics had no effect on PRL levels in patients 
treated acutely with neuroleptics (although an enhancement was 
observed during chronic neuroleptic treatment).
The effects of neuroleptic treatment in Lli and FSH 
secretion in schizophrenia have been less widely studied and 
are the cause of some dispute. A few studies have reported 
reduced LH and FSH after neuroleptic administration (Shader and 
de Mascio, 1970) but several others have not (e.g. Beumont et al, 
197^ a). Animal studies have generated similarly conflicting data
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(Weiner and Ganong, 19?8). However in the case of LH and FSH 
secretion in schizophrenics treated with neuroleptics the 
situation is more clearcut. Several studies have shown no effect 
of neuroleptic administration on LH and FSH where they have been 
prescribed for the treatment of acute psychotic episodes 
(Beumont et al, 197%; Cotes et al, 1978). Chronic neuroleptic 
treatment was reported by Brambilla et al (1976) to be associated 
with an elevation of LH and FSH levels in chronic schizophrenics. 
On the other hand Beumont et al (I9?4a) found no change in LH 
and FSH secretion after chronic neuroleptic withdrawal (but 
reported that testosterone rose during this period).
An interesting finding has recently been reported by Yen's 
group of colloborators (Quigley et al, I980). They found in 
female patients with stress induced amenorrhoea that the acute 
administration of a DA blocking drug elevated the low LH but not 
the low FSH secretion characteristic of this condition. No 
effect on LH and FSH levels of normal controls was noted. There 
was also some evidence of a return of episodic IH secretion after 
DA blockade. This work ties in well with the observations that 
DA administration reduces LH but not FSH secretion and reduces 
the frequency of LH secretory episodes in normal controls 
(Kaptein et al, I980). This implies that the mechanism of 
amenorrhoea following stress in the female is dopaminergic over­
activity.
Acute DA blockade was achieved in the study of Quigley 
et al (1980) by the intravenous administration of metoclopramide 
(MGP). This drug is commonly prescribed as an anti-emetic.
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The pharmacological profile of MGP is principally one of blockade 
of DA receptors. There is an unconfirmed report from an open 
study (Stanley et al, 198I) that regular oral medication with 
metoclopromide is therapeutically effective in the treatment of 
8chi zophrenia.
This chapter reports on three separate studies which 
investigate the effects of neuroleptic administration in schizo­
phrenia. The first two studies investigate respectively the 
effect of chronic (Study 1) and acute (Study 2) DA blockade on 
APHS in chronic schizophrenia. The third (Study j) investigates 
the relationships between neuroleptic blood levels, APHS, the 
clinical effects of neuroleptics and the effect of additional 
anticholinergic medication over a wide range of neuroleptic 
dosage in acute schizophrenics.
MATERIALS AND METHODS 
Patients studied
Study (1). 3 patients were studied. These patients were
part of the group of 20 chronic schizophrenics described in 
chapter 4 who had been Ë:udied by . a 3 hour period of serial 
venous sampling. Some months after the original study, neuroleptic 
therapy was prescribed by the medical teams responsible for the 
care of these patients. These psychiatrists were unaware of the 
findings of the original study. This group were representative 
of the main original group in terms of age and length and severity 
of illness. The clinical details of these patients, together with 
the doses of neuroleptics administered can be seen in Table 6.1,
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These patients were restudied after several months of therapy by 
exactly the same methods as on the first occasion (see below).
At the time of the retesting there was no discernable difference 
in the clinical state of these patients following the intro­
duction of neuroleptic therapy.
Study (2). Acute DA blockade in male chronic schizophrenics 
and controls with metaclopramide (MGP). 10 chronic schizophrenics 
and 10 controls took part in this study. The chronic schizophrenics 
conformed to the criteria for selection set out in chapter 4 
which are briefly that a) they conformed to the criteria of 
Feighner et al (1972) for the diagnosis of schizophrenia b) 
none of them had had neuroleptic medication for at least a year 
prior to study c) they were physically healthy and d) they 
were agreeable to study. Clinical data are given in Table 6.1.
10 controls were studied. All were men who had previously 
attended outpatient clinics at Northwick Park Hospital with a 
diagnosis of neurotic illness, reactive depression or personality 
disorder, none of these being severe. Examination of their 
casenotes by the Feighner criteria lead to them being placed in 
the "unspecified psychiatric disorder*’ category. Several had 
received a course of benzodiazepines and/or tricyclic anti­
depressants but all had been off medication for several years 
at the time of study (see Table 6.1). One patient was receiving 
diuretics for the treatment of mild hypertension. The day to 
day functioning of these patients was unimpaired and most were 
working at the time of study.
Study (3). Relationship between APHS, neuroleptic level
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and clinical features in patients with acute schizophrenia treated 
with and without anticholinergic medication. patients were
studied (22 males and l4 females). All had been admitted to the 
research ward of the Clinical Research Centre with acute schizo­
phrenic symptoms (developing within the month proceeding 
admission). Only patients with nuclear schizophrenic symptoms 
(as defined by the Present State Examination) were included. 
Details of previous psychotic illnesses, presence of family 
history and previous drug administration are documented in 
Table 6.1. 2 of these subjects refused to participate in the
study sometime during the first week of study and are excluded 
from further analysis.
Methods
Drug regimes and sampling schedules
Study (l). 3 patients were studied. They were tested in
a similar manner to that described in chapter 4 i.e. an IV 
cannula was inserted in the fasting state and serial venous 
samples withdrawn at 20 minute intervals for 1 - 3  hours. Since 
the patients were fasting they had not ingested their neuroleptic 
medication for approximately l4 hours prior to the first sample 
(see Table 6.1 for details). One patient could not be sampled 
as fully as the first occasion due to external factors.
Study (2). 20 patients were all studied in an identical
manner. After a light breakfast at 8 - 8.30 a.m. a butterfly 
cannula was inserted at ^ a.m. serial samples obtained at 19 
minute intervals for 3 hours (13 samples) in the manner described 
in the methods section in chapter 3- After 90 minutes of
TABLE 6.1 1 7 2
Study Diagnosis Age and Sex Clinical details Drug History
1
Chronic 
schizophrenics 
n = 3
5 8 ± L 3
3CT
Chronically hospitalised 
(mean length of illness 
33 yrs)
Patient A Un medicated till 6/12 
ago. CPZ 50 mg tds 
Patient B Stopped neuroleptics 3 
yrs ago. 3/12 ago 
fhiordiaztne 25 mg tds 
Patient C Un medicated 3/12 —► 
Thiordiazine 50 mg bd
2
Controls 
n " 10
5 6 1 2 .7
10 c f
Patients with history 
of neurosis or reactive 
depression. Symptom- 
free
2 on Benzodiazepines 
1 on Diuretics
Chronic 
schizophrenics 
n = 10
60 12. 9 
lOCT
Chronically hospitalised 
(mean length of illness 
32 yrs)
6 off neuroleptics for 1 -1 2  yrs 
4 never medicated 
1 on Diuretics
3
Acute
schizophrenics 
n = 36
3 0 1 1 .8  
22Cf 149
Patients with acute 
symptoms in past month. 
1st episode for 15, >1 
episode for 21. -h/e FH 
in 12 patients
26 off medication for >±/12 
10 receiving neuroleptics in month 
prior to study
Clinical details of main groups tested with neuroleptics, 
Age as mean ± SEM.
TABLE 6.2
Va!'iat)le Means of Ata oanwent Hayn of AanuaaMeUt
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of ntatu of 
y g liour of
tor /O day a of utudy
■îontal Slate Krawiocka Scale (1 9 ,’,’) 
(incongruity & flat L e n i n ; -  nf 
affocL cepai'ate.; to ;;ive a 
total of 9 variai lea)
U (i.e. (lay befcjre commencement 
of ) - , V, iu, I'l, IV,
? l, V I, .9i
l;-.l !M]jy I'aKi.ia 1 
r ; e e  L a
CHC lUtrapyrai'iid 
nciilr (Johnstone
al katim; 
ct al, 1 9 :0)
/, IV, V', IV, ;-i, rV
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Schedule of assessments carried out in Study ' (ei'fect of 
flupentliixol on symptoms,motor behaviour, plasma fiuponthixol 
and anterior pituitary hormone secretion in v6 acute schizo­
phrenics (see above)).
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sampling (7 samples) 10 mg of metocloprornide (Primperan : MGP) 
was injected intravenously over a 2 minute period. There were 
no marked clinical effects of this injection other than minimal 
drowsiness in a few of the subjects from both groups.
Study (3). These patients were studied over a four week 
period. These patients were blindly allocated to one of three 
groups treated with capsules containing either 1 mg, 2 mg or 
4 mg flupentliixol. The number of capsules prescribed was that 
required to produce 10 hours sleep in 24 hours. The dose was 
increased by one capsule every 2 days and adjusted to this level 
over the first 10 days of the study and was thereafter fixed for 
the remaining I8 days of the study. At 10 days either procy- 
clidine 9 mg tid or identical placebo was randomly and blindly 
allocated to equal numbers of patients. No additional neuro­
leptic medication was prescribed throughout the trial but the 
design of the trial did allow for the administration of intra­
venous procyclidine (IO mg) if required to manage dystonie 
neuroleptic side effects. Assessments carried out included 
clinical ratings, measurements of extrapyramidal side effects, 
and venous sampling for anterior pituitary hormone secretion 
and flupenthixol blood levels. The schedule of these assessments 
is summarised in Table 6.2
Measurements
A) Laboratory
1) Anterior pituitary hormone secretion- LH, FSH and
PEL were estimated by the methods outlined in chapter 9 . In
the case of study 1, LH and FSH were estimated in one assay.
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This assay also included samples from the first besting session 
of these patients and there was a close inter-assay concordance 
with previous assays. Study 2: LH, FSH and PRL were measured
in one of three assays which contained samples from patients 
and controls and a range of quality controls and duplicate 
samples with acceptable inter-assay correlation of variation 
(see chapter 3)» Study 3: LH and FSH samples were both
estimated in a single assay. PRL was measured in 3 separate 
assays each of which included samples from several treatment 
groups. All samples from each patient were measured in one 
assay. The mean co-efficient of variation between estimations 
for QG's tested in each of the three assays (n = 3) was 7.8%.
2) Flupenthixol assays. Flupenthixol was measured by 
Miss R. Bourne, Research Officer, CRC, under the supervision 
of Dr. P.M. Cotes and myself. Flupenthixol was estimated in 
heparinised plasma by a modification of the radioimmunoassay 
method of Robinson and Risby (1977) using an antiserum supplied 
by Dr. A- Jorgensen. Duplicate samples of plasma (O.l ml) were 
incubated for 60 hours at 4 °C with 1.44 riN (^H) cis (z)- 
flupenthixol (^H-flupenthxiol) and antiserum (final dilution 
1:120,000). Bound and free radioactivity wore separated using 
0.2 ml dextran coated charcoal (Dextran T-40 0.023% W/V and 
Norit A charcoal 0.25 W/V) at 4 °C, followed by centrifugation.
The bound fraction, in the supernatant, was measured by liquid 
scintillation counting. Duplicate tubes for each sample 
containing no antiserum were also assayed to estimate non-specific 
binding which was subtracted from the bound sample counts.
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Sample concentrations were estimated from a log-logistic plot 
of a standard curve of a-flupenthixol serially diluted in 
heparinised drug-free plasma. The assay has a working range 
of 1 - 30 ng flupenthixo]/ml plasma. Flupenthixol was estimated 
in 5 separate assays, each of which included samples from 
several treatment groups. All samples from each patient were 
estimated in a single assay. The mean coefficient of variation 
for a range of quality controls (made up from a pool of heparin­
ised plasma samples from patients receiving flupenthixol) was
13%.
B) Clinical ratings
1) Mental state was rated twice weekly, the rating scale 
devised by Krawiecka et al (1977) as described in chapter 3»
2) Movement and tone were rated with a simple scale 
(CRC Extrapyramidal Rating Scale - Owens and Johnstone (1980)) 
rating a) general motor restlessness, b) facial dyskinesia, 
c) facial rigidity, d) facial tremor, e) upper limb rigidity,
f) hand tremor, g) abnormality of gait, each on a four point 
scale.
RESULTS
Study (1). The results of this study are depicted in 
Fig 6-1 which shows the results of serial LH, FSH and PRL from 
these particular patients on the two occasions studied. It 
can be seen that in all the patients there was a slight rise in 
PRL secretion on the second occasion of testing following the 
prescription of neuroleptics. It was not possible, due to
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different sampling times, to assess PRL secretion rhythm on 
this occasion. In two patients (A and C ; Fig 6.1) there was 
an elevation of LH and FSH secretion on the second occasion, 
with the development of evidence of pulsatile LH secretion in 
one patient (patient A - Fig 6.1). However there was no evidence 
of the development of episodes of LH secretion with a greater 
than increment above baseline (the criteria of Boyar et al,
1972) in this patient. In patient B's case there was no change 
in LH or FSH secretion whilst on neuroleptics and he continued 
to show a low flat gonadotrophin secretion profile.
Study (2). The results of this study are shown in Figs 
6.2 and 6.3 and in tabulated form in Table 6.3»
a) PRL. There was a large rapid and sustained rise in 
PRL secretion following MCP administration which was identical 
in both groups (Fig 6.2). There was no difference in the PRL 
secretion before or after MCP between the two groups at any 
time point or in terms of maximal PRL increment (Table 6.3)*
b) LH, Mean LH was significantly lower in the chronic 
schizophrenic patients compared to controls prior to MCP 
administration. As can be seen from Fig 6-3 there was little 
spontaneous fluctuation of serial LH estimates from the chronic 
schizophrenics whereas there is a markedly different pattern
in serial samples from the controls. The shorter sampling period 
of this study (90 mins) compared to that reported in chapter 4 
(180 mins) and the reduced numbers studied (10 vs 10 and 20 vs 1? 
respectively) precludes an adequate statistical evaluation of 
this difference on this occasion.
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Group
LH iU /1 FSH U/1 PRL nilU/1
PRE
MCP
POST
MCP
+90min
MCP
PRE
MCP
POST
MCP
+90min
MCP Basal
Peak 
POST MCP
C o n tro ls 10.5 11.2 10.8 8.2 8.4 7 .9 122 1854
n=10 11.3 + 1.7 11.7 +1.9 +2.0 +2.1 +12 +164
* #
Cnron lc 5 .9 7 .3 8,0 2 .9 3 .1 3 .0 139 1872
S ch izopn re n ie s
r r l O 10.6 10.5 10.5 +0.2 10.3 +0.3 +15 +227
IjH, FSH and PFL levels before and after 10 mg IV MCP in 10 chronic 
schizophrenics and 10 controls. Values as means ± SEM. LH: reduced 
in chronic schizophrenics compared to controls prior to MCP 
*  p  < 0.05. Significant (* p < 0.05) rise post MCP in chronic 
schizophrenics. FSH; significant reduction (** p < 0.01) in chronic 
schizophrenics with no chan|’;es post MCP. Large I'ise in PPL, equal 
in both groups.
TABLE 6.4
Group
PRL m iU/1 LH lU/1 FSH U/1
I n i t i a l Mean I n i t l G l Mean I n i t i a l Mean
Week U. Weeks 3 ,4 ,5 . Week 0. Weeks 3 ,4 ,5 . Week 0. Weeks
Male acute 
sch izopnren lcs 257 590 7.6 6.5 2.1 2,2
n=22 +50 +64 10.7 +0,4 +0.2 +0.3
Male aged 
matched c o n tro ls 234 6.1 2.4
n = l l +23 +0.5 +0.5
Female acute 
sch izophren ics 955 1648
n=14 +364 +268
(ii=12)
PPL, LH and FSH levels prior to and during weeks 5, 1 and 5 of oral 
flupenthixol therapy in 22 male and lb female acute schizophrenics. 
Large rise in PRL secretion but no change in LH or FSH secretion.
No difference between male patients and age-matched controls in any 
measure.
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After MCP administration there was no difference in the 
mean LH level compared to the mean pre-MGP level in the controls 
nor was any difference at any particular time point noted (for 
example at the 180 minute time point). By contrast there was 
a statistically significant rise in LH level in the chronic 
schizophrenic group. The LH level rose from 5*9 ± 1.8 (before 
MCP) to 7*3 i 1.6 (after MCP) (lU/l ; means ± SEM) a difference 
that was significant at the p < 0.03 level. This difference 
was more marked at the 90 minute post MCP point when the LH 
level was 8.0 ± 1.6 (p < O.O3 compared with the mean pre-MCP 
level). The difference in LH levels between chronic schizophrenic: 
and controls which was evident and significant prior to MCP 
administration disappeared following MCP administration (see 
Table 6.3).
c) FSH. FSH was significantly reduced in the chronic 
schizophrenic group compared to controls (p < Ü.03). Neither 
group showed much fluctuation in serial FSH estimates. There 
was no change in FSH secretion following MCP administration in 
either group (see Fig 6.2) such that the significant difference 
in FSH between the groups was still evident after MCP adminis­
tration.
Study (3). The results of this study are complex and 
only those with direct relevance to the effects of drugs on 
APHS in schizophrenia will be described in any detail. Basal 
levels of LH, FSH, PPL, GH and oestradiol from the male patients 
were discussed in chapter 4. Briefly the results of the clinical 
study showed:-
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1) The dosage (titrated to produce an equal amount of sedation 
in each patient) varied widely from 1 - 4 8  mg of flupenthixol/day.
2) Positive symptoms (see chapter 3 section 2.1 for definition) 
were the most prominent symptoms and they showed a striking 
improvement throughout the period of the trial. There was no 
clearcut change in the infrequent negative symptoms.
3) The addition of procyclidine to I6 of the patients on day 
10 was associated with a temporary worsening of psychotic 
symptoms. There was in addition a reduced amount of total 
sleep time, but these two changes did not appear to be statis­
tically related.
4) Extrapyramidal effects developed rapidly following the 
introduction of neuroleptics and increased throughout the course 
of the study. The introduction of procyclidine prevented 
further increases in extrapyramidal effects but did not abolish 
those already present.
As regards the laboratory measures and their relationship 
with clinical measures the following findings were demonstrated 
(Table 6.4):
1) There was a significant rise in PRL secretion following 
neuroleptic administration which rose to a plateau after lb 
days of therapy. Some female patients had very high levels of 
PRL before commencing the study probably due to prior neuroleptic 
medication. These changes are depicted in Fig 6.4. The mean 
PRL level of weeks 3i 4, 3 of the female patients was considerably 
higher than that of the male patients which was not entirely 
due to the slightly higher mean steady state dose in the females
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(Table 6.4).
2) III and FSH levels did not show any change with neuroleptic 
medication in the male schizophrenics. Furthermore LH and FSH 
levels were not different from an age - sex matched control 
group (Table 6.4).
3) The addition of procyclidine on day 10 did not affect either 
PRL levels (Fig 6.4) or flupenthixol levels (fig 6.3).
4) A significant relationship was found between the plateau 
level of flupenthixol (mean weeks 2 , 3 and 4) and plateau level 
of PRL (mean weeks 2, 3 and 4) in both females (p < 0.01) and 
males (p < 0 .01) and between steady state dose of flupenthixol 
and plateau levels of PEL in females (p < 0.001) but not in 
males. Among the males one patient had a steady state dose of 
48 mg/day, the mean steady state dose of the whole sample being 
8.3 mg/day. With this patient included the relationship between 
flupenthixol and plateau PEL was not statistically significant. 
If this patient is excluded the relationship between steady 
state flupenthixol dose and plateau PEL levels was significant 
at the 0.01 level.
3) The relationship between plasma level of flupenthixol and 
antipsychotic effect appears to be curvilinear. This relation­
ship is not significant using polynomial regression but when the 
sample is placed in arbitrary categories a relationship which 
is significant when tested by unifed analysis of variance by 
ranks test is found.
6) No significant relationships were established between PEL 
levels and either antipsychotic or extrapyramidal effects. The
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mixed sex and very variable pre-trial neuroleptic experience of 
the patients necessitate a subdivision of the sample into groups 
too small for meaningful graphical representation.
DISCUSSION
In brief, the results of these studies on the effects of 
neuroleptics on APHS in schizophrenia show that acute or chronic 
administration of DA blocking drugs is associated with some 
evidence of elevation of low gonadotrophin secretion in chronic 
schizophrenia. Despite close inter-relationships between PRL 
secretion and neuroleptic dose and serum level, neuroleptic 
administration to acute schizophrenics is not associated with 
changes in APHS that are likely to be clinically relevant or useful.
Looking at the results from chronic schizophrenics first, 
it was found that six months of oral neuroleptic therapy v/as 
associated with an elevation of FSH and LH secretion in 2 out 
of 3 patients. Acute DA blockade with metaclopramide was 
associated with a significant elevation in LH in the chronic 
schizophrenic group but not significant change in FSH or signifi­
cant difference in the PPL response. These results are of 
potential interest since they can be taken as evidence that the 
mechanism of low gonadotrophin secretion in chronic schizophrenia 
may be increased dopaminergic tone.
These results to some extent confirm the findings of 
Brambilla et al (1973) who reported that one month's therapy with 
haloperidol to a group of chronic schizophrenic patients restored 
normal level of LH, FSH and testosterone secretion. It would
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appear that an elevation of all the measured hormones took place 
in all of their cases. The reason for the non-response in one 
of the patients in the present study is not clear. While LH 
levels rose to a greater or lesser extent following acute DA 
blockade in all of the chronic schizophrenics, there was no 
change in FSH secretion which remained significantly below that 
of the control population.
These results should be considered in the light of the 
recent evidence conerning dopaminergic influences on gonado­
trophin secretion which was discussed fully in chapter 2 (l,3)«
To review the data briefly, while it is more or less established 
that acute or chronic DA blockade does not induce any change in 
gonadotrophin secretion in normal individuals, the infusion of 
DA markedly reduces HI secretion but does not alter FSH secretion. 
Apparently therefore it is important when studying the effect of 
dopaminergic drugs on gonadotrophin secretion to consider the 
type and length of drug administration and whether normal or 
abnormal hormonal levels are being considered. It seems from 
the above data that DA influences on FSH are of minor importance. 
However it may be the case that due to differences in feedback 
effects (see below) FSH is influenced by only long term adminis­
tration of dopaminergic drugs and perhaps only when the FSH 
level is abnormal for some reason (e.g. Brambilla's study, 1976).
These considerations are also relevant to the discussion 
of the study of Quigley et al (I980) who found that the adminis­
tration of 10 mg MCP IV was associated with an elevation of LH, 
but not FSH, in female patients with hypothalamic hypogonadotrophic
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arnenorrhoea. They found that MCP administration had no effect on 
gonadotrophin secretion in normal subjects (confirmed in the present 
study). It would be interesting to study the effect of longer 
term DA blocking therapy on gonadotrophin secretion in the type 
of patients described by Quigley et al (I98O) specifically to 
observe if any change occurred in FSH secretion under this 
circumstance as appears to be the case in chronic schizophrenia 
(Brambilla et al, 1973)- A major difference however between the 
present study and that of Quigley et al (19BO) is that in the 
latter case the PRL levels of the patient group were subnormal 
supporting the presence of increased dopaminergic tone as a cause 
of the aberrant LH levels whereas in the schizophrenic group PRL 
levels were normal. It is conceivable that in the case of the 
schizophrenic group the illness is of such long standing that 
feedback mechanisms operate to return PRL, but not gonadotrophins, 
to normal. Such a process has been observed in rats (Gudelsky et 
al, 1976) : PRL reversed to normal but LH fell when. DA turnover in 
the hypothalamus was high. However to establish this process in 
schizophrenia requires intensive investigation. PRL levels also 
appear normal in acute schizophrenia (this study and others) and 
so these putative feedback changes in hormonal levels must be 
complicated.
As alluded to above these results are of potential interest 
since they give evidence of increased dopaminergic tone in some 
patients with schizophrenia. This is of interest since this is 
evidence which supports the DA hypothesis of schizophrenia which 
so far has rested only on indirect pharmacological evidence and 
on post-mortem biochemistry (both methods being fraught with
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difficulties of measurement and. interpretation). This hormonal 
finding is in living patients who have undoubted schizophrenia. 
These results (as seems to be the case with all research) only 
raise more questions. One of these is why these effects are 
seen only to patients with chronic schizophrenia (patients with 
acute schizophrenia have normal gonadotrophin secretion and no 
change induced by neuroleptics). Chronic schizophrenics as a 
general rule have an inadequate therapeutic response to neuro­
leptics (Letemendia and Harris, 196?) and this almost certainly 
applies to the group of patients studied here. For example the 
three patients in the present study who were placed on neuroleptic 
treatment for six months showed no clinical amelioration of their 
disabling symptoms. Thus the abnormalities detected here (i.e. 
low LH with loss of pulsatility (see chapter 4) and its correction 
by neuroleptics) supports the DA hypothesis of schizophrenia.
It is however found in a group of patients who have either never 
had neuroleptics or in whom neuroleptics were discontinued at 
least to some extent because of lack of response. These patients 
therefore cannot be said to have a clinical response to neuro­
leptics which supports any hypothesis based on overactivity of 
dopamine neurotransmission. Difficulties are also associated 
with the finding of increased post-synaptic DA receptors in 
schizophrenia (Owen et al, 1978) which was detected in a series 
of brains mostly from patients with chronic schizophrenia.
However in a subsequent study it was found that the increased 
DA receptors correlated with the positive, but not negative, 
symptoms of these patients (Crow et al, I980). Thus there are
indications of two separate pathophysiological processes in 
schizophrenia which may run in parallel viz 1) increased 
dopaminergic neurotransmission (responsible for acute drug 
responsive symptoms) and 2) an other slower, perhaps destruc­
tive, process (responsible for chronic drug unresponsive symptoms). 
The present study and the PM study indicate that DA overactivity 
may be present and detectable in drug unresponsive chronic 
schizophrenics. To clarify this position further a study looking 
at the hormonal effects of acute DA blockade with IV MCP in a 
variety of acute and subacute cases of schizophrenia is underway.
Further aspects of the interpretation of the present 
results to consider in the light of the broadly comparable 
result of Quigley et al (1980) in patients with stress induced 
amenorrhoea are a) that increased dopaminergic tone may be a 
pathophysiological counterpart of stress and that this operates 
in the chronic schizophrenic group and b) that increased 
dopaminergic tone may be the final common process of any form 
of hypogonadism. These questions are not easy to answer due to 
the paucity of data but to take them in turn:- a) this appears 
an unlikely idea since:- 1) most research indicates no role for 
DA in the mediation of stress 2) the chronic schizophrenics 
did not appear "stressed" and 3 ) the controls used had neurotic 
illness and were subjected to the same technical manipulations.
Point ' b) . cannot be refuted or confirmed since comparable 
studies on a variety of causes of hypogonadism have not been 
performed (however, theoretically, DA tone is likely to be high, 
rather than low, in patients with hyperprolactinaemic hypogonadsim).
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Finally the PRL response to IV MCP was identical in the 
chronic schizophrenic group compared to the control group 
(see Table 6.4). This confirms the work of Gruen et al (19?8) 
and indicates that an abnormality of the lactotrophe and/or 
pituitary DA receptors is unlikely in cases of schizophrenia.
The possible reasons for the normality of the PRL response to 
neuroleptics but the blunted response to TRIl (Chapter 5) in 
comparable chronic schizophrenics will be discussed in chapter 8.
Turning to the results from the study on acute schizo­
phrenics (study 3)i the following points are evident and 
important. Flupenthixol and PRL levels rose during treatment 
and significant relationships were established between them and 
daily flupenthixol dose. The PRL response to flupenthixol was 
very variable even when male and female patients are separated, 
and did not relate to the clinical effects or side effects of 
neuroleptics nor was it affected by anticholinergic medication. 
Gonadotrophin levels were not significantly affected by neuro­
leptics.
Similar relationships between neuroleptic dose, plasma 
level of neuroleptic and prolactin level were established by 
Rao et al (I980) studying females with chronic schizophrenia on 
stable doses of haloperidol but in two series of schizophrenic 
patients treated on an acute basis with chlorpromazine (Kolakowska 
et al,'1973; Wiles et al, 1976; Kolakowska et al, 1979) a signifi­
cant relationship between plasma level of neuroleptics and 
prolactin but no relationship with dosage was found. In these 
studies the numbers were relatively small and the dosage of
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chlorpromazine was determined by clinical judgement.
It is of interest that there is a relationship between the 
dose of neuroleptic, the blood level obtained and the consequent 
PEL secretion because it implies that PRL secretion can be used 
as an index of neuroleptic (and probably DA blocking) activity. 
There are however several important limitations to the use of 
PRL secretion as a marker of drug ingestion. The most notable 
of these is that these relationships are only statistically 
significant in large groups of patients and that individual 
patients fairly frequently exhibit large variations (e.g. patients 
given a very high dose of drug exhibit low blood levels and 
low PRL secretion and vice versa). The use of PRL secretion as 
an index of neuroleptic drug compliance is also problematical 
since it has been shown that long terra drug therapy is associated 
with a tolerance to the PRL elevating effects of neuroleptics 
and that in many cases, particularly in elderly men, PRL levels 
return to the normal range (de Rivera et al, 1976; Huws and Groom,
1977).
In the present study no significant relationships were 
demonstrated between PRL and either antipsychotic effects or 
extrapyramidal side effects. Positive relationships between the 
antipsychotic effect of neuroleptics and the associated elevation 
of PRL have previously been demonstrated by some workers (Meltzer 
and Fang, 1976; Langer et al, 1977; Cotes et al, 1978) but not 
by others (Kolakowska et al, 1973; Kolakowska et al, 1979). It 
is clear from all these studies that the relationship is not 
strong (i.e. many patients with high PRL levels frequently exhibit
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minimal or no clinical response and vice versa) and the effect is 
only obvions at low doses of neuroleptics as a ceiling effect 
develops (Gruen et al, 1978). A time-lag between the rapid 
elevation of PRL secretion and the slower anti-psychotic effects 
of neuroleptics was noted in a previous study (Cotes et al, 1978) 
but was not so marked in the present study.
The relationship between PRL level and extrapyramidal side 
effects has been less widely studied, Rao et al (I980) did 
find the two to be significantly related but was studying female 
chronic patients who had been on a stable dose of neuroleptic 
for 6 months. In the study of Wiles et al (1976) there is a non­
significant tendency for extrapyramidal side effects to be 
associated with higher prolactin levels and a similar tendency 
significant in some but not all comparisons was found in the 
study of Kolakowska et al (1979). These two studies like the 
present one include patient samples of variable age, sex and 
past neuroleptic experience and it may be that these features 
have tended to obscure a relationship between extrapyramidal 
effects and prolactin which might otherwise have been found.
In this study the administration of anticholinergic drugs 
did not significantly affect either flupenthixol blood levels 
or PEL levels. There are several conflicting reports in the 
literature on the effects of anticholinergics on neuroleptic 
blood levels probably resulting from differences in design and 
methodology (see Simpson et al, I980, for review). Whatever 
the true nature of the relationship between these two types of 
drugs it is clear that in the present study the effects of
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procyclidine upon the extrapyramidal and mental state ratings 
(see clinical results page 18I ) must result from a mechanism other 
than reduction of neuroleptic blood levels.
The question of the effect upon PRL levels of the addition 
of anticholinergics to the drug regime of patients on neuroleptics 
has been less widely studied though as disputed. De Rivera et al 
(1976) found that anticholinergics had no effect upon PRL levels 
in patients treated acutely with neuroleptics but that in patients 
on chronic neuroleptic treatment those on concurrent anticholinergics 
had higher PRL levels than those without anticholinergics.
A similar study concluded that an effect of anticholinergics 
on PRL secretion was only obvious at high doses of anticholinergics 
and low doses of neuroleptics (Halbreich et al, I980). Lai et 
al (1979) but not Halbreich et al (I980) found an increase in 
the PRL elevation induced by neuroleptics following acute anti­
cholinergic administration to normal volunteers. The findings 
in acutely treated patients in this ffcudy are consistent with the 
earlier findings of de Rivera et al in acute patients-
The male patients in this acute study had mean gonadotrophin 
(LH and FSH) levels which were exactly comparable with an age- 
matched control group (results shown in section 3i chapter 4) 
confirming the indication that gonadotrophin control is not 
disturbed in acute schizophrenics. Furthermore neuroleptic 
administration did not significantly alter gonadotrophin secretion 
in these patients (although in the 3 patients with the lowest 
pre-drug levels rose into the normal range after 4 weeks of 
flupenthixol). The contrast with chronic schizophrenics and
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implications of this finding were discussed above.
In conclusion these studies on the effects of neuroleptics 
on anterior pituitary secretion in schizophrenics reveal that 
the most marked effect is an elevation of PRL secretion but that 
this does not prove a useful clinical measure or a discriminating 
feature of schizophrenia. However a most interesting effect 
has been noted, namely that low gonadotrophins of chronic schizo­
phrenia are at least partly reversed by acute and chronic 
neuroleptic administration, which may prove to be a valuable 
research tool in the understanding of the pathophysiological 
process(es) of schizophrenia.
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CHAPTER 7
Effect of a dopamine agonist on hormonal and clinical state of 
acute and chronic schizophrenics
INTRODUCTION
Since the DA overactivity hypothesis of schizophrenia was 
first postulated, researchers have been interested in testing it 
by examining the effects of DA agonists in schizophrenic patients. 
Particular attention has been paid to the clinical effects of 
these drugs but evidence of altered DA receptor sensitivity has 
also been sought.
An outline of the pharmacology of various DA agonists was 
given in Chapter 2. As was mentioned in that section (1.3) there 
are several reservations about the use of amphetamines and L-DOPA 
as DA agonists and so the choice lies between apomorphine (APO), 
a synthetic derivative of morphine with direct DA receptor agonist 
properties (and no opiate-like activity), and the ergot derivatives. 
The latter drugs, while more specifically agonists at DA2 
receptors (the predominant DA receptor in the pituitary), have 
more activity than APO on other neurotransmitter systems (notably 
3HT). In addition there are problems associated with the adminis­
tration of the ergot derivatives in that they can only be given 
orally and therefore their pharmacological effects are of gradual 
onset and are prolonged. These considerations lead to the choice 
of APO as the drug to study the hormonal and clinical effects of 
dopamine agonists in schizophrenia. APO can be administered 
s.c.with good, rapid absorption into blood and the CNS and is 
rapidly metabolised in the liver.
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The hormonal effects of APO have been extensively documented 
during the past decade. It has been shown that APO induces a 
rapid and large elevation of GH secretion in man in doses of 0.23- 
1.5 mg s.c. (Lai et al, 1973). Doses below 0.23 mg are without 
any effect and doses above 1.3 g cannot be given as the frequency 
of side effects (nausea, vomiting) is too high. Cleghorn et 
al (1982) have shown a stepwise dose-response curve with 
increasing doses of APO in this range. It has been shown that 
repeated doses of 0.73 mg of APO produce reprocticible response 
within individuals. There is a large difference in the magnitude 
of the GH increment after APO between individuals (Rotrosen et 
al, 1979)• Ettigi et al (1973) reported some of the factors 
which are responsible for this variable response. These include 
reductions in the response induced by high oestrogen levels, by 
elevated glucose levels and by alterations in posture. It is 
clear that there is also a large inherent inter-individual 
variability. The GH response to APO is consistently blocked by 
neuroleptics, but not by other neuroactive drugs (Lai et al, 1977) 
which indicates that DA receptors are involved in the mediation 
of this response. However the site of this mediation (i.e. 
within the CNS or the periphery) is still unclear despite 
intensive research but is most probably at the hypothalamic level.
APO also suppresses PRL secretion and this effect is seen 
in a variety of circumstances e.g. pituitary cell culture lines, 
animals, normal subjects and hyperprolactinaemia (Johnstone and 
Ferrier, I980 for review). The effect is much more striking when 
PRL levels are high, through any cause, and the effect is minimal
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when PRL levels are low as there appears to be a PRL level below 
which even massive doses of the drug do not further depress PRL 
secretion. The effect of proceeding neuroleptic drug therapy 
in humans on PRL suppression by APO has not been clarified. In 
animals evidence of functional supersensitivity of this response 
can be detected after neuroleptics have been withdrawn for a 
few days (Lai et al, 1978) (despite the fact that there is no 
increased sensitivity of pituitary DA receptans at this time 
(Friend et al, 1978)).
It seems clear from the literature that the administration 
of APO is not associated with any change in LH, FSH, ACTH, TSH, 
or cortisol secretion (Checkley, I98O). The GH increment after 
APO is blunted in a substantial proportion of chronic schizophrenic 
patients (Rotrosen et al, 1979)- The significance of this 
findings has not been established. It has been suggested that 
prolonged neuroleptic therapy leads to this blunting of response 
(Ettigi et al, 1976) but this has been disputed by other workers 
(Cleghorn et al, I982). It would appear from the cumulative data 
of several studies (see Table 2.4, chapter 2) that the mean GH 
increment after APO is normal in acute schizophrenia (Ettigi et 
al, 1976; Rotrosen et al, 1979). However all these studies 
have reported that the GH response in acute schizophrenics is 
very variable and that there are many outliers above and below 
the control range. Cleghorn et al (1982) suggest that those 
patients in the process of relapsing are those who exhibit the 
enhanced response. This requires confirmation and the possible 
confounding effects of the short withdrawal time from neuroleptic
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drugs (often as little as ? days) needgto be taken into account. 
For these reasons a study looking at the hormonal response to 
APO in acute and chronic schizophrenics in male only, fasting 
patients was carried out. These patients had been drug free 
for at least six months.. An appropriate control group were also 
studied.
The clinical effects of apomorphine in schizophrenia have 
recently provoked much interest- Before the discovery of the 
antipsychotic properties of the phenothiazine drugs, APO was 
administered to schizophrenic patients when temporary relief 
of psychotic symptoms was necessary. Case reports in the older 
literature describe its beneficial action as a short acting 
"tranquilliser" (Feldman et al, 1945)- Sedation was thought to 
be the principal mode of action, but recent preclinical obser­
vations suggest that APO may exert any antipsychotic efficacy 
via a reduction in DA neurotransmission. DA agonists at low 
doses appear to activate presynaptic DA receptors preferentially 
(Meltzer, I980 for review) such that DA synthesis and release is 
inhibited. Therefore as opposed to predicting (according to 
the increased DA receptor theory of schizophrenia) that APO 
should exacerbate psychotic symptoms it is conceivable that 
exactly the opposite effect might be noted. There have recently 
been some clinical observations to support this notion.
Tamminga et al (1978) reported significant reductions in the 
psychotic symptoms of a group of 18 schizophrenic patients 
following 3 mg of APO s.c. It should be noted that these patients 
were also on neuroleptic medication at the time of the study.
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Corsini et al (1977) reported a similar effect in about half a 
large group of unmedicated schizophrenic patients (although have 
subsequently modified this therapeutic claim to apply mostly to 
Bchizo-affective patients (personal communication)). Meltzer 
et al (reported in Meltzer, I980) noted a striking therapeutic 
effect in a subgroup of schizophrenic patients. However none of 
these studies have performed blind clinical ratings and acute 
schizophrenics have not been studied. Furthermore if this effect 
was a real or marked one, then it should also be found with ergot 
derivatives which have a similar pharmacological profile.
However it would appear that bromocriptine and other ergolines, 
are not associated with therapeutic efficacy and may exacerbate 
psychotic symptoms (Tamminga et al, 1979)* Accordingly a study 
of the clinical effects of APO, blindly rated in well diagnosed 
acute and chronic schizophrenic patients to supplement the 
hormonal studies seemed appropriate. Recent evidence suggests 
that spontaneous eye blink rates may be an indicator of central 
DA activity. Blink rates are decreased in Parkinson's disease.
APO increases blink rates in monkeys in a dose-related fashion 
and this dose response curve shifts to the left after three weeks 
haloperidol treatment (Karson et al, I98I).
It has been reported that blink rates are increased in 
some schizophrenic patients (Stevens, 1978) and show a decrease 
in such patients following neuroleptic therapy (Karson et al, 
1981). It has recently been reported that the change in eye blink 
rates caused by haloperidol therapy corresponds . to a change in 
the thought disturbance syndrome (Karson et al, I982).
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The effects of APO on clinical side effects, symptoms and 
eye blink rates in acute and chronic schizophrenics and controls 
are reported here along with a description of concommitant 
hormonal changes.
MATERIAL AND METHODS
Patients studied. Three groups of patients were studied
a) 15 male chronic schizophrenic patients were selected according 
to the criteria of age, diagnosis, health and drug free 
status outlined in chapter 3 (section 1.1) and as described
in chapter 4 (section 2).
b) 13 male acute schizophrenic patients were selected according 
to the criteria outlined in chapter 3 (section 1.2) and as 
described in chapter 4 (section 2).
c) 10 male controls were studied. Normal laboratory and medical 
staff volunteers were chosen to age match the acute schizo­
phrenic group (b, above).
Clinical characteristics of the patients studied in terms of 
age, length of illness, drug history and mean positive and 
negative symptom scores (rated on the Krawiecka scale (see 
chapter 3 i section 2.1)) are shown in Table ?.1.
Experimental Protocol
The following protocol was carried out in all patients 
and is schematically represented in Fig ?.1.
1) All patients were studied after a 10 hour fast. A butterfly 
cannula was first inserted between 8 and 8.15 a.m. and left 
in situ for 15 - 30 mins prior to the first sampling.
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TABLE 7.1
Group n Age
(yrs)
Age at onset 
of Illness 
(yrs)
Positive
symptoms*
Negative
symptoms*
Drug history
Controls 10 27 ± 2 .0  
(20-36)
- None
Acute 15 30.1 ± 2.0 2 7 1 2 .0 6 1 9 patients never
schizophrenics (18-41) (16-49) (2-10) (0-5) received neuro­
leptics. 6 patients 
stopped neuro ­
leptics for 1/12 - 3 
yrs (mean 10/12)
Chronic 15 62 ± 2 . 0 25 ±1 .1 3 3 5 patients never
schizophrenics (39-70) (15-30) (0-9) (0-7) received neuroleptics 
10 stopped 1 - 8 yrs 
previously (mean 3 
yrs). 1 patient on 
Brufen. 1 patient 
on Diuretics
Clinical data in terms of age, age at onset of illness, positive and 
negative symptom ratings and drug histories of groups studies with 
apomorphine. Values as means ± SEM - range given in parentheses.
* values as modes.
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Schematic representation of apomorphine study. Videos were 
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taken as indicated by AI - A7 and B1 - By.
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2) Two venous samples were then taken at 15 min intervals.
3) A semi-standardised interview was carried out by a consultant 
psychiatrist and recorded on videotape. In the case of 
controls a short perception test was carried out at this 
time (listening to a tape recording and listing the fre­
quency of key words).
4) A further venous sample was taken followed by the administration 
of 1 ml B . C .  of either 0.73 mg APO or identical vehicle into
the upper arm (the order of injections being determined by 
a random schedule).
5) The patient then lay recumbent for 30 mins during which
time 2 further venous samples were taken at 15 min intervals.
An assessment of side effects experienced by the subjects 
(drowsiness, nausea, vomiting, yawning) was made during this 
time on a simple absent/mild/moderate/severe scale by means 
of a mixture of objective and subjective observations.
6) A further videotaped interview was then made lasting approxi­
mately 5 - 1 0  mins. The perception test was repeated on the 
controls.
7) Two further venous samples were obtained at +45 mins and +60 
mins post APO/placebo.
8) On the following day the procedure was repeated giving either 
vehicle or APO whichever had not been administered the 
previous day.
9) Sera was prepared from venous samples as outlined in chapter 
3 (section 3)« Samples were assayed for LH, PEL, GH and 
oestradiol by the methods outlined in chapter 3 (section 4,3).
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10) Videotapes were rated according to the scheme devised by 
Krawiecka et al (chapter 3 i section 2.l) by two separate 
psychiatrists who were not aware of the order of injections 
(or of the other's rating). There was a high degree of 
concordance between these ratings,
11) Eye blink rates were measured by two investigators from
the videotapes by counting blinks (with the aid of a computer 
programme) in the 2nd and 5th minute of the tape.
A close correlation was found between the ratings of these 
two investigators and between the two different test minutes 
such that the mean of all four figures is included for the 
purpose of the present analysis.
Radioimmunoassays
1) GH was estimated by RIA by the method given in Chapter 3*
GH was measured in 8 separate assays each of which contained 
samples from each treatment group, but all samples from an 
individual patient were measured in the same assay. Dilution 
steps were performed if the result exceeded 12 rriU/L. The co­
efficient of variation for high, medium and low quality controls 
was l4%, 8% and 10% respectively.
2) PRL and LH were estimated by RIA by the method given 
in Chapter 3* PRL and LH were measured in 5 separate assays
which conformed to the principles laid down above. The co-efficient 
of variation for high, medium and low quality controls for PRL 
and LH respectively were 12%, 10% ; 8%, 7% : 10%, ?%.
3) Oestradiol was estimated in the pre-placebo sample 
according to the method set out in chapter 3 in two assays
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containing samples from patients and controls (which were subject 
to stringent external quality control).
RESULTS
A) Hormonal results
a) Results in normal subjects. The mean GH and PRL 
responses to APO in normal subjects are shown in Fig 7.2. It
can be seen that there was a large, but variable, GH response
'I
with a mean peak increment at +4$ . The GH levels peaked at 
+45 post APO in samples from 8 of the 10 controls (one subject 
exhibited a GH peak at +30 minutes post APO and one subject at +60
minutes). PRL suppression post APO was a slower and less marked
phenomenon. As discussed in chapter 2 (section 1.3 on hormonal 
rhythms) PRL levels tend to fall in the early post waking period 
of the morning and this effect was seen in all of the controls 
studied here. Thus there was no significant APO induced reduction 
in PRL secretion till +45 minutes post APO (see Fig 7.2 for 
significance levels). LH levels were unaffected by APO adminis­
tration (Table 7.2).
b) Differences in hormonal responses of acute and chronic 
schizophrenics compared to controls. The results for the patient 
groups are depicted in Figs 7*3 and 7.4 and comparisons in Table 
7.2. The timing of the changes in GH and PRL in schizophrenics 
was similar’'to those of controls (Fig 7.2).
1) GH, There was no difference in the mean baseline level of 
GH (mean of 3 pre-drug levels) between the groups studied (Table 
7.2). A scattergram of peak GH increments after APO (max GH
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level after APO - mean baseline level) is shown for the three 
groups in Fig 7.4. There was no significant difference between 
the acute schizophrenics and the controls but the chronic 
schizophrenic group's mean peak GH increment was reduced compared 
to both groups (p < O.O7).
It was noted that there was a vepy large variation in the 
post APO GH increment in the acute schizophrenic group (ranging 
from +1mlU/l to +120 mlU/l). This variability just failed to be 
statistically significantly greater than that of the control 
group (f = 3.24 (2,12) NS:7% level f = 3.28).
2) PRL levels. There was no difference in basal PRL levels 
between acute schizophrenics and controls but the levels were 
lower in the chronic schizophrenic group compared to either group 
above (p < 0.05). This no doubt reflects the greater age of 
this group (see chapter 4, page 133 and results (section 0 below).
There are several ways of assessing PRL suppression after 
APO. These include the percentage reduction at 60 minutes post 
APO compared to 0 minutes, the finite reduction in mlU/l at these 
two times and the finite reduction in mIU/1 between these times 
less the finite reduction between these times on the occasion of 
placebo administration. The results for the first two of these 
methods of assessment for the three groups are shown in Fig 7.4 
in scattergram form and the mean values for the third are 
detailed in the text.
It can be seen from Fig 7*4 that there was no significant 
difference between the groups in the PRL reduction following APO 
either in percentage terms or in terms of finite reduction in
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mlU/l. As can be seen from Fig 7.4 there was a very large variation 
in the magnitude of PRL reduction in the acute schizophrenics. 
Analysis revealed that this increased variability related to the 
increased variability in the level of PRL prior to APO adminis­
tration. There was a highly significant relationship between 
the reduction in PRL after APO and basal levels of PRL (r = O.9I 
n = 4o p < 0.001 i.e the reduction was greatest where levels 
were higher and least when levels were low). There was no statis­
tical relationship between the increment in GH after APO and PEL 
levels or suppression.
3) LH levels. Mean LH levels before and after APO and placebo 
are given for the three groups in Table 7*2. It can be seen that 
APO administration was not associated with any change in LH 
secretion.
4) Oestradiol levels in the three groups studies are shown in 
Table 7*2. As can be seen there was no statistical difference 
between the groups.
B) Clinical effects of apomorphine
a) Side effects. The frequency of side effects - 
drowsiness, nausea, vomiting and yawning - are shown for each 
group in Table 7-3-
It can be seen that there was a considerable variation in 
the frequency and severity of these effects, but there were no 
significant differences between the groups. Approximately a 
third of each group had no subjective or objective signs but a 
similar proportion felt quite unwell with severe nausea and/or
TABLE 7.3
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Group
Sedotlon N gl seo/vonii t ng Yowning
None Mild/Moderate Marked None
Mild/
Moderate Marked None
Mild/
Moderate Marked
Controls
n=10
n=
%=
4
40
4
40
2
20
3
30
5
50
2
20
3
30
5
50
2
20
Acute
Scnlzophrenics
n=15
n=
%=
5
33
7
47
3
20
7
47
4
27
4
27
10
66
4
27
1
7
Cnronic n= 9 5 1 9 4 2 10 2 3
scnlzophrenics
n=I5 %= 60 33 7 60 27 13 66 14 20
Number of subjects exhibiting and frequency in each group of side 
effects following 0.75 mg APO s.c. in controls and acute and chronic 
schizophrenics. No significant differences.
TABLE 7.5
Group
Acute
Schizophren ics
n=12
Chronic
Sch lzopnren ics
n=13
Mean
SEM
Range
%
Change
Mean
SEM
Range
%
Change
PRE
PLACEBO
13.5
1.2
5-20
12.5
2.3
3-37
BLINK RATES (B l in k s /m ln )
POST
PLACEBO
PRE
APOMORPHINE
POST
APOMORPHINE
14.7 12.8 13.8
1.7 1.2 1.5
4-23 5-18 4-20
+ 7 - + 8
14,3 12.1 13.2
2.1 1.9 2.5
4-29 3-30 4-34
+ 26 - + 12
Blink rates before and after placebo and apomorphine in 
12 acute schizophrenics and 15 chronic schizophrenics. 
No sigpii.fleant group or apomorphine effects.
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vomiting. In these latter cases the unpleasant feeling came on 
about 15 minutes after administration of APO but passed off 
rapidly usually by +30 minutes. It was found that there was 
no correlation between GH increments, PPL suppression and the 
frequency or severity of APO side effects.
b) Effect on clinical ratings. Clinical ratings before 
and after APO have been depicted in Fig 7-5 and Fig 7*6. Mean 
values are set out in Table 7*^ i-. It can be seen that there was 
a large variation in the symptoms of these patients at the time 
of testing with positive symptoms (delusions, hallucinations, 
incoherence of speech and incongruity of affect) more prominent 
in the acute schizophrenic group than the chronic schizophrenic 
patients where negative symptoms (poverty of speech and flattening 
of affect) predominated. Non-specific features (anxiety, 
depression, retardation) were relatively uncommon in both groups. 
Ihble 7«^  shows that, while there was some change in some symptoms 
in a few patients, there was no significant change in any of the 
typically schizophrenic symptoms (i.e. positive or negative 
symptoms) following the APO injection. Positive symptoms improved 
in 6 out of 7 patients whose rating changed but the magnitude 
of this improvement was small. The improvement of positive 
symptoms was not frequent enough to be statistically significant 
(p = 0.07, Sign test). There was however a significant reduction 
in the anxiety ratings of the acute schizophrenic patients 
following APO (p < 0 .03, Sign test). This was not due to a 
placebo effect of becoming accustomed to the videotaped interview 
since anxiety ratings on the pre- and post placebo occasion were
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Positive and negative symptoms and anxiety ratings before 
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TABLE 7.4
211
Symptoms'
Mean ra t ing Mean
.. . 1
ra t ing
Acute schizophrenics n=15 Chronic schizophrenics n=15
PRE APO POST APO PRE APO POST APO
Delusions 3 3 3
H alluc ina t ions 2 2 i 1
Incongru ity of a f fe c t 1 0 1 1
incoherence of speech 1 1 1 1
P os it ive  symptoms 
subscore 7 6 7 6
F la tten ing  o f a f fe c t 0 0 2 2
Poverty of speech 0 0 1 2
Negative symptoms 
subscore 0 0 3 4
Anxiety 1 * 0 0 0
Depression 0 0 0 0
Retardation 0 0 1 1
Total mean 
score 8 5 11 11
Clinical effect of APO in acute and chronic schizophrenia. Scores 
are means for each group on each symptom of the Krawiecka scale. 
Also shown are subscores for positive and negative symptoms (see 
text). p < 0.05 (Sign test).
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comparable with pre-APO anxiety ratings. It was found that there 
was no correlation between the sedation following APO and the 
reduction in anxiety.
c) Effect of APO on eye blink rates. Results for eye 
blink rate measurements are set out in Table 7•5» No data are ■ 
available from controls. It was not possible to obtain results 
from 2 of the chronic schizophrenics and 3 of the acute schizo­
phrenics for a variety of reasons (e.g. poor quality videos, 
hand in front of face etc.).
It was found (Table 7-5) that there was a wide variation 
in the eye blink rates within the acute and the chronic schizo­
phrenic group. There was, however, high degree of intra­
individual stability in the eye blink rate (for example there 
was a highly significant relationship between the pre-drug 
eye blink rates on the two separate test days r = 0.86 n = 25
p < 0.001).
There was no significant difference between the pre-drug 
eye blink rates of the acute schizophrenics and those of the 
chronic schizophrenics. There was no significant effect of APO 
on eye blink rates in either group - in both groups there was 
a slight increase in eye blink rates half an hour after APO 
administration but this was matched by a comparable increase in 
eye blink rates after placebo.
C) Correlation between hormonal and clinical ratings
A whole series of correlations between all of the measured 
variables was performed. Very few significant relationships 
were established. These are outlined below for the whole group
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studied together with several cases where a lack of correlation 
is of some importance.
1) Age. There were significant negative relationships 
between age and a) basal PEL level (r = -0.43, n = 40, p < 0,01) 
b) reduction in PEL post-APO (whether measured by percentage 
reduction in PEL compared to baseline (r - -0.4l, n = 40, p <
0.01) or finite reduction in PEL in mlU/l (r = -0.37, n = 40,
p < 0.03)) and c) the GH increment following APO (r = -0.31, 
n =: 40, p < 0.03). Since there was a close relationship 
between basal PEL levels and the subsequent APO-induced PEL 
suppression (r = 0.59, P 0.001 for percentage and r - O.9I, 
p < 0.001 for finite reduction) it is likely that the effects 
of age of APO induced PEL suppression are mediated by effect on 
baseline PEL levels. There was a positive correlation between 
age and oestradiol levels (r - 0.48, n = 30, P 0.01). This 
relationship was also found though non-significantly in the 
study reported in Chapter 4.
2) GH Increments after APO. There was no relationship 
between the increase in GH secretion after APO and the suppression 
in PEL found after APO. There was also no relationship between
GH increments and oestradiol levels.
Looking at the patient group alone, it was found that 
there was a significant relationship between positive symptom 
ratings and GH increment (r = O.36, n = 30, p < O.05 Spearman's 
Eanlc Correlation) and a significant negative relationship 
between negative symptom ratings and GH increments (r = -0.44, 
n = 30, p < 0.05 Spearman's Eank Correlation). However it was
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found that the former relationship was based on the effects of age 
on both variables. While GH increments were found to fall with 
increasing age across the schizophrenic groups, the frequency of 
positive symptoms also fell with increasing age. Analysis of 
these correlations by the method of partial co-efficients (see 
Appendix E) reduced the relationship between positive symptoms and 
GH increments to non-significant levels. The relationship between 
negative symptoms and GH increments however remained significant 
following this analysis (r = -.40, n - 30, P 0.0$). Moreover 
this negative relationship was also seen within the chronic 
patient group alone (r = -.36, n - 13) p < 0,03) whereas there 
was no evidence of a relationship between positive symptoms and 
GH increments in either patient group alone.
3) PRL levels. A significant negative relationship was 
established between basal PRL levels and APO induced PRL 
suppression and positive symptom scores in the acute schizophrenic 
group ( r - -O.36, n = 13, p < O.O3) but not in the chronic 
schizophrenic group or in the total schizophrenic group.
4) Eye blink rates. There was no correlation between eye 
blink rates before or after APO (nor the percentage change 
between them) and any other variable measured.
DISCUSSION
In summary this study reveals that the only clearcut 
difference in the hormonal response to a dopamine agonist between 
acute and chronic schizophrenics and controls was a blunting of 
the GH response in the chronic schizophrenic group. The effects 
of apomorphine (APO) administration were similar between the
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groups. There was no therapeutic effect of APO on typically 
schizophrenic symptoms, but a reduction in anxiety was noted in 
acute schizophrenics following APO administration. Eye blink 
rates were unaffected by APO and unrelated to clinical state.
The hormonal effects of APO in normal control subjects 
found here parallel those previously described. There was a 
large variable increment in GH levels which was maximal at 4-3 
minutes. The variability of GH levels after APO was striking 
even though most of the known factors which relate to this response 
were controlled for (i.e. only male subjects were studied and 
all subjects were fasting and recumbent throughout the procedure).
It was found that oestradiol levels were not related to the GH 
increment in contrast to the study of Ettigi et al (1973) who 
found large differences in the GH response to APO between males 
and females and between females on and off oestrogen supplementation. 
It is probable that oestrogens do suppress this response (and 
there is animal evidence in support of this notion) but that the 
effect of oestrogens cannot be seen in the present experiment 
due to the limited range of oestradiol levels found amongest 
males. Age was shown to have a significant negative relationship 
on the GH response to APO in the present experiment. This 
effect has not been previously described, but no previous study 
has examined such an age range of subjects. There is however a 
significant methodological problem in the interpretation of this 
age effect on GH secretion since it was found across a mixed 
group of acute and chronic schizophrenics and controls and 
therefore may be brought about by the effects of illness, rather
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than age.
PEL suppression following APO administration leads to 
similar interpretative difficulties. As was mentioned in the 
theoretical section in chapter 2 (section 1.3) and again in the 
results section of the present chapter, there are several ways 
in which this suppression can be assessed. Since PEL levels 
fall to a certain extent during the placebo administration, the 
best method of assessment is to take this into account and 
calculate the specific (APO - placebo) APO induced suppression. 
Using this method, the mean specific APO-induced PEL reduction 
was 20^ in the controls. It was apparent that there was a 
strong effect of the baseline PEL level on the specific 
reduction associated with APO (i.e. the higher the PEL level 
the greater the reduction induced by APO). This is in agreement 
with previous reports (e.g. Rotrosen et al, 1978) and fits in 
with the observations from dose-response studies where it has 
been shown that there is a PEL level below which even massive 
doses of APO do not further suppress PEL levels.
IiH levels were unaffected by APO administration in any 
group studied. This supports previous observations. This lack 
of effect of APO contrasts with the LH lowering effect of DA 
infusions. It is probable that the main reason for this 
contradiction is pharmacodynamic : APO has only a very short 
half life whereas LH reduction only follows prolonged DA infusion 
(Kaptein et al, I98O; Huseman et al, 1980). It is possible 
that the difference lies in the mode or site of action of these 
two drugs. The evidence is in favour of both drugs exerting
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their PRL lowering actions via DA receptors on the pituitary 
and GH elevation action via the hypothalamus.
Turning to the hormonal results in acute schizophrenics, 
no clear evidence cf any abnormality or change in receptor 
sensitivity emerged. GH increments after APO showed an enormous 
variation in the acute schizophrenics, but this variability 
was not statistically different from that of controls. The 
cause of this large variability is not clear in controls, far 
less in acute schizophrenics (see discussion on controls above). 
This large variation in the GH response to APO in acute schizo­
phrenia has been reported in previous studies (Pandey et al,
1977; Rotrosen, 1979)» The time of withdrawal from drugs in 
these previous studies was short and variable and this lead 
these authors and others to consider the possibility that 
neuroleptic withdrawal had induced pituitary receptor supersensi­
tivity in some of the schizophrenic patients leading to a 
variable response in the group as a whole. However since all the 
patients in the present study had been off drugs for at least 
6 months, and variability was still pronounced, drug withdrawal 
effects seem an unlikely cause of these widely differing responses.
Another point to consider is that the GH increment after 
APO is related to clinical state, i.e. that large GH increments 
are found in a particular subgroup of patients or are related 
to a particular group of symptoms. No such clinical correlate 
emerged in the analysis of the results in the present study. No 
relationship was found between GH secretion and clinical symptoms 
(such as positive and negative symptoms (or their components)) in
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the acute patient group and the group with high GH output were 
clinically indistinguishable from the low GH output group in 
terms of age, symptoms, previous episodes etc.
Cleghorn et al (I982) have suggested that clinical state of 
schizophrenics is not the critical factor which relates to GH 
secretion after APO. They suggest that GH secretion depends on 
whether or not this state is changing, i.e. whether the patient 
is relapsing or remitting. According to this scheme (and the 
evidence to support it is not overwhelming) patients relapsing 
or about to relapse have high increments and those in stages of 
remission have low increments. Unfortunately we have no data 
from the present study to confirm or refute this hypothesis.
It has also been suggested that the magnitude of the GH 
secretion following APO is positively related to clinical response 
to drugs (Pandey et al, '1977)* This claim has subsequently been 
retracted (Rotrosen et al, 1979)*
Turning to PRL suppression following APO in the acute 
schizophrenics there was no significant differences between 
groups by any of the measures used to assess this. The mean 
specific APO induced reduction (finite reduction in lU/l post 
APO - finite reduction in lU/l post placebo / basal PRL X 100^) 
was 16^ in the acute schizophrenics (and 20% in the controls).
PRL levels were not significantly different between acute 
schizophrenics and controls. These results are in general agree­
ment with previously published studied (Rotrosen et al, 1979 
for review).
It is of interest that there was no relationship between
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APO induced PRL suppression and PRL induced GH secretion in 
either the schizophrenics and controls. This has been reported 
previously (Rotrosen et al, 1979)- This seems to imply that 
these two hormonal responses are mediated differently. There 
is experimental evidence to support this contention: APO has 
a direct effect on suppressing PRL secretion from pituitary cells 
in vitro but has no effect on GH secretion under these circum­
stances. Several other lines of evidence indicate that APO 
induced GH secretion is mediated at the hypothalamic level. For 
example Brown et al (1982) have demonstrated the domperidone, 
a peripheral DA blocker, eliminates the PRL response to APO but 
not the GH response. This implies that the dopamine receptors 
controlling PRL release are peripheral (located within the 
pituitary and/or median eminence) while those involved with GH 
are within the blood brain barrier (perhaps in the anterior 
hypothalamus where DA receptors have recently been described 
(List and Seeman, I981)).
It was found that there was a significant negative 
relationship between PRL secretion and APO induced PRL suppression 
and the positive symptoms score of the acute schizophrenics i.e. 
the greater the positive symptom score the lower the basal PRL 
and the smaller the reduction in PEL secretion. Since there is 
a close relationship between PRL suppression and basal PRL 
levels, the main important relationship is probably between 
basal levels and symptoms. This relationship is of great 
theoretical interest, since DA tonically inhibits PRL secretion, 
and DA has been implicated in the causation of positive symptoms.
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This relationship has previously been reported in a group of 
unmedicated chronic schizophrenics (Johnstone et al, 1977).
However in the larger group of acute schizophrenics studied and 
reported in Chapter 4 only a negative trend between positive 
symptoms and PEL secretion was demonstrated. Thus it is apparent 
that the relationship between positive symptoms of schizophrenia 
and PRL secretion is a weak one and is not applicable to 
individual patients. It is not really a surprise that this 
relationship is so weak since so many factors influence PRL 
secretion and positive symptoms. Nevertheless this relationship 
is a phenomenon which could repay further study. For example, 
it has recently been demonstrated (Kleinman et al, I982) that 
there is an inverse relationship between positive symptoms and 
PRL secretion in those schizophrenics with normal CAT scans 
and where ventricular dilation is present this relationship is 
not found. This could be considered as evidence that acute 
and chronic schizophrenia may be separate overlapping syndromes 
with separate underlying pathophysiologies (Grow, I98O).
The hormonal results from the chronic schizophrenic patients 
also revealed no evidence of a clearcut abnormality in PRL levels 
or sensitivity. The specific suppression of PRL following APO 
administration was 13^ of mean basal level in the case of the 
chronic schizophrenics. This was smaller than either the acute 
schizophrenic group (16%) or control (20%). However, as mentioned 
above, statistical analysis revealed that baseline PRL levels 
were closely related to the degree of suppression caused by APO. 
PRL levels were lower in the chronic schizophrenic patients and
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so this is the likely cause of the reduced APO suppression in 
this group. Basal PEL levels are known to be lower in chronic, 
as opposed to acute, schizophrenics (Meltzer et al, 1974). In 
this study this reduction was shown to be an age effect. This 
reduction of basal PEL with increasing age was shown in the 
large series of controls reported in chapter 4 and has been 
shown in some but not all previously published reports (see 
chapter 4 for details).
As can be seen from Fig 7-4 and Table 7*2 GH increments 
after APO were significantly reduced in the chronic schizo­
phrenics compared with acute schizophrenics and/or controls. 
Blunting of the GH response to APO in chronic schizophrenics 
has been demonstrated in some (Pandey et al, 1977; Rotrosen et al,
1979) but not all (Meltzer, I982) previous studies.
The pathophysiological basis of this blunted response is 
not clear. Rotrosen et al (1979) suggest that this is due to 
pathological subsensitivity of pituitary DA receptors in chronic 
schizophrenia induced by chronic neuroleptic therapy. The 
evidence cited in favour of this contention is that Ettigi et al
(1976) found a relationship between blunted GH responses and 
duration of neuroleptic therapy and that chronic neuroleptic 
therapy in rats appears to induce subsensitivity of DA receptors 
in the pituitary (Friend et al, 1978).
However there are several reasons to doubt the validity 
of this explanation. Firstly the results of Ettigi et al 
( ' I 9 7 6 )  may relate not to duration of neuroleptic therapy, but 
to chronicity of illness. Meltzer et al (1982) have described
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such a relationship in a large study. This latter finding may 
relate to the observation of Jeste (1981) who found that a 
blunted GH response to APO is more common in those patients who 
have evidence of enlarged ventricles on CAT scan. Further 
evidence against neuroleptic drugs as the cause of blunted GH 
response in chronic schizophrenics was found in the present 
study. Of 5 patients who had never been treated with neuro­
leptic drugs 3 had GH responses well below the control mean.
There ai*e two further problems with the argument that 
neuroleptic therapy is implicated in the causation of blunted 
GH responses in chronic schizophrenia. Firstly, although Friend 
et al detected biochemical evidence of neuroleptic induced 
subsensitivity, there is in fact evidence in rats (Lai et al,
1977) of functional supersensitivity to dopamine agonists 
following neuroleptic withdrawal. Comparable evidence is not 
yet available in man, but the small study of Brambilla et al 
(1979) did suggest enhanced GH responses to L-DOPA in the period 
following neuroleptic withdrawal.
Finally, and most importantly, it is unlikely that pathology 
of the pituitary dopamine receptor is involved in the mediation 
of this abnormality, since most evidence (Brown et al, 1978; Brown 
et al, 1982) points to a hypothalamic site of action for APO 
in the induction of GH secretion. The exact mechanism of action 
of APO in the GNS which leads to a GH surge from the pituitary 
is not clear. APO is virtually certain not to have its GH 
elevating effect via central DA pathways (see Brown et al, I978 
for review). This effect appears to be mediated either via DA
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pathways within the hypothalamus (and associated receptors) or 
by an action on the hypothalamic releasing hormones involved in 
GH regulation (GRF and SRIF see chapter 2, section 1.3)
In summary the cause of blunted GH secretion after APO 
in chronic schizophrenia, which has now been reported by several 
groups, is not certain. Drugs appear an unlikely cause and in 
view of the relationships between blunted responses and length 
of illness) ventricular enlargement and negative symptoms it is 
conceivable that a degenerative or destructive process in the 
hypothalamus or closely related structure underlies these 
impairments.
The significance of this finding is open to doubt until 
further research can answer some of the questions raised above.
A post-mortem examination of pituitary DA receptors from schizo­
phrenics is underway which should throw some light on some of 
these issues. A further problem is how these findings in a 
selected (if only by their drug free status) group of chronic 
schizophrenics relate to the deficits and impairments of chronic 
schizophrenia population as a whole. This question will be 
addressed in the next (final) chapter which discusses these 
issues with respect to all the studies reported here.
The study of the clinical response to APO in schizophrenics 
produced almost entirely negative results. Nevertheless these 
results are of interest as they refute some earlier studies 
which had made some controversial and theoretically important 
conclusions.
Firstly, it was found that the clinical effects of APO
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administration such as sedation and nausea were of comparable 
frequency and severity in the schizophrenic groups and in the 
controls. This finding is in direct contrast to that of 
Meltzer's group (Meltzer, I980) who reported reduced degrees 
of sedation to APO (also at a dose of 0.75 mg s.c.) in a group 
of schizophrenics. On this basis, Meltzer proposed that DA 
receptors in schizophrenia were subsensitive and that this could 
lead to a reflex increase in DA metabolism. This hypothesis 
is not supported by biochemical evidence from post-mortem brain 
work (see Table 1.1 for details). The experimental data on 
which this hypothesis rests appears, on the basis of the present 
results, to be somewhat tenuous. A previous study (Corsini et 
al, 1977) reported similar results to the present study - 
sedation, sleep and nausea were "in comparable proportions" 
following 1 mg of APO in schizophrenics and in normal controls.
There is evidence that the sedative and emetic effects of 
APO can be blocked by DA receptor blockers and are therefore 
mediated by DA receptors. Therefore the present study is 
evidence that there is no alteration in the sensitivity of these 
receptors in schizophrenia. The exact site and nature of these 
receptors is not fully established. Nausea/vomiting is probably 
mediated via DA receptors in the area postrema of the medulla 
and the effect of APO here is probably on post synaptic receptors. 
The site of the receptors mediating sedation is unknown. It 
has been suggested that sedation following APO is mediated by 
low dose stimulation of pre-synaptic receptors ("autoreceptors") 
(Meltzer, I980) but the evidence for this, in man, is not
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overwhelming. If autoreceptors are involved in APO-induced 
sedation, then the dose administered here may have been too high 
for their preferential stimulation. A study of the clinical 
effects of low and high dose APO in schizophrenia is probably 
required to be absolutely certain that there was no change in 
receptor sensitivity (as far as these responses are concerned) 
in schizophrenia.
There were no consistent or significant effects of APO 
administration on the typically schizophrenic symptoms in patients 
with that diagnosis. Positive symptoms (delusions, hallucinations, 
thought disorder, incoherence of affect) were not changed after 
APO administration in either group. Negative symptoms (poverty 
of speech, flattening of affect) which were found almost 
exclusively in the chronic schizophrenic group were similarly 
unchanged. The only significant effect noted was a reduction in 
anxiety ratings in acute schizophrenics after APO. This appeared 
to be a specific effect since no change was noted following 
placebo administration. Anxiety was rated as being present to 
a morbid degree (score of 2 or more on the Krawiecka scale) in 
8 of the 15 acute schizophrenics; 7 of these exhibited a 
reduction in anxiety, into the non-morbid range (score of < 2). 
There was no relationship between sedation induced by APO and 
this reduction in anxiety.
The reduction in anxiety following APO administration in 
acute schizophrenics is in agreement with the work of Feldman 
et al (19^5) who noted that APO (in a dose of 1.5 mg) was 
effective in calming excited or agitated psychiatric patients.
2 2 6
These results however do not agree with those of Corsini et al,
(1977) and de Chiara et al, (1978) who found that there was a rapid 
reduction in psychotic symptoms (e.g. delusions, "bizarre 
behaviour" and "suspiciousness") after APO administration. Both 
of these studies were effectively open studies and ratings were 
therefore not performed blind. A 'double blind' study of the 
clinical effects of APO carried out by Taraminga et al (1978) 
showed a significant reduction in the New Haven schizophrenia 
scale (NHSS) score of I8 schizophrenics following 3 mg of APO 
S . C . ,  but not following identical placebo. The reduction in the 
NHSS was principally due to a reduction in delusions and hallucin­
ations. The patients were also on neuroleptic medication at the 
time of study which accounts for the reported tolerance of such 
a high dose of APO. This,however, leads to interpretative 
difficulties because an effect of APO on pre-synaptic DA receptors 
which these authors suggest is the mechanism of the antipsychotic 
effect would be blocked by concomraitant neuroleptic drug exposure. 
It is conceivable that in schizophrenic brain there could be 
differential effects of neuroleptics and/or APO on presynaptic 
receptors, but there is no direct evidence for this notion at 
present.
The lack of significant effect on positive symptoms is 
in agreement with that reported by Meltzer's group (Meltzer,
1980) and by Angrist (Angrist et al, I980 and personal communi­
cation). Indeed Corsini has now extended his original study and 
has found that the antipsychotic effect of APO is restricted to 
a group of schizo-affective patients (often a group of patients
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who are difficult to classify and define). Several groups of 
workers have reported that ergot derivatives are without anti­
psychotic efficacy (e.g. Tamminga et al, 1979). The proponents 
of the theory that APO is antipsychotic suggest that in these 
studies the dose of ergots may have been too high in achieve 
selective stimulation of autoreceptors. Further studies are 
indicated so that these matters can be resolved.
It would appear, taking all the above studies and the 
present one into account, that the administration of APO does 
not exacerbate or provoke schizophrenic symptomatology.
Because of uncertainty about the receptor effects of the dose 
range employed in these studies (0.5 - 1.5 mg), a statement 
about the significance of this finding vis a vis the DA over­
activity theory of schizophrenia cannot reliably be made. It 
could be that presynaptic and postsynaptic effects cancelled 
themselves out in the present study leading to no change in 
symptomatology. In partial support of the notion that dose 
effects are critical, it has been reported that high dose oral 
APO may have psychotogenic effects in Parkinson's disease. 
However Angrist et al (1980) reported that APO in doses up to 
0.06 mg/kg (--A mg) did not exacerbate schizophrenic symptoms.
It could also be postulated that there is no change in receptor 
sensitivity in schizophrenia or that DA receptors are not 
involved in schizophrenia. Since there is no evidence for and 
considerable evidence against these notions (see Table 1.1) 
these postulates can be discarded for the moment but should be 
borne in mind.
The results of measuring eye blinks in the schizophrenic 
patients were almost entirely negative. Since the eye blink 
rates were not measured in control subjects we cannot directly 
confirm or deny the observation of Stevens (19?8) that blink 
rates are increased in schizophrenia. The blink rates measured 
in the schizophrenic subjects accord well with previously 
published blink rates in normal subjects (e.g. Karson et al,
1982) and are lower than those measured in the schizophrenics 
studied by Stevens (19?8) and Karson et al (I982). The reasons 
for the difference are not clear : one possibility is the short 
period of neuroleptic withdrawal in the studies cited above 
induced a degree of DA receptor sensitivity.
The mean percentage increment in eye blink rates in the 
schizophrenics after APO was 10/. However the increase in the 
rate following placebo was 12/ which means that no pharmacological 
effect of APO was demonstrated. An effect of APO on eye blinks 
has been previously demonstrated only in monkeys (Karson et al, 
1982). This discrepancy may represent a true species difference 
or a dose-dependant difference.
No relationship between eye blink rates and schizophrenic 
symptoms (positive or negative symptoms or their individual 
components) was demonstrated in the acute or chronic schizophrenic 
patients or both groups combined. This confirms the finding of 
Karson et al (1982). These authors only found a relationship 
between the change in eye blinks after haloperidol therapy and 
the change in some aspects of positive symptom ratings (e.g. 
thought disturbance) after haloperidol therapy. They found this
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effect to be more marked in those patients with normal ventricular 
size. Unfortunately CAT scans were performed only in a small 
number of the schizophrenic studied here so we cannot comment 
on the validity of this distinction.
There was no relationship between eye blink rates before 
or after APO (and the percentage change between them) and APO- 
induced GH secretion or PPL suppression. Since these latter 
two responses are mediated by dopaminergic influences, this could 
be taken as evidence for non-involvement of DA in the blink 
reflex. However since the anatomical and physiological basis 
of these responses differ so widely and since these measures 
are liable to be affected by so many extraneous factors, a 
statistical comparison (like a correlation co-efficient) is 
not a valid assessment of the involvement or non-involvement 
of d a in eye blink rates.
SUMMARY
The results of this study indicate that the administration 
of apomorphine to schizophrenic patients is not associated 
with any specific clinical change other than a reduction in 
anxiety in acute schizophrenics. Blink rates changes and the 
frequency of 'side-effects' of apomorphine were equally distri­
buted amongst schizophrenics and controls. There was no 
difference in the PRL suppression induced by APO between the 
groups but the GH response characteristics of acute and chronic 
schizophrenics were quite different. The reduced GH secretion 
of chronic schizophrenics may reflect an abnormality in DA- 
peptide interaction in long standing schizophrenia.
CHAPTER 8
Concluding remarks: Analysis and synthesis
8.1 General points
The search for the cause of schizophrenia has mirrored 
social and scientific change. In earlier times demonical 
possession, witchcraft and vapours were seen as undeniably the 
cause of madness. In the 19th century descriptive science came 
to the fore and scientists began to observe and classify 
psychiatric illness more closely. In the earlier part of the 
20th century behavioural and social science held sway and schizo­
phrenia was seen in this light. Since the mid part of the 
century great strides in physiology, pharmacology and patho­
physiology have been made and schizophrenia is now examined in 
the context of a great wealth of neuroscientific knowledge.
Much has been achieved in the management of schizophrenic 
patients particularly with the advent of neuroleptic drugs and 
changes in social awareness. However the basic pathophysiology 
of the disease remains obscure. Part of the problem with 
research into schizophrenia is that study of the central nervous 
system is involved. It is clear that the brain has many complex 
overlapping and interacting anatomical and physiological systems. 
Another problem is that schizophrenia appears to be a hetero­
genous disease in terms of symptoms, onset, course and outcome. 
Consideration therefore should be given to the notion that the 
clinical condition called schizophrenia represents the end point 
of various pathophysiological processes in the same way as 
anaemia can be caused by blood loss or B12 deficiency.
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The work presented here is largely concerned with studying 
schizophrenic patients by means of neuroendocrine techniques.
The advantages of this method are that it is relatively non- 
invasive and can be performed on a variety of patients at 
different stages of the disease. The principal aims are that 
either a diagnostic or prognostic marker will be discovered or 
that a particular pattern of hormonal secretion will be discovered 
whose elucidation will lead to an understanding of the disease 
process. As regards the first aim no clear abnormality in 
schizophrenia or depression has emerged despite considerable 
research. The DST test in depressive illness has some potential 
but there are major difficulties evident as outlined in chapter 
2 (section 2.2). Research towards the second aim is similarly 
problematical at present. This leads to a consideration of 
the major disadvantages of this technique which are discussed 
below.
The disadvantages of the neuroendocrihe approach to 
studying psychiatric illnesses are basically twofold. Firstly, 
as was discussed in chapter 2 there are many factors which affect 
pituitary hormone secretion. Examples include sleep, "stress", 
age, puberty, glucose and protein intake, posture and drug 
ingestion. Even if all these factors are controlled for then 
there is the problem that many of the hormones have a pulsatile 
secretion. Moreover,when these factors are taken into account 
the problem of the large individual variation in pituitary 
hormone secretion remains and leads to interpretative difficulties. 
Even when an abnormality in pituitary hormone secretion is
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reliably identified there is still a considerable problem in 
ascribing this defect to one neurotransmitter system since it 
is apparent that several known neurotransmitters have modulating 
effects on pituitary hormone secretion. A second problem of 
the neuroendocrine strategy of studying psychiatric patients is 
that even if a defect of hormonal secretion is identified and 
the pathophysiological mechanism in terms of neurotransmitters 
and hypothalamic hormones is established one is still left with 
the problem that this process may not be representative of events 
in the remainder of the brain and may be a secondary process.
The disadvantages of the neuroendocrine strategy are how­
ever diminished by several other factors. Firstly all other 
approaches of studying psychiatric patients from the biological 
point of view have somewhat similar problems. Pharmacological 
studies are indirect and many of the drugs used lack specificity. 
Post mortem studies are not suitable for studying dynamic systems 
e.g. does the findings of (say) an increase in the level of a 
neurotransmitter reflect increased or decreased secretion and/or 
turnover? In addition there are some problems with agonal status. 
Peripheral .(urine, blood, GSF) measures of neurotransmitters or 
their metabolites have not demonstrated consistent changes in 
psychiatric disease probably partly due to their indirectness. 
Secondly, in many respects the hypothalamo-pituitary axis responds 
in a pharmacologically similar way to the rest of the central 
nervous system and therefore this system is useful for monitoring 
the central effects of drugs. Finally there is evidence for 
important hormonal perturbations in both of the major psychoses
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(schizophrenia and affective illness),some evidence of disturbed 
hypothalamic function in these diseases (particularly depression) 
and possible associations of hormonal disease and both these 
illnesses. These facts indicate that some disturbance of hypo­
thalamo-pituitary control is likely to be present in both these 
diseases.
A frequent objection to the studies of the type reported 
here is that the patients selected for study are unusual and 
untypical of the total population of schizophrenic patients. A 
complementary argument is that any differences demonstrated are 
a result of hospitalisation as an ideal control group cannot be 
found. In respect of the chronic schizophrenic patients it is 
true that due to the selection criteria adopted the patients 
studied were from the unfavourable end of the prognostic spectrum. 
In fact most of the patients studied had been hospitalised for 
several years. While a few of the patients had never had neuro­
leptics, the remainder of the patients' drugs had been stopped 
due to non-response, non-compliance or both. This also raises 
the possibility of a selected group of patients. However it 
was apparent from a study of the casenotes that the patients 
history and clinical course were very typical of schizophrenia 
in général. In addition the sample of patient studied here were 
representative of the total schizophrenic population of their 
hospital (Owens and Johnstone, 1980) in terms of symptomatology, 
cognitive functioning and behavioural performance. Finally a 
similar range and frequency of disabilities have been detected 
in non-institutionalised outpatient chronic schizophrenics
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(Johnstone et al, I98I).
There is no simple answer to the question that prolonged 
hospitalisation may have been responsible for the neuroendocrine 
abnormalities reported here although the mechanism of such an 
effect is far from clear. Research into the disabilities of chronic 
schizophrenia is always problematical because of the problems 
of selection of a suitable control group. However there are 
several pointers against the hypothesis that hospitalisation is 
involved in the causation of neuroendocrine abnormalities in 
chronic schizophrenia. Firstly the effects of such an environment 
have not been noted in humans. In animals reduction in gonado­
trophin secretion have been reported in various environmental 
situations e.g. overcrowding (Tache et al, 1979)î exposure to 
aggressive males (Barkley, I98O) and low position in a hierarchy 
(Ebehart and Keverne, 1979). The only comparable evidence for 
an effect on environment on hormones in man is the report of 
Rose et al (I988) of reduced testosterone in male army personnel 
under stressful circumstances. Secondly the control group studied 
here contained some patients which to a certain extent control 
for the effects of environment. Three long stay patients of 
the same hospital as the chronic schizophrenic patients were 
studied. These patients had been hsopitalised for comparable 
periods with a diagnosis of manic-depressive illness. All of 
them showed a perfectly normal hormonal profile. A second group 
of controls for the chronic schizophrenic patients had a history 
of reactive depression and/or neurotic illness and had been 
treated in the past with psychotropic medication. This group, to
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a certain extent, act as controls for the non-specific effects 
of psychiatric illness. In the absence of an ideal control 
group (presumably normal people receiving inpatient care for 
more than 20 years in a psychiatric hospital) the present mixture 
of chronically hospitalised non-schizophrenics, depressed or 
neurotic outpatients and normal controls (not selected on the 
basis of perfect physical health) seems the best available 
compromise.
As regards the acute schizophrenic patients studied here 
there can be little doubt about the diagnosis. All of the 
patients had a recent onset of positive, florid symptoms of 
schizophrenia and , all had Schneiderian first rank symptoms and 
fell into the nuclear schizophrenia (NS+) category on Present 
State Examination. This group of patients is one on which there 
is most agreement about the diagnosis of schizophrenia.
8.2 Overview of results in context of psychoneuroendocrinology
a) Chronic schizophrenia
In summary the results of these studies demonstrate 
selective reductions in gonadotrophin secretion in a subgroup 
of chronic schizophrenics which is associated with a reduction 
in the frequency but not amplitude of LH, secretory episodes.
While this pattern of abnormal secretion appeared to be stable 
and reproducible within individual patients, the administration 
of acute or chronic DA antagonists was associated with a return 
towards normal levels. This suggests that DA overactivity may 
be implicated, at least in part, with the genesis of these 
abnormalities and this contention is supported by the finding
that those patients with the most marked derangement of gonado­
trophin secretion had the lowest prolactin levels. These patients 
also exhibited the most evidence of hypothalamo-pituitary 
derangement in that their responses to hypothalamic releasing 
hormones was disturbed with blunted FSH and PEL responses and 
aberrant GH responses to TRH/LHRH administration. The GH 
response to a dopamine agonist was also reduced in chronic 
schizophrenics as a group and markedly so in a subgroup of the 
patients, particularly those with predominant negative symptoms.
The clinical associations of these abnormalities have not yet 
been fully established. This is partly due to the relatively 
small numbers of patients studied but also to the general 
difficulty of comparing a biological variable with a clinical 
or phenomenological one. For example it is more meaningful to 
look for correlations across an entire group of patients or 
should one divide them into groups on one or other vairable and 
then do comparisons? Both methods have the inherent danger that 
the greater number of relationships examined the greater number 
liable to be significant by chance.
With these reservations in mind it appears from these and 
other studies that in chronic schizophrenia:-
a) FSH secretion is lowest in those patients with the most 
positive symptoms and the earliest age of onset (Shader et 
al, 1969; Johnstone et al, 19"^  andpresent study).
b) LH secretory profiles are most deranged in those patients
with the longest length of illness and there is a trend for more 
marked abnormalities in patients with more prominent positive symptoms.
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c) PRL secretion does not relate to psychopathology in chronic 
deteriorated patients (this study and Kleinman et al, I982) 
and
d) GH secretion to apomorphine is reduced in those patients 
with the longest history , those with CAT scan deficits 
(Meltzer et al, I98O; Jeste, 1981)and negative symptoms (see below).
The most likely . explanation of these hormonal findings 
and clinical associations is that in chronic schizophrenia there 
are abnormalities of DA - hypothalamic peptide interaction. The 
reduced LH and FSH secretion are probably related to reduced 
LHEH secretion from the hypothalamus. The evidence for this was 
discussed in chapters A and 5* DA blockade to a certain extent 
reversed these abnormalities. DA has been shown to play a role 
in the extracellular degradation of LHRH in the hypothalamus 
(Marcanno de Cotte, 1980). There is a close anatomical 
relationship between DA and loHRH in the median eminence (McNeil 
and Sladek, 1978). It is therefore conceivable that in schizo­
phrenia excess DA inhibits or reduces LHRH release and this 
effect is reversed when DA blockade is induced. The site of 
action of dopamine blockers in the mediation of his response is 
however not clear. It would be of interest to observe if 
domperidone (a DA blocker which does not cross the blood - brain 
barrier) also induced a rise in gonadotrophin secretion in 
chronic schizophrenia. The association of reduced FSH secretion 
and increased positive symptoms and the similar trend for IH 
secretion is of interest since DA blockade tends to ameliorate 
both reduced gonadotrophin secretion and positive symptoms. This
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would, seem to support the contention that DA overactivity is a 
process underlying the positive symptoms of schizophrenia (Crow,
1980).
As was discussed at length in chapter 7 it is probable 
that the GH elevating effects of apomorphine are mediated within 
the hypothalamus. It is probable that such an effect is 
mediated by either a release of the putative hypothalamic 
peptide GH releasing hormone (GHRH) or an inhibition of somato­
statin (GH inhibiting hormone or SRIF) from the hypothalamus.
The blunting of the GH response to APO could therefore result 
from a deficiency of GHRH release, an excess of SRIF release or 
ai defect of the apomorphine-peptide interaction. The fui'ther 
elucidation of this deficit must await more detailed knowledge 
of the mechanism of APO induced GH secretion.
Blunting of GH response to APO has been found to relate 
to increasing length of illness (Meltzer et al, I980) and to 
CAT scan abnormalities (Jeste, I98I) in schizophrenics. In 
this study the patients with blunted responses tended to be 
those with long histories, those with negative symptoms (possibly 
a marker of organic deterioration of schizophrenic patients 
(Owens and Johnstone, 1980)) and those with poor cognitive 
performance.' The relationship with symptoms reached statistical 
significance. What is clear is that the abnormal blunted response 
does not relate to positive symptoms in the same way as 
gonadotrophin secretion appears to. The clinical associations 
tend to point towards this blunting related to some organic, 
perhaps destructive process, in the hypothalamus. The clinical
2 3 9
associations of the two basic hormonal deficits (reductions in
LH and FSH secretion and blunted GH responses to APO) may indicate
separate processes underlying them supporting Crow's (1980) hypothesis (eeepP^C
It is difficult to conceive of one process that could 
lead to these somewhat selective deficits and leave the 
remainder of the HPA axis working normally. A lesion in the 
supra-charismatic nucleus could reproduce the LH secretory pattern 
seen in these patients but is unlikely to be associated with 
GH response blunting. However it is possible that the anterior 
hypothalamus in which both LHRH pathways (Barry, 1977) and 
dopamine receptors (List and Seeman, I981) have recently been 
observed could be an important area to investigate in schizophrenic 
brain. It is also conceivable that one neurotransmitter 
abnormality underlies both these abnormalities and the symptoms 
of schizophrenia. A long lasting abnormality may lead to
adaptive changes in biochemical and receptor function that may subsequently 
be difficult to separate.
The question of long lasting changes in neurotransmitter 
function and secondary adaptive change is relevant to the 
discussion of the PRL stimulation test results of the chronic 
schizophrenics. The PRL response to TRH was blunted and aberrant 
GH responses were seen in some cases. On the other hand the 
PRL responses to both DA antagonist (metaclopramide) and agonist 
(apomorphine) were normal. This pattern of response is distinct 
from that seen in cases of known organic lesions of the hypo­
thalamus (Ferrari et al, 1982). In these cases the PRL response 
to TRH is more or less preserved but that to DA blockade is
Labolished. However it is probable that the chronic hyperprolactin- 
aemia present in these cases is responsible for this pattern: 
it appears to induce impaired DA levels within the pituitary 
itself possibly by a short-loop feedback on DA turnover. The 
results from schizophrenic patients indicate that DA receptors,
DA levels and PRL reserve of the pituitary are normal. The 
blunted TRH response indicates either an abnormality of the 
TRH receptor on the lactotrophe itself or some change in dopamin­
ergic tone within the HPA. There is however some dispute on 
the effect of DA tone on the PRL response to TRH: Healy and 
Burger (1977) reporting opposite effects from Kauppila et al 
(1982). Paired testing with TRH and DA blockers in the same 
patients is recommended to separate these various possibilities 
(Ferrari et al, I982).
Two final problems need to be discussed before leaving the 
chronic schizophrenic studies. These are 1) what is the 
significance of the fact that these changes are only found in 
a subgroup of patients and 2) are the defects specific for 
diagnosis. Some of these matters have been dealt with in the 
discussion sections of chapters 4, 5, 6 and 7 but an overview is 
presented here.
In general terms consistent abnormalities of pituitary 
hormone secretion were only detected in about 50/ of the chronic 
schizophrenics studies. 25/ were in the normal range on every 
variable tested and the remainder were in the equivocal range.
The cause of this heterogenity is not at all clear at present.
A similar situation is encountered in neuroendocrine studies
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with depressed patients. This elucidation of this heterogenity 
represent a major challenge to psychiatrists and neuroendo­
crinologists. Mis-diagnosis is unlikely as all of the patients 
studied appeared to have had classical schizophrenic illness.
It is conceivable that the endocrine differences within chronic 
schizophrenics reflect different underlying disease processes 
but there is no confirmatory evidence of this at present.
The specificity of these changes to chronic schizophrenics 
is somewhat uncertain. However it does appear that the particular 
pattern of changes is different from several other important 
psychiatric, neuropsychiatrie and endocrinological conditions 
as outlined below.
1) Affective illness. While there are unconfirmed reports of 
reduced LH, FSH and LH cycling in depression (see chapter 2, 
section 2.2 ), there are several dissimilarities between the 
results in chronic schizophrenics and depression. For 
example the TSH response to TRH is blunted in a number of 
depressives but is normal in schizophrenia. The GH response 
to apomorphine is normal in depression but abnormal in 
chronic schizophrenics. Differences found in manic or 
bipolar affective patients were outlined in chapter 2(section 
2.2).
2) Anorexia nervosa. While there are some similarities in 
gonadotrophin secretion between anorexia nervosa and chronic 
schizophrenia the most important differences are that in 
schizophrenia abnormalities do not relate to body weight 
and that testing with LHRH and/or TRH produces a completely
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different pattern of results.
3) Dementia. No clear abnormalities of pituitary hormone secretion 
have been identified in dementia.
4) Neurotic illness. Stress in females has been reported to 
impair the LH secretory profile. Such changes are often 
associated with low PRL levels. The PRL responses to TRH 
and GH response to DA agonists is usually within normal 
limits in these cases.
Similarities and differences between the hormonal profile 
of chronic schizophrenic patients and I.G.D. patients and organic 
hypothalamic conditions have been outlined in chapter 5 and 
above.
Thus the abnormalities described here exhibit diagnostic 
specificity for the diagnosis of schizophrenia, but only when 
the entire range of abnormalities is considered. The relation­
ship of these abnormalities to subgroups of patients with reported 
evidence of testicular pathology, reduced fertility, menstrual 
abnormalities and reduced urinary testosterone (discussed in 
chapter I) remains to be established.
b) Acute schizophrenia
No clear-cut abnormalities of pituitary hormone secretion 
were detected in this group of patients. Some potentially 
interesting results relating hormone secretion to clinical 
symptoms, drug dosage and levels were demonstrated.
The levels of several hormones notably LH, FSH, GH and PRL
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were unaltered compared to an age-matched control group. The 
normality of LH and FSH secretion, the lack of any change in 
them following neuroleptic medication and the evidence of normal 
episodic LH secretion demonstrated in this group of patients 
compared to the chronic patients is of interest since it indicates 
that gonadotrophin secretion abnormalities are unlikely to be 
aetiologically significant in schizophrenia as was postulated by 
amongest others Kraepelin (1919) and McCartney (1929). Rather 
these abnormalities may be an index of processes involved with 
chronicity.
Basal GH secretion was normal in these patients as was 
the overall GH response to a DA agonist. There was a very 
marked variation in this response with some patients with a 
markedly blunted response and others with an exaggerated response.
This elucidation of this pattern (previously reported by others 
e.g. Rotrosen, 1979) may prove to be a useful clinical indicator 
particularly as blunting is seen in a very much higher proportion 
of chronic schizophrenics. One possible cause of this large variation - 
the effects of neuroleptic drug withdrawal - was excluded by the pi’eœnt study.
PRL secretion was not abnormal in these patients. This 
could be taken as evidence against the DA hypothesis of schizo­
phrenia as was discussed in chapter 4. However in view of the 
short-loop feedback control system of PRL secretion it is 
conceivable that PRL levels tend to return to normal even in the 
face of a perturbation in the DA system. In support of this 
thesis is the trend (significant in some groups) for a negative 
relationship between PRL secretion and positive symptom scores.
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Thus those patients with the greater positive symptoms and 
therefore the best likelihood of a therapeutic response to a DA 
blocker were those with the lowest PRL levels and by extra­
polation possibly the highest hypothalamic DA release. This 
relationship may become more clinically relevant in the future.
A close relationship between PRL secretion and neuroleptic 
dose and blood levels was established but PRIi secretion did not 
relate to clinical improvement nor to drug induced side effects. 
The main problem with these types of relationship is that they 
can only be tested in groups of patients : there are too many 
exceptions in the individual case to make these observations 
clinically relevant.
3 . Results other than neuroendocrine
The important non-neuroendocrine findings of these studies 
were that apomorphine administration is not associated with 
any clinical improvement in schizophrenics and that the frequency 
of side effects was similar in controls and schizophrenics.
This study, carried out double-blind on unmedicated patients, 
weakens the experimental basis of a number of hypotheses which 
have been recently put forward. Such studies are not easy to 
perform but as discussed in chapter 7 there remains a need to 
explore the clinical effects of different doses of dopamine 
agonists in schizophrenia.
No effects of apomorphine on blink rates were demonstrated. 
This puts doubt on the relevance of the changes in blink rates 
in schizophrenics on and off medication. Recently Karson has 
found no effect of L-DOPA on human blink rates (personal
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communication) which concurs with the results of the present 
study. Clearly the pathophysiological significance of blink 
rates to psychiatry requires much further evaluation.
8.4 Future work
Much further experimentation is required in the field 
of neuroendocrinology as applied to psychiatric disease. At 
present there are too many variables and inconsistencies to 
allow proper evaluation of true deficits. Possible lines of 
enquiry in schizophrenia include
a) Tests on patients
1) More cross diagnostic studies need to be done.
2) A study of the effect of acute and chronic DA anta­
gonists in a range of acute, subacute and chronic schizophrenic 
patients on Ltl and FSH secretion may indicate more clinical 
associations of this response.
3) The clinical and hormonal effects of repeated
small doses of synthetic LHEH on schizophrenic patients requires evaluation.
4) The only other drug which consistently enhances LH 
episodic secretion in the opiate antagonist naloxone (Moult 
et al, 1981). This drug was also effective in restoring LH 
episodic release in patients with hypothalamic amenorrhoea who 
responded to metaclopramide (Quigley et al, I98O). A combined 
clinical and endocrinological study with naloxone in schizophrenics 
may prove interesting.
3) A more complete analysis of gonadal steroids other than 
total testosterone and oestradiol is indicated in view of the 
abnormalities detected by Hoskins and Pincus (1949) (see chapter
1) and the observations on the different relationship between 
LH and age and testosterone secretion in schizophrenics reported 
in chapter 4.
6) Measurements of LHRH and SRIF in blood and CSF are 
being developed and may correlate interestingly with the 
neuroendocrine changes in schizophrenics.
b) Post-mortem studies
1) A more complete analysis than previously performed of 
pathological states in pituitary, hypothalamus and testes of 
schizophrenics needs to be performed.
2) Measurements of neurotransmitters, receptors and 
peptides (e.g. LHRH and SRIF) in accurately dissected areas 
of the hypothalamus in clinically documented patients are 
indicated to complement these neuroendocrine investigations of 
living patients.
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APPENDIX A
Feighner criteria for diagnosis of schizophrenia
These criteria (Feighner er al, 1972) were applied to the 
casenotes of hospitalised chronic schizophrenics. The chronicity 
of the illness was further established by adopting a policy of 
one year's continuous hospitalisation.
Schizophrenics
For a diagnosis of schizophrenia A through C are required
A. Both of the following are necessary:
1) A chronic illness with at least six months of symptoms 
prior to the index evaluation without return to the premorbid 
level of psychosocial adjustment.
2) Absence of a period of depressive or manic symptoms 
sufficient to qualify for affective disorder or probable affective 
disorder.
B. The patient must have at least one of the following:
1) Delusions or hallucinations without significant 
perplexity or disorientation associated with them.
2) Verbal production that makes communication difficult 
because of a lack of logical or understandable organization.
C. At least three of the following manifestations must be present 
for a diagnosis of "definite" schizophrenia and two for a 
diagnosis of "probable" schizophrenia.
1) Single.
2) Poor premorbid social adjustment or work history.
3) Family history of schizophrenia.
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4) Absence of alcholism or significant drug abuse within
one year of onset of psychosis.
5) Onset of illness prior to age 40.
Feighner et al (1972) state that they have demonstrated 87 - 95/ 
inter-rater concordance in the diagnosis of schizophrenia. Of 
the 28 chronic schizophrenics studied here 20 were classified 
as "definite" and 8 as "probable" schizophrenia.
28 chronic schizophrenics were studied. I8 of the 20 
who took part in the study reported in chapter 4 took part in
the study reported in chapter 5- 3 of these patients were
restudied in chapter 6 (effects of chronic neuroleptics). The 
effects of metoclopramide were studied in 10 patients - this 
number included 3 patients never previously studied and 3 of 
the 18 discussed above. 13 patients were given apomorphine 
including the 3 new patients discussed above, 3 additional never 
studied patients and 7 of the original cohort of I8 .(above). No 
patient took part in more than two studies.
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APPENDIX B 
The Present State Examination (PSE)
The Syndrome check list of the PSE (Wing et al, 197^) 
was applied to the casenotes of the chronic schizophrenic 
population identified by the Feighner criteria. The features 
of the illness at its worst were examined. The diagnostic 
categories in which the patients were placed were:- NS (nuclear 
schizophrenia - 7 patients), DS (schizophrenia without first 
rank symptoms - 13 patients), DS? (possible schizophrenia without 
first rank symptoms - 6 patients), CS (catatonic schizophrenia - 
1 patient and DP/AP (paranoid psychoses combined with affective 
psychoses ~ paranoid psychosis predominant - 1 patient). These 
categories show a high degree of agreement between the PSE and 
Feighner criteria for schizophrenia. 'NS' and 'DS' cannot 
really be separated in this samples, as the fact that nuclear 
symptoms were not recorded in the casenotes does not mean that 
they were not present and indeed it is likely that in many cases 
they were not specifically sought. The DS? category results 
from insufficent information in the casenotes. The DP/AP 
category is one of possible schizophrenia. The syndrome check 
list records not only symptoms but also behaviour. The 
DP/AP category results from a recording of 'excitement' which 
comes under the classification of an affective behaviour (but 
which of course could occur for several reasons including schizo­
phrenia). Thus the PSE classification supported the diagnosis 
of schizophrenia to a large extent. However it is not primarily 
a method of diagnosis rather of classifying an identified group
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of patients. This classification did not relate to the neuro­
endocrine changes as has been mentioned in the main text.
The acute schizophrenics (as defined in chapter 3 section 
were examined by an interview constructed round the Present State 
Examination (Wing et al, 1974). A total 48 acute schizophrenics 
were included in the present studies. All of them were classified 
as NS (nuclear schizophrenia) on the PSE classification.
Of the 48 acute schizophrenics, l4 were female and were 
included only in the study on anticholinergics and neuroleptics 
on clinical state and anterior pituitary secretion reported in 
chapter 6. 3 patients were acute patients in remission and
results from these patients were reported in chapter 4. Of the 
remaining 31 male acute schizophrenics, 13 were studied in the 
apomorphine study (chapter 7). The remaining 16 along with 6 
of the patienbs given apomorphine took part in the neuroleptic 
study (chapter 6).
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APPENDIX C
Krawiecka scale for rating chronic psychotic patients
This scale - "standardized psychiatric assessment scale for 
rating chronic peychotic patients" was published in 1977 by 
Krawiecka, Goldberg and Vaughan. Videotaped interviews were made 
of known psychotic patients. A manual of guidelines for the 
rating of each symptom or sign was produced. There were 4 
ratings based on replies to questions (depression, anxiety, 
delusions and hallucinations) and 4 ratings based on observation 
(incoherence of speech, poverty of speech, flattened incongruous 
affect and psychomotor retardation). Each rating v/as made of 
a 3 point scale. Examples from both kinds of ratings are given 
below. In the present study flattening and incongruity of 
affect were rated separately. Krawiecka et al demonstrated 
significant co-efficients of concordance for each of the ratings 
except that related to flattened incongruous affect. This 
concordance applied to psychiatrists without prior experience of 
the rating scale.
Example (1) Coherently expressed delusions
Eating 0 "Absent" No abnormality detected at interview.
1 "Mild" Eccentric beliefs and trivial misinterpretations
e.g. that bad weather is cuased by nuclear
tests, superstitions etc.
2 "Moderate" Over valued ideas and ideas of reference or
undoubted misinterpretations. Special meanings.
3 "Marked" Undoubted delusions or delusional perception
are described as having occurred in last month.
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4 "Severe"
but the patient denies that he still holds 
the beliefs 
or
delusional ideas are still held but they are 
not strongly held or incorrigible.
Undoubted delusions are present and are still 
held by the patient.
Example (2) Poverty of speech, mute
Rating 0 "Absent" Speech normal in quantity and form.
1 "Mild" Patient only speaks when spoken to; tends
to give brief replies.
2 "Moderate" Occasional difficulties or silences but
most of interview proceeds smoothly 
or
conversation impeded by vaguness, hesitancy 
or brevity of replies.
3 "Marked" Monosyllabic replies; often long pauses or
failure to answer 
or
reasonable amount of speech but answers 
slow and hesitant, lacking in content or 
repetitions and wandering so that meaningful 
conversation was impossible.
4 "Severe" Mute throughout interview or speaks less
than 3 words.
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APPENDIX D
Radioimmunoassay
1) lodination of proteins
a) LH, FSH and GH were iodinated by the chloramine T (CT) 
method. CT oxidises iodide to iodine which can then be attached
to tyrosine residues on the peptide chain.
Method (1) 23 pi of 0.23M POq was added to 0.3 mCu Na^^^I.
(2) Above mixture was added to 2 pg or 3 Pg portions of
proteins (see table 3.1 for details).
(3) 13 pi of 3*3 mg/ml CT was added.
(4) After 15 seconds 25 pi of T.8 mg/ml sodium metabi­
sulphite was added.
(3) 100 pi of human serum albumin was added.
(6) Reaction mixture was added to a G30 column for initial
lesaltry for all protein.
(7) Protein fraction peak was added to either a 12 ml 
GI30 column or a 60 cm ACA 44 column and 3OO pi 
fractions were collected and tested.
b) PRL was iodinated by the lactoperoxidase method, an 
enzyme that induces slower and more gentle oxidation.
Method (1) 30 pi of O.3M PO4 was added to 0.3 mCu of Na123l,
(2) Above mixture was added to 3 Pg of HPRL.
(3) 4 pi of lactoperoxidase was added to above.
(4) After 20 mins 2 pi of hydrogen peroxidase (10 pi of 30% 
w/v in 100 ml) were added.
(3) After a further 10 mins another 2 pi of H2O2 was added.
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(6) 500 pi of buffer (Table 3-1) was added and the
mixture applied to a 6o cm ACA 44 column and 500 pi 
fractions collected.
The fractions were tested for specific binding by incubating 
aliquots of the column fractions with and without antiserum at 
assay concentrations (Table 3*1) and suitable fractions were 
stored at -40^ until assay time. Specific binding was of the 
order of 40 - 60% for each of these proteins and non-specific 
binding 2%. Iodinated material could be used for 1 - 2  months.
2) Dose-response curves (D-R curves)
D-R curves were generated by a computer program written by 
Dr- R. Wooton based on Healey's (1972) log-dose logit^response 
standard curve. Several concentrations above and below the 
detection limit of the assay were included so that the ends of 
the curve were assymptotic using this plot. The slope of the 
curve was effectively linear in the regions of assay sensitivity 
(15 " 85 percent of total bound).
3) Quality control data
As was discussed in chapter 3 (section 3»8) it is most 
important to run quality control samples in each assay. The data 
for quality control samples for each series of studies for the 
hormones measured has been given in the appropriate chapter (4,
5, 6, 7)' The overall co-efficients of variation over all the 
assays performed are given below.
2 5 5
Total number of assays Go-efficient of variations (%
n High QG Medium QC Low QC
PRL 23 15 8 10
111 22 15 8 11
FSH 13 10 7 7
GH 16 16 11 13
Testosterone 4 11 “ 15
TSH 3 11 - 10
Oestradiol External quality control at 
Chelsea Hospital
It can be seen that co-efficients of variation were lower 
in the medium range of quality control and the errors were 
greater (though acceptable) towards the levels of sensitivity. 
This type of 'precision profile' for an assay is the common 
experience and is important to examine prior to interpretation 
of the experimental data.
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APPENDIX E
Partial correlation co-efficients
When 3 variables have been measured and one is interested 
in the relationship between them the following formula is use­
ful : -
r12.3 - r12 - r 13 • r23 df = n-3
y(l-r132) (l-r23^T
where 1,2 and 3 are the variables
r12 is the correlation between variables 1 and 2
r13 is the correlation between variables 1 and 3
and r23 is the correlation between variables 2 and 3
r12.3 is then the correlation co-efficient between 
variables 1 and 2 taking their relationship with variable 5 into 
account. In other words, r12.3 tells one if the relationship 
between variable 1 and variable 2 is dependant or independant 
of their relationship with variable 3 - if r12 is significant 
but r12-3 is not then significance is attributable to relation­
ships with variable 3*
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DECLARATION OF WORK DONE BY AUTHOR
Tile idea for these studies came from discussions involving 
Dr. T.J. Crow, Dr. E.G. Johnstone and myself but the design 
of each study and the appropriate search of the literature 
was ray own. Dr. E.G. Johnstone and Dr. D.G.C. Owens identified, 
classified and rated the schizophrenic patients but 1 made all 
the arrangements for these patients to be studied (including 
discussion with relatives). I identified and classified all 
the controls studied.
All venous sampling and preparation of sera was performed 
by the author. I also performed all the radioimmunoassays with 
the exceptions documented in the text (T3, T4 assay - Miss S. 
Gopping, oestradiol - Dr. R. Rodriguez and flupenthixol - Miss 
R. Bourne). I prepared all the solutions and iodinated material 
with some technical assistance from Mr. W. Bartlett and Miss G. 
Canning in the early stages- Clinical ratings and eye blink 
ratings in the apomorphine study were carried out by Dr. E.G. 
Johnstone and myself, with some help from Dr. T.J. Crow. Drs. 
Johnstone and Owens performed the clinical ratings and extra- 
pyramidal ratings described in chapter 6. Mr. S. Gamble wrote 
a microcomputer programme which aided eye blink rate measurements 
and he also provided some assistance with statistical packages. 
All statistics were performed by myself following discussions 
with Drs. P. Royston and C.D. Erith.
In writing up these studies 1 have drawn on papers written 
by Drs. Crow and Johnstone and many useful ideas have come from 
discussion with these workers. Nevertheless the ideas expressed
in the introductions and discussions of this thesis are my own 
and come from my own survey of the literature and review of 
these results.
DR, I.N. FERRIER
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